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ABSTRACT 
 
Jessica L. Petrick: Dietary Intake of Flavonoids, Barrett’s Esophagus Development, and 
Esophageal and Gastric Cancer Incidence and Survival  
(Under the direction of Marilie D. Gammon) 
 
 
Flavonoids, polyphenolic compounds concentrated in fruits and vegetables, have 
experimentally demonstrated chemopreventive effects against esophageal and gastric cancer 
and Barrett’s esophagus, a precursor lesion for esophageal adenocarcinoma. Few 
epidemiologic studies have examined flavonoids and incidence of esophageal and gastric 
cancers, and none have considered flavonoids with survival. Additionally, only one 
epidemiologic investigation has reported an inverse association between isoflavone intake and 
Barrett’s esophagus risk, yet no study has considered other flavonoid classes, which are more 
commonly consumed in the U.S. This ancillary study built upon the U.S. Multi-Center Study 
(esophageal adenocarcinoma cases n=274, gastric cardia adenocarcinoma cases n=248, 
esophageal squamous cell carcinoma cases n=191, other gastric adenocarcinoma cases 
n=341, and frequency-matched controls n=662) and the Study of Reflux Disease (Barrett’s 
esophagus cases n=170 and matched controls n=183). Esophageal and gastric cancer cases 
were followed until 2000 for vital status. Participants completed a food frequency questionnaire, 
and responses were linked with USDA Flavonoid Databases and available literature for six 
flavonoid classes and lignans. Multivariable-adjusted odds ratios (ORs) and hazard ratios (HRs) 
[95% confidence intervals (CI)] were estimated, comparing highest versus lowest intake 
quartiles, using logistic and proportional hazards regressions, respectively. Little or no 
association was found for total flavonoid intake (main sources in this population: black tea, 
orange/grapefruit juice, and wine) and development or survival for any tumor type. Intake of 
 iv 
 
anthocyanidins, common in wine and fruit juice, was associated with a reduction in the risk of 
57% for developing esophageal adenocarcinoma (OR=0.43, 95% CI: 0.29-0.66), 57% for 
developing squamous cell carcinoma (OR=0.43, 95% CI: 0.26-0.70), and 41% for developing 
Barrett’s esophagus. ORs for isoflavones, for which coffee was the main source, were increased 
for all cancer types, except esophageal squamous cell carcinoma. A modest increased risk of 
Barrett’s esophagus development was observed for flavones, for which the main dietary source 
in this population was pizza. Anthocyanidins were associated with decreased risk of mortality for 
gastric cardia (HR=0.63, 95% CI: 0.42-0.95) and more modestly for esophageal 
adenocarcinoma (HR=0.87, 95% CI: 0.60-1.26). Our findings, if confirmed, suggest that 
increased dietary anthocyanidin intake may reduce risk of developing these tumors and improve 
survival. 
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CHAPTER 1: BACKGROUND 
 
 
Introduction 
Esophageal and gastric cancers have very poor survival prognoses (normally less than a 
year).1 Thus, significant research efforts have focused on identifying strategies to reduce 
the risk of developing these cancers, which could also potentially decrease the risk of 
mortality among those diagnosed with these cancers. This approach is further enhanced 
if precancerous lesions are also considered, which facilitate determination of key 
windows of susceptibility. In other words, this novel approach aids in identifying optimal 
times along the cancer continuum (normal tissue  precancerous conditions  invasive 
cancer  mortality) that could be targeted for intervention with a specific 
chemopreventive to enhance risk reduction. The only known potential precursor of 
esophageal and gastric cardia adenocarcinoma is Barrett’s esophagus (BE).2 Thus, the 
goals of this dissertation were to examine the role of a potential risk reduction strategy – 
namely dietary intake of flavonoids, which are potent anti-carcinogens found in fruits, 
vegetables, and other dietary sources – in reducing the risk of developing or dying from 
esophageal or gastric tumors along the cancer continuum.  
The study hypothesis was that flavonoids would reduce the risk of esophageal 
and gastric tumors. This study is significant because esophageal and gastric cardia 
adenocarcinoma (EA/GCA) have rapidly increasing incidence rates in the United States 
(U.S.) and other Western countries,3-7 but incidence rates in Asian countries remain 
comparatively low.8 However, incidence rates of esophageal squamous cell carcinoma 
(ESCC) and non-cardia gastric adenocarcinoma (NCGA) remain high in Asian countries, 
2 
and not the U.S.5,8,9 The rates of esophageal and gastric cancer subtypes (EA, GCA, 
ESCC, and NCGA) vary 50- to 60-fold between high and low incidence countries.8 
These geographic differences in incidence do not appear to be only due to genetic 
variation between ethnic groups, as incidence rates of esophageal and gastric cancer in 
Asian migrants to the U.S. tend to move in the direction of European-American incidence 
rates.10-12 The geographic variation in incidence rates of esophageal and gastric cancer 
and results of migrant studies have led to the hypothesis that the variability is in part due 
to differences in energy intake/composition and micronutrient intake.5,13 
The rationale for considering flavonoid intake as a potential chemopreventive is 
supported by evidence from population and laboratory research. Epidemiological studies 
have shown that diets high in fruit and vegetable consumption are inversely associated 
with esophageal and gastric cancer and Barrett’s esophagus.14-28 It is hypothesized that 
flavonoids, which are a group of bioactive polyphenolic compounds that are naturally 
occurring in fruits, vegetables, and beverages of plant origin, could partially account for 
these risk reductions. Experimental studies have supported this hypothesis and have 
shown that flavonoids regulate cell cycle, proliferation, and apoptosis, which have 
important chemotherapeutic effects against these tumors.29 Additionally, Phase I and II 
clinical trials are also using synthetic classes of flavonoids to produce cell cycle arrest 
and inhibit tumor growth in patients with metastatic cancer, including gastric cancer.30-32 
In sum, the purpose of this study was to identify key windows of susceptibility for the 
potential association between flavonoids and esophageal and gastric tumors. 
Specifically, aims were to: 1) examine if flavonoid intake was associated with 
esophageal and gastric cancer incidence, 2) examine if flavonoid intake was associated 
with Barrett’s esophagus (BE) development, and 3) examine if flavonoid intake was 
associated with mortality among individuals diagnosed with esophageal and gastric 
cancer. Determining the association between flavonoids and risk of developing or dying 
3 
from esophageal or gastric tumors is innovative because there is potential to use 
flavonoids as a risk reduction strategy. This could allow some esophageal and gastric 
cancer to be prevented before individuals develop these deadly cancers or offer support 
for use of flavonoids as a novel chemotherapeutic. 
A more thorough discussion of the scientific background, significance, and 
innovation that motivated the dissertation goals is presented below.  
 
Epidemiology of Esophageal and Gastric Cancer Incidence 
In 2008, esophageal cancer was the eighth most common cause of cancer morbidity 
worldwide, with an estimated 481,000 incident cases,33 and gastric cancer was the 
fourth most common cause of cancer morbidity worldwide, with an estimated 989,000 
incident cases.34 Approximately 83% of esophageal cancers occur in developing 
countries (399,000 incident cases), with over 50% of all esophageal cancers occurring in 
China alone (258,000 incident cases). Esophageal cancer also has huge geographic 
variation, varying more than 15-fold in men [age-standardized incidence rate (ASIR) 22.3 
per 100,000 in Southern Africa versus 1.4 in Western Africa] and close to 20-fold in 
women (ASIR 11.7 per 100,000 in Southern Africa versus 0.6 in Micronesia/Polynesia).33 
Almost 72% of gastric cancers occur in developing countries, with over 45% of all gastric 
cancers occurring in China alone (463,000 incident cases). Similar to esophageal 
cancer, gastric cancer has huge geographic variation, varying more than 10-fold in men 
(ASIR 42.4 per 100,000 in Eastern Asia versus 3.9 in Northern Africa) and over 8-fold in 
women (ASIR 18.3 per 100,000 in Eastern Asia versus 2.2 in Southern Africa).34 
The majority of esophageal cancers histological types are either adenocarcinoma 
or squamous cell carcinoma. Over 90% of gastric cancers are adenocarcinomas.35 
Gastric adenocarcinomas are usually classified according to their anatomic location 
within the stomach: cardia (proximal portion of the stomach found next to the 
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gastroesophageal junction) or non-cardia (distal portion of the stomach).36 Esophageal 
squamous cell carcinomas generally occur in the upper two-thirds of the esophagus, 
whereas esophageal adenocarcinomas cluster in the lower third of the esophagus at the 
gastroesophageal junction.9 Esophageal squamous cell carcinoma and non-cardia 
gastric adenocarcinoma are the most common forms of esophageal and gastric cancer 
worldwide.8,37 
Between 2003 and 2007 in the U.S., the average age of diagnosis for 
esophageal and gastric cancer was 68 and 70 years, respectively. During this 
timeframe, the age-adjusted incidence rate (AAIR) for esophageal cancer was 4.5 per 
100,000 (AAIR 7.8 per 100,000 men, 1.9 per 100,000 women). For gastric cancer, the 
AAIR was 7.8 per 100,000 (AAIR 10.9 per 100,000 men, 5.5 per 100,000 women). 
Between 1975 and 2007, the annual percentage change (APC) in gastric cancer 
incidence was -1.6%. The APC in esophageal cancer incidence was -0.4% in the U.S. 
between 2001 and 2007.38  
While overall incidence of esophageal and gastric cancers has been decreasing, 
esophageal adenocarcinoma and gastric cardia adenocarcinomas have been among the 
most rapidly increasing cancer types in the United States (U.S.) and other Western 
countries.5,8,9,39 As reported in population-based cancer registries, the incidence of 
esophageal adenocarcinoma and gastric cardia adenocarcinoma has increased 300-
575% over the last 30-40 years.3-7 Esophageal adenocarcinoma and gastric cardia 
adenocarcinoma are often considered as one clinical entity because they are both 
cancers of the gastroesophageal junction, have similar overall 5-year survival rates of 
approximately 26%, and have comparable survival according to tumor stage.40 In 2009, 
approximately half of the 16,470 anticipated incident esophageal cancers in the U.S. 
were expected to be adenocarcinomas;5,41-43 and approximately 35% of the anticipated 
21,130 incident gastric cancers were expected to be gastric cardia adenocarcinoma.5,43   
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Summary. Esophageal and gastric cancers are two of the most common causes 
of cancer morbidity worldwide.33,34 In the U.S. and other Western countries, esophageal 
and gastric cardia adenocarcinomas have been among the most rapidly increasing 
cancer types.5,8,9,39 However, esophageal squamous cell carcinoma and non-cardia 
gastric adenocarcinomas are the most common forms of esophageal and gastric cancer 
worldwide.8,37 Therefore, it is of importance to determine the risk factors for these four 
types of cancers because of high morbidity worldwide and increasing incidence of 
EA/GCA in the U.S. Specifically, it is of interest to determine if flavonoids can be used as 
a risk reduction strategy for these cancer types. 
 
Epidemiology of Esophageal and Gastric Cancer Survival 
Worldwide in 2008, esophageal cancer was the sixth most common cause of cancer 
mortality, with an estimated 406,000 deaths,33 and gastric cancer was the second most 
common cause of cancer mortality, with an estimated 737,000 deaths.34 Approximately 
83% of esophageal cancer mortality occurs in developing countries (338,000 deaths), 
with over 50% of all esophageal cancer mortality occurring in China alone (210,000 
deaths). The highest mortality rates for esophageal cancer are found in Eastern Africa 
[age-standardized morality rate (ASMR) 14.3 per 100,000 in men, 6.2 per 100,000 in 
women], Southern Africa (ASMR 21.4 and 11.1, respectively), and Eastern Asia (ASMR 
16.2 and 6.4, respectively).33 Over 75% of gastric cancer mortality occurs in developing 
countries (555,000 deaths), with over 45% of all gastric cancer mortality occurring in 
China alone (352,000 deaths). The highest mortality rates for gastric cancer are found in 
Eastern Asia (ASMR 28.1 per 100,000 in men, 13.0 per 100,000 in women), and the 
lowest mortality rates are found in Northern America (2.8 and 1.5, respectively).34 
 Between 2003 and 2007 in the U.S., the average age of death from esophageal 
and gastric cancer was 69 and 73 years, respectively. During this timeframe, the age-
6 
adjusted death rate (AADR) for esophageal cancer was 4.4 per 100,000 (AADR 7.8 per 
100,000 men, 1.7 per 100,000 women). For gastric cancer, the AADR was 3.8 per 
100,000 (AADR 5.3 per 100,000 men, 2.7 per 100,000 women).38 Between 1999 and 
2006, the 5-year relative survival for all stages of esophageal cancer was 17.7%. The 
stage distribution of esophageal cancer was 23% for localized, 31% for regional, 32% for 
distant, and 15% for unknown stage cancer. The respective 5-year relative survival was 
37.4%, 18.8%, 3.2%, and 12.1%. The 5-year survival for all stages of gastric cancer was 
26.0%. The stage distribution for gastric cancer was 23% for localized, 32% for regional, 
34% for distant, and 11% for unknown stage cancer. The respective 5-year relative 
survival was 62.5%, 27.0%, 3.4%, and 17.3%.38 
 Studies have shown little survival difference between esophageal and gastric 
cardia adenocarcinomas.40,44-48 In a study by Wijnhoven et al. of 252 patients,40 the 
overall 5-year survival rates for esophageal and gastric cardia adenocarcinoma, 
respectively, were 26% and 27%, with a combined, overall 5-year survival rate of 26%. 
Tumors were staged using TNM Classification of Malignant Tumors. For patients with 
esophageal cancer (n=111), tumor size was 16% Tis/T1, 14% T2, 70% T3-4, lymph node 
involvement was 44% N0 and 56% N1-2, and distant metastases were 81% M0 and 19% 
M1. For patients with gastric cardia adenocarcinoma (n=141), tumor size was 6% Tis/T1, 
20% T2, 74% T3-4, lymph node involvement was 38% N0 and 62% N1-2, and distant 
metastases were 96% M0 and 4% M1. Overall 5-year survival rate by TNM classification 
for patients was 70% for Tis/T1, 37% for T2, and 14% for T3-4. The overall 5-year survival 
rate for patients with negative lymph nodes (N0) was 42%, but for patients with positive 
lymph nodes (N1) the survival rate was 11%. For patients without distant metastases 
(M0), the overall 5-year survival rate was 27%, whereas for patients with distant 
metastases (M1), the overall 5-year survival rate was 0%.
40 
 Summary. Esophageal and gastric cancers are two of the most common causes 
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of cancer mortality worldwide,33,34 and these cancers have very poor survival prognoses 
(normally less than a year).1 Therefore, demonstration of an association between 
flavonoids and BE development, esophageal or gastric cancer incidence or survival 
among esophageal and gastric cancer cases suggests potential to use flavonoids as a 
risk reduction strategy for these tumors. This would offer support for use of flavonoids as 
a novel chemotherapeutic, which could potentially decrease the risk of mortality among 
those diagnosed with these cancers. 
 
Esophageal and Gastric Cardia Adenocarcinoma 
Esophageal and Gastric Cardia Adenocarcinoma Risk Factors 
Medical Conditions/Clinical Characteristics. The strongest risk factors for 
esophageal adenocarcinoma (EA) and gastric cardia adenocarcinoma (GCA) are 
gastroesophageal reflux disease (GERD), esophagitis, and Barrett’s esophagus 
(BE).49-52 While the dominant paradigm is that the major risk factor for EA/GCA is a 
precursor lesion, Barrett’s esophagus, that arises from GERD and esophagitis, 
studies have shown that GERD in the absence of BE appears to be a risk factor for 
EA/GCA as well.53,54 In the U.S. Multi-Center Study, risk of EA/GCA was associated 
with history of GERD [odds ratio (OR)=2.1, 95% confidence interval (CI): 1.3-3.5] 
and esophagitis or esophageal ulcer (OR=5.2, 95% CI: 1.7-15.7).54 In a study by 
Lagergren et al., among Swedish participants with symptomatic GERD at least once 
a week or more, compared to participants without symptoms, the odds ratios were 
7.7 (95% CI: 5.3-11.4) for EA and 2.0 (95% CI: 1.4-2.9) for GCA. As frequency, 
severity, and duration of symptomatic GERD increased, the risk for EA/GCA 
increased. Among individuals with GERD symptoms more than three times a week, 
compared to participants without symptoms, the odds ratios were 16.7 (95% CI: 8.7-
28.3) for EA and 2.3 (95% CI: 1.2-4.3) for GCA. Among individuals with greater than 
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20 years of GERD symptoms, compared to participants without symptoms, the odds 
ratios were 16.4 (95% CI: 8.3-28.4) for EA and 3.3 (95% CI: 1.8-6.3) for GCA. 
Among individuals with long standing symptomatic GERD (>20 years) and severe 
symptoms, compared to participants without symptoms, the odds ratios were 43.5 
(95% CI: 18.3-103.5) for EA and 4.4 (95% CI: 1.7-11.0) for GCA. Additionally, 118 of 
189 EA patients (62%) had BE, and 113 EA patients (60%) had reflux symptoms at 
least once a week. The association with symptomatic GERD was almost identical 
between EA participants who had BE versus those that did not.53 Another study 
examined the GERD, esophagitis, and BE as risk factors for EA. The estimated 
standardized incidence ratios for EA were 3.1 (95% CI: 0.6-14.2) for GERD, 4.5 
(95% CI: 1.04-19.6) for esophagitis, and 29.8 (95% CI: 9.6-106.0) for BE compared 
with a reference cohort.50  
 Demographic Factors. Age, Sex, and Race. The risk of developing EA/GCA 
has been associated with several non-modifiable risk factors, including age, race, 
sex, family history, and low socioeconomic status. Similar to other cancers, risk of 
EA/GCA increases with increasing age.49,51,55,56 Age specific incidence of EA and 
GCA increases until 75-79 and 80-84 years of age, respectively, before declining in 
the older age groups.56 Additionally, Caucasian males are at a higher risk of EA/GCA 
than African-Americans and women.49,51,55-59 Age-adjusted incidence of EA in males 
is 6-8 times higher than in females and 3-4 times higher in Caucasians than African-
Americans. While the increase in incidence of EA has been seen in all age and sex 
groups, Caucasian males comprise more than 80% of the EA cases and have 
experienced the largest increase in incidence rates.56 The differences between race 
and sex are less pronounced in GCA. Age-adjusted incidence rates of GCA in males 
are 3-5 times higher than females and 1.5-2 times higher in Caucasians than African-
Americans.56  
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 Family History. Due to the association of EA/GCA in male gender and 
Caucasian race, it has been hypothesized that there is an inherited component of 
EA/GCA.49 This has been supported in studies that have shown a family clustering of 
BE and EA/GCA.49,60-65 In a recent study, the odds of having BE or EA/GCA in 
individuals with a positive family history (first or second degree relative with BE or 
EA/GCA) were 12.23 (95% CI: 3.34-44.76) times the odds of BE or EA/GCA in 
individuals without a positive family history.65 However, the family clustering seen in 
BE and EA/GCA could also be due in part to shared cultural factors, especially diet.66 
 Education and Income. In the U.S. Multi-Center Study, low socioeconomic 
status (SES), quantified by both education and income, was a risk factor for 
EA/GCA. For participants that completed graduate school versus those with less 
than high school education, the OR was 0.7 (95% CI: 0.3-1.3) for EA and 0.8 (95% 
CI: 0.4-1.6) for GCA. For participants with an income greater than $75,000 compared 
to those with an income of less than $15,000 per year, the OR was 0.5 (95% CI: 0.3-
1.0) for EA and 0.8 (95% CI: 0.4-1.6) for GCA.67 In a more recent Swedish study 
comparing unskilled manual workers to professionals, the OR was 2.0 (95% CI: 0.9-
4.5) for EA and 1.0 (0.6-1.8) for GCA.68 
 Epidemiologic Factors. Obesity. Modifiable risk factors for EA/GCA include 
obesity49,51,69-74 and cigarette smoking.49,51,67,72,75-81 Increasing rates of obesity in the 
general population have paralleled the increasing rates of EA and GCA. Elevated body 
mass index (BMI, defined as weight in kilograms/height in meters squared) has 
consistently been shown to be a significant risk factor for EA and a somewhat weaker 
risk factor for GCA. While the exact mechanisms are unclear, it is hypothesized that 
central adiposity may increase intra-abdominal pressure, thus promoting 
gastroesophageal reflux disease and the transition to Barrett’s esophagus.10 Two recent 
cohort studies examined the risk of both EA and GCA by obesity status. In the study by 
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Abnet et al., compared to participants with a BMI of 18.5-25 kg/m2, participants with a 
BMI of 25-<30, 30-<35, and ≥35 kg/m2 had respective hazard ratios for EA of 1.65 (95% 
CI: 1.26-2.18), 1.91 (95% CI: 1.38-2.66), and 2.27 (95% CI: 1.44-3.59) and for GCA of 
1.06 (95% CI: 0.79-1.41), 1.70 (95% CI: 1.22-2.36), and 2.46 (95% CI: 1.60-3.80).69 In 
the study by Merry et al., compared with participants with a BMI of 20.0-24.9 kg/m2, 
participants with a BMI of 25.0-29.9 and ≥30.0 kg/m2 had respective rate ratios for EA of 
1.40 (95% CI: 0.95-2.04) and 3.96 (95% CI: 2.27-6.88) and for GCA of 1.32 (95% CI: 
0.94-1.85) and 2.73 (95% CI: 1.56-4.79).70 In a meta-analysis of the association between 
BMI and EA/GCA, the OR for EA comparing overweight (BMI 25-28 kg/m2) and obese 
(BMI ≥ 28) to normal weight (18.5-25 kg/m2) individuals was 2.2 (95% CI: 1.8-2.7; 
phomogeneity=0.11) for men and 1.9 (95% CI: 1.5-2.5; phomogeneity=0.20) for women. The OR 
for GCA comparing overweight and obese to normal weight was 1.5 (95% CI: 1.3-1.8; 
phomogeneity=0.38) for studies conducted in the U.S. and European countries.
82  
Cigarette Smoking. Smoking is a risk factor for both types of esophageal and 
gastric cancers. In a pooled analysis of cigarette smoking from the International Barrett’s 
and Esophageal Adenocarcinoma Consortium (BEACON),81 the summary OR for ever 
versus never cigarette smoking for EA was 1.96 (95% CI: 1.64-2.34) and 2.18 (95% CI: 
1.84-2.58) for gastroesophageal (GE) junction adenocarcinoma. Additionally, there was 
a trend of increasing risk of EA and GE junction adenocarcinoma by pack-years smoked. 
Compared to non-smokers, pack-years of smoking <15, 15-<30, 30-<45, and ≥45 had an 
OR for EA of 1.25 (95% CI: 1.02-1.53), 1.96 (95% CI: 1.58-2.45), 2.07 (95% CI: 1.66-
2.58), and 2.71 (95% CI: 2.16-3.40) and for GE junction adenocarcinoma of 1.32 (95% 
CI: 0.99-1.75), 2.44 (95% CI: 1.98-3.00), 2.64 (95% CI: 2.07-3.38), and 2.68 (95% CI: 
2.23-3.23), respectively.81 Additionally, alcohol has been evaluated as a risk factor. Most 
studies have not shown an association between alcohol consumption and EA, however 
a few studies have shown a slight increase of EA risk among drinkers.10 There is also 
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some evidence that alcohol may increase the risk of GCA.10 
 Asprin. Risk reduction factors for EA/GCA include non-steroidal anti-
inflammatory drugs (NSAIDs), such as aspirin, and other COX-2 inhibitors,49,51,74,83-87 
fruits and vegetables,14-25 and dietary antioxidants, including vitamin C88-91 and 
vitamin E.88,89,91 In a recent meta-analysis, aspirin was inversely associated with EA 
(OR=0.64, 95% CI: 0.52-0.79) and GCA (OR=0.82, 95% CI: 0.65-1.04). Other 
NSAIDs were also inversely associated with EA (OR=0.65, 95% CI: 0.50-0.85) and 
GCA (OR=0.80, 95% CI: 0.67-0.95).86 In a prospective cohort study of BE patients, 
the hazard ratio for EA in current NSAID users was 0.32 (95% CI: 0.14-0.76).85  
 Dietary Intake. Epidemiological studies have shown that diets high in fruit and 
vegetable consumption are inversely associated with EA14-23 and GCA.14,15,23-25 In the 
U.S. Multi-Center Study, the adjusted odds ratios (OR) were calculated based on 
increasing fruit/vegetable intake by one serving per day. Total fruit and vegetable 
intake were associated with decreased risk of EA (OR=0.88, 95% CI: 0.82-0.95) and 
potentially decreased risk of GCA (OR=0.97, 95% CI: 0.90-1.03).15 Additionally, 
studies have shown that dietary antioxidants, including vitamin C88-91 and vitamin 
E,88,89,91 have risk reduction effects against EA/GCA. In the U.S. Multi-Center Study, 
Mayne et al. found an inverse association between vitamin C and E, comparing the 
highest versus lowest quartile of consumption, for EA (OR=0.45, 95% CI: 0.33-0.61 
and OR=0.73, 95% CI: 0.54-1.00, respectively) and GCA (OR=0.64, 95% CI: 0.49-
0.84 and OR=0.75, 95% CI: 0.55-1.02, respectively).91 
 Summary. Risk factors of EA/GCA include GERD,49-52 esophagitis,49-52 
Barrett’s esophagus,49-52 age,49,51,55,56 obesity,49,51,69-74 gender, race,49,51,55-59 cigarette 
smoking,49,51,67,72,75-81 family history,49,60-65 and low SES.67 Risk reduction factors 
include non-steroidal anti-inflammatory drugs (NSAIDs) and other COX-2 
inhibitors,49,51,74,83-86  fruits and vegetables,14-25 and dietary antioxidants, including 
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vitamin C88-91 and vitamin E.88,89,91 These risk factors were important to consider 
when designing the directed acyclic graph of the association between flavonoids and 
EA/GCA risk, as these are potential confounders or intermediates of this association.  
 
Flavonoids and Esophageal/Gastric Cardia Adenocarcinoma: Biologic Mechanisms 
Flavonoids are a group of bioactive polyphenolic compounds that are naturally occurring 
in fruits, vegetables, and beverages of plant origin and are thought to partially account 
for the risk reduction of fruits and vegetables on EA and GCA.29 Experimental studies 
have shown that some classes of flavonoids regulate cell cycle, proliferation, and 
apoptosis, and modulate carcinogen metabolism and inflammatory pathways, which 
have important chemopreventive effects against EA and GCA.29 Lignans are another 
polyphenolic compound that has been shown to have antioxidant and anti-inflammatory 
effects, induce apoptosis, and promote cell cycle arrest.92 There are six classes of 
flavonoids (anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols, and 
isoflavones), and different foods and beverages contribute to each class of flavonoid.  
 A recently published review93 has outlined the different foods and beverages that 
contribute to the flavonoid classes and the mechanism of chemoprevention for each 
class and is briefly described below.   
 
 Anthocyanidins (e.g., cyanidin, delphinidin, malvidin, pelargonidin, peonidin,  
and petunidin) are found in berries, grain, grape seed extracts, wine, red 
cabbages, and purple sweet potatoes. The chemopreventive mechanisms for 
anthocyanidins are through antioxidant effects, induction of apoptosis, anti-
inflammatory effects, and cell cycle arrest.93  
 Flavan-3-ols (e.g., (+)-catechin, (+)-catechin-3-gallate, (-)-epicatechin, (-)-
epicatechin-3-gallate, (-)-epigallocatechin, (-)-epigallocatechin-3-gallate, (+)-
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gallocatechin, (+)-gallocatechin-3-gallate, theaflavin, theaflavin-3-gallate,  
theaflavin-3’-gallate, theaflavin-3,3’-digallate, and thearubigins) are found in 
apple skin, celery, berries, citrus fruits, soybeans, onions, green tea, and cocoa. 
The chemopreventive mechanisms for flavan-3-ols are through antioxidant 
effects, anti-inflammatory effects, and inhibition of telomerase.93  
 Flavanones (e.g., eriodictyol, hesperitin, and naringenin) are found in oranges 
and grapefruit. The chemopreventive mechanisms for flavanones are through 
induction of apoptosis and antiproliferative effects.94  
 Flavones (e.g., apigenin and luteonin) are found in legumes, broccoli, parsley, 
thyme, olives, cherries, and tea. The chemopreventive mechanisms for flavones 
are through induction of apoptosis, anti-inflammatory effects, suppression of 
mitogen-activated protein kinase, cell cycle arrest, and suppression of NF-κB 
activation.93  
 Flavonols (e.g., isorhamnetin, kaempferol, myricetin, and quercetin) are found in 
olive oil, red wine, tea, citrus fruits, tomato, onion, cotton seed, and yellow 
vegetables. The chemopreventive mechanisms for flavonols are through 
antioxidant effects, anti-inflammatory effects, induction of apoptosis, suppression 
of NF-κB activation, suppression of protein kinases (PTKs), suppression of 
angiogenesis, cell cycle arrest, and inhibitor of telomerase.93  
 Isoflavones (e.g., daidzein, genistein, and glycitein) are found in soybean and 
citrus fruits. The chemopreventive mechanisms for isoflavones are through 
induction of apoptosis, anti-inflammatory effects, suppression of PTKs, cell cycle 
arrest, and suppression of angiogenesis.93  
 Lignans (e.g., secoisolariciresinol and matairesinol) are found in sesame oil and 
sunflower oil. The chemopreventive mechanisms for lignans are through 
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antioxidant effects, induction of apoptosis, cell cycle arrest, and anti-inflammatory 
effects.93  
 
 Only three flavonoid classes (flavan-3-ols, flavones, and flavonols) have been 
studied and also directly linked to adenocarcinomas of the esophagus and gastric 
cardia in laboratory experiments, as discussed below. 
 Flavan-3-ols. The effects of flavan-3-ols on two cell lines – one a poorly 
differentiated esophageal adenocarcinoma and one a moderately differentiated 
gastric cardia/gastroesophageal junction adenocarcinoma – were investigated, and 
exposure of these cell lines to flavan-3-ols reduced the number of cancer cells. This 
was attributed to increased apoptosis and arrest of the cell cycle at G0/G1 phase, 
and reduction of cells in cell cycle S phase.29 A more recent study95 looked at human 
EA cells and showed that Polyphenon E, a green tea extract of Epigallocatechin 
gallate (which is found to a lesser extent in black tea),96 inhibited growth, produced 
cell cycle arrest (G1 phase), and down-regulated the expression of cyclin D1 protein 
in EA cells.95 
 Another study found that cranberry proanthocyanidins inducted apoptosis and 
cell cycle arrest (G1 phase) and inhibited acid-induced proliferation of human EA 
cells.97 Using a grape seed proanthocyanidin extract (GSPE) against human gastric 
adenocarcinoma cells in vitro, researchers found that GA cancer cells treated with 50 
mg/liter GSPE had 41% inhibition of cellular growth compared with GA cancer cells 
treated with 25 mg/liter GSPE that had a 34% inhibition of cellular growth.98  
 Flavones. In human esophageal adenocarcinoma cells, flavones (i.e., 
luteolin, apigenin, and chrysin) induced cytotoxicity, which was mediated by G2/M 
cell cycle arrest and apoptosis. Of the flavones, luteolin had the most cytotoxic 
potency.99 
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 One animal study has shown that a synthetic flavone, Flavopiridol, reduces 
the development of EA. In this study, mice were exposed to a carcinogen that is 
known to induce esophageal cancer. Experimental mice (n=71) were given 
Flavopiridol and control mice (n=50) received diluent. Prevalence of EA in 
experimental mice was 11% compared to 32% in control mice (p=0.001).100 
 Flavonols. In a study mentioned above, researchers also found that 
flavonols (i.e., quercetin, kaempferol, and myricetin) induced cytotoxicity in human 
esophageal adenocarcinoma cells, which was mediated by G2/M cell cycle arrest 
and apoptosis. Of the flavonols, quercetin had the most cytotoxic potency.99 
 Summary. Experimental studies have shown that some classes of flavonoids 
have important chemopreventive effects against EA and GCA.29 This gives biological 
plausibility to the hypothesis of an inverse association between flavonoid 
consumption and EA/GCA incidence and survival among EA/GCA cases. 
Demonstration of an association between flavonoids and incidence of EA/GCA or 
survival among EA/GCA cases suggests potential to use flavonoids as a risk 
reduction strategy for these cancers. 
 
Epidemiology of Flavonoids and Esophageal/Gastric Cardia Adenocarcinoma 
Four previous epidemiological studies101-104 have analyzed the association between 
esophageal adenocarcinoma (EA) or gastric adenocarcinoma (GA) and total 
flavonoid consumption. These studies found no association with total flavonoid 
consumption, but two studies101,102 did find positive associations with specific classes 
of flavonoids. In a U.S.-based study of EA, the odds ratio for EA comparing 
individuals in the highest quartile of consumption of one class of flavonoid 
(anthocyanidins) to participants in the lowest quartile of consumption was 0.47 (95% 
CI: 0.24-0.91). This study was limited by small sample size (161 cases of EA), which 
16 
can result in unstable effect estimates.101 In a Greece-based GA study, the odds 
ratio (OR) per one standard deviation increase in intake of one class of flavonoid 
(flavanones) was 0.55 (95% CI: 0.31-0.96). However, the study examined all 
adenocarcinoma of the stomach and did not consider anatomical subsites (i.e., 
cardia versus non-cardia), and it was also limited by small sample size (100 cases of 
GA).102  
 The European Prospective Investigation into Cancer and Nutrition examined 
the association between flavonoid intake and esophageal and gastric cancer, 
stratifying by histology (i.e., adenocarcinoma versus squamous cell carcinoma for 
esophageal cancer) and anatomic subsite (i.e., cardia versus non-cardia for gastric 
cancer).103,104 No associations were found in the main analyses. There was 
suggestion of total flavonoids being associated with decreased risk of gastric cancer 
in women and esophageal cancer in current smokers. When results were stratified 
by histology or anatomic subsite, risk reductions were not detected for esophageal or 
gastric cardia adenocarcinoma possibly due to small sample size (EA n=142, GCA 
n=201).103,104  
 One other study, which was conducted in Sweden, examined the association 
between a specific flavonoid, quercetin of the flavonol class, and gastric 
adenocarcinoma risk, both by cardia and non-cardia type. The study showed a non-
significant decrease for the association between quercetin and gastric cardia 
adenocarcinoma (GCA) (highest versus lowest quintile OR=0.76, 95% CI: 0.40-
1.44). This study included 81 cases of GCA.105 
 Two Swedish studies, by the same authors, have examined the association 
between dietary lignan intake and esophageal or GE junction adenocarcinoma.106,107 
In the case-control study, which included 181 EA cases and 255 GE junction 
adenocarcinoma cases, decreased risk of EA (OR=0.65, 95 % CI: 0.38-1.12) and GE 
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junction adenocarcinoma (OR=0.37, 95 % CI: 0.23-0.58) was found for the highest 
quartile of lignan intake compared to the lowest.107 However, in a cohort study there 
was no association found between lignan intake and EA or GE junction 
adenocarcinoma. This study was limited by small sample size of 83 cases of EA or 
GE junction adenocarcinoma.106     
 Summary. The association between flavonoids and EA/GCA risk has been 
studied previously.101-105 However, the sample sizes have been small; this can result 
in unstable effect estimates. No previous studies have been conducted examining 
survival among EA/GCA cases in relation to flavonoid intake. 
 
Role of Cell Cycle-Related Genes: Cyclin D1 and p53 
There is evidence that cyclin D1 (which regulates cellular proliferation, differentiation, 
and carcinogenesis)108 and p53 (which regulates cell cycle control, DNA repair, and 
apoptosis)109,110 mutations may reflect exposure to etiologic factors.84,108,111,112 Cyclin 
D1 regulates cell cycle in the mid to late G1 phase by phosphorylating retinoblastoma 
protein, which releases E2F and transitions to S-phase.113 Cyclin D1 has been 
implicated in EA and may be involved in the development of BE by predisposing the 
epithelium to malignant transformation.114 In the U.S. Multi-Center Study, 80 of 159 
(50.3%) esophageal adenocarcinomas (EA) and 55 of 149 (36.9%) gastric cardia 
adenocarcinomas (GCA) were positive for cyclin D1.108  
 P53 is a tumor suppressor that halts the cell cycle in the G1 and G2 phases to 
assess DNA damage. If damage has occurred, p53 determines if the damage is 
repairable or not. If the damage can be repaired, p53 triggers cell cycle arrest until 
reparation. If not, p53 triggers apoptosis. Mutations in this gene can result in check-
point errors.110 In the U.S. Multi-Center Study, p53 overexpression was detected in 
122 of 170 (71.8%) of EA and 102 of 147 (69.4%) of GCA.84 
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 An in vivo experiment has suggested that overexpression of cyclin D1 may be 
an early event in the tumorgenesis process for esophageal cancer in rats induced by 
the carcinogen 2,6-dimethylnitrosomorpholine (DMNM), by causing an increase in 
proliferation of esophageal stem cells. In this study, increased p53 expression began 
at the dysplastic stage of carcinogenesis.115 It was hypothesized that cyclin D1 is an 
initiating event during Barrett’s metaplasia, and abnormal p53 is required during 
dysplasia to promote the development of EA.113,115 
 Summary. Cyclin D1 and p53 are involved in tumor differentiation, 
proliferation and apoptosis,84,108,109,111,112 and mutations may reflect exposure to 
etiologic factors.84,108,111,112 We will examine if the association between flavonoids 
and EA/GCA varies by p53 or cyclin D1 overexpression. Categorizing cases by these 
markers was conducted to examine potentially etiologically distinct subgroups. 
 
Flavonoid use During Cancer Progression and Chemotherapy 
Carcinogenesis is characterized by multistage genetic and cellular changes, and this 
sequence of events has many points for intervention, with the purpose of preventing, 
slowing down, or reversing the process.116 Therefore, targets for chemoprevention could 
be multiple and could vary by stage – from initiation to promotion to progression.117 In a 
normal cell, targets for chemoprevention include scavenging reactive oxygen species 
and altering carcinogen metabolism. In an initiated cell, targets for chemoprevention 
include preventing further DNA damage and inducing apoptosis. In a preneoplasic cell, 
targets for chemoprevention include preventing further DNA damage, inducing cell-cycle 
arrest, inducing apoptosis, and inhibiting angiogenesis. In a tumor cell, targets for 
chemoprevention include preventing further DNA damage, inhibiting angiogenesis, and 
inhibiting invasion.116,117  
Flavonoids have been shown to have a wide array of cellular effects and can 
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influence the carcinogenic process during initiation, progression, and promotion.116 
However, some concerns have been raised about using antioxidants, such as 
flavonoids, for chemoprevention or chemotherapy. Some scientists have expressed 
concerns that antioxidants may not differentiate between healthy cells and tumor cells 
and may protect tumors from cytotoxic cancer treatments.118-120 In a breast cancer study 
where participants were given mega-doses of antioxidants, including beta-carotene, 
vitamin C, niacin, selenium, coenzyme Q10, and zinc, risk of breast cancer-specific 
mortality and breast cancer recurrence was increased for the group given the antioxidant 
vitamins and minerals compared to a group given standard therapy [hazard ratio 
(HR)=1.75, 95% CI: 0.83-2.69; 1.55, 95% CI: 0.94-2.54, respectively].121  
In addition to mortality, there are potential adverse effects from antioxidants in 
high-risk patients. In both the alpha-tocopherol, beta-carotene trial (ATBC) and β-
carotene and retinol efficacy trial (CARET), participants were at high-risk for lung cancer 
(i.e., participants in both trials were current or former heavy smokers and participants in 
CARET were also exposed to asbestos). Vitamins A and E were given to participants as 
a chemopreventive, but the chemoprevention had unintended consequences. 
Participants in both ATBC and CARET that were given vitamins A or E had higher risk of 
incident of lung cancer (HR=1.18, 95% CI: 1.03-1.36; HR=1.28, 95% CI: 1.04-1.57, 
respectively) and higher risk of mortality (HR=1.08, 95% CI: 1.01-1.16; HR=1.17, 95% 
CI: 1.03-1.33, respectively).122 While it is of interest to determine if there is potential to 
use flavonoids as a risk reduction or chemotherapy of these tumors, flavonoids will need 
to be carefully evaluated in the future for these therapy options. 
 Summary. The specific aims were to determine the association between 
flavonoids and incidence of esophageal and gastric tumors or survival among 
esophageal and gastric cancer cases. There could be potential to use flavonoids as 
a risk reduction strategy or chemotherapy of these tumors. This could allow some 
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esophageal and gastric cancer to be prevented before individuals develop these 
deadly cancers or offer support for use of flavonoids as novel chemotherapy drugs. 
While this study allowed investigation of these aims by utilizing data on dietary intake 
of flavonoids, care needs to be taken when thinking of utilizing flavonoids as a risk 
reduction or chemotherapy of these tumors in the future. There is potential, as 
evidenced by previous research with other antioxidants, that the use of flavonoids as 
a chemopreventive or chemotherapy could have unintended consequences.  
 
Esophageal and Gastric Cardia Adenocarcinoma Prognostic Factors 
As discussed above, EA and GCA are extremely lethal cancers, and there are very 
few factors that contribute to a better prognosis and survival benefit. However, 
several factors that have been explored include age, sex, BE, GERD, tumor location, 
stage, grade, dysphagia at presentation, weight loss, obesity, education, income, 
cigarette consumption, alcohol use, non-steroidal anti-inflammatory drugs (NSAIDs), 
type of surgical operation, and surgical complications.1,123 
 Demographic Factors. Non-modifiable factors of age, sex, and education 
have not been shown to have a prognostic impact on EA and GCA.1 In the U.S. 
Multi-Center Study,1 income was an important prognostic factor. The adjusted 
hazard ratio (HR) comparing individuals with ≥$15,000 income to those with 
<$15,000 income was 0.64 (95% CI: 0.48-0.87) for EA and 0.62 (95% CI: 0.43-0.88) 
for GCA. It was suggested that decreased survival among low income cases may 
indicate lack of access to medical care or death from other comorbidities.1  
 Epidemiologic Factors. Modifiable factors of cigarette consumption, alcohol 
use, and NSAIDs use also did not have a prognostic impact on EA and GCA.1 
However, adiposity and weight loss have been shown to be prognostic factors. The 
survival benefit from adiposity is complex, with overweight individuals having the 
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better overall survival compared to normal weight and obese individuals. This 
relationship between weight and survival was more defined for EA patients. 
Compared to normal weight participants (BMI <25 kg/m2), the adjusted HR for EA 
was 0.67 (95% CI: 0.51-0.88) for overweight participants (BMI 25-29.9 kg/m2) and 
0.78 (95%CI: 0.55-1.12) for obese participants (BMI 30+ kg/m2). Compared to 
normal weight participants, the unadjusted HR for GCA was 0.90 (95% CI: 0.67-1.20) 
for overweight participants and 0.98 (95% CI: 0.67-1.43) for obese participants.1 Pre-
treatment weight loss is thought to indicate advanced disease. Patients, including 
both EA and esophageal squamous cell carcinoma, with pre-treatment weight loss of 
>10% body weight had a worse prognosis than those without weight loss (HR=0.63, 
95% CI: 0.26-1.00).124  
 Medical Conditions/Clinical Characteristics. The presence of precursor 
lesions or dysphagia at diagnosis, as well as characteristics of the first primary such 
as tumor location, stage, and grade, have prognostic importance for patients with 
adenocarcinomas of the GE junction. Patients presenting with dysphagia have worse 
prognosis, likely reflecting an advanced disease.123 In a study of esophageal 
adenocarcinoma, tumors arising in BE were associated with better survival than 
tumors not arising in BE (overall 5-year survival 64% and 32%, respectively).125 
Tumors associated with BE are detected earlier, with smaller diameter and more 
differentiation. This suggests that tumors not associated with BE more advanced 
tumors that may have overgrown the BE.123 This is supported by a study where 79 
patients underwent endoscopy, biopsy, and neoadjuvant chemotherapy. Prior to 
chemotherapy, 59 patients (74%) had associated BE, and the other 20 patients 
exhibited no evidence of BE. After chemotherapy, BE was “unmasked” through 
biopsy or histopathological assessment in 18 of the 20 patients without signs of BE 
pre-treatment. This resulted in 97% of EA associated with BE.126  
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 Gastroesophageal reflux disease (GERD) has also been found to be 
associated with survival among patients diagnosed with GE junction cancers. 
Unadjusted HR comparing those with GERD to those without were 0.80 (95% CI: 
0.63-1.03) for EA and 0.74 (95% CI: 0.56-0.98) for GCA.1  
 Tumors located in the esophagus have better prognoses than tumors in the 
gastric cardia. This is thought to be because tumors might be detected in the 
esophagus due to screening or possibly because adenocarcinoma in the esophagus 
presents with dysphagia earlier than adenocarcinoma arising in the gastric cardia.123  
 As expected, stage is an important prognostic factor. Compared with distant 
stage, the adjusted HRs for regionalized, localized, and unknown stage, respectively, 
are 0.32 (95% CI: 0.23-0.45), 0.22 (95% CI: 0.15-0.31), and 0.42 (95% CI: 0.30-0.60) 
for EA and 0.48 (95% CI: 0.35-0.65), 0.18 (95% CI: 0.11-0.31), and 0.54 (95% CI: 
0.35-0.83) for GCA.1  
 Grade of the tumor did not appear to be as important. Compared to 
poor/undifferentiated tumors, the unadjusted HR for well/moderately differentiated 
tumors was 0.85 (95% CI: 0.65-1.11) for EA and 0.83 (95% CI: 0.62-1.10) for GCA.1 
 Summary. Prognostic factors of EA/GCA include income,1 adiposity,1 weight 
loss,124 BE,125 GERD,1 dysphagia,123 tumor location,123 stage,1 and grade.1  These 
prognostic factors were important to consider when designing the directed acyclic 
graph of the association between flavonoids and survival among EA/GCA cases, as 
these are potential confounders or intermediates of this association. Flavonoids may 
also reflect the presence of a tumor at a particular stage. The association between 
flavonoids and stage of EA/GCA was explored to examine potentially etiologically 
distinct subgroups. 
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Precursor Lesion of Esophageal/Gastric Cardia Adenocarcinoma:  
Barrett’s Esophagus 
 
The only known potential precursor of esophageal adenocarcinoma (EA) and gastric 
cardia adenocarcinoma (GCA) is Barrett’s esophagus (BE).2 EA appears to develop from 
normal mucosal lining through a sequence of pathologic events.42 Animal studies have 
shown that the squamous mucosa must be destroyed to allow for reepithelialization of 
the esophagus.127 The normal squamous mucosa is believed to be destroyed by chronic 
gastroesophageal reflux disease (GERD), which is an extremely common condition that 
affects 10-20% of individuals in Western countries. GERD is a digestive disease that is 
characterized by reflux of gastric contents, including gastric acid and potentially bile, into 
the esophagus.128 This reflux can cause ulceration of the esophagus, known as 
esophagitis,129 followed by development of Barrett epithelium, commonly referred to as 
BE.130 The important metaplastic change from GERD to BE is intestinal metaplasia, 
which can progress from low-grade to high-grade dysplasia. It is not known if BE is a 
necessary precursor of EA,42 but high-grade BE dysplasia will be detected with 
simultaneous EA approximately 25% of the time.128  
It has been postulated that gastric cardia adenocarcinoma (GCA) arises from a 
similar process where there is intestinal metaplasia of the gastric cardia;44,131-133 
however, this is still controversial.128 In a study focused on early-stage cancers in an 
attempt to avoid concealment of underlying intestinal metaplasia, intestinal metaplasia 
was detected in 96% (25 of 26 patients) of esophageal adenocarcinomas and 69% (11 
of 16 patients) of gastric cardia adenocarcinomas.131 
Studying precursor lesions, such as BE, provides insight into the etiology of 
cancer by elucidating key risk factors that act early in disease onset. However, not all 
precursor lesions develop into cancer. Therefore, understanding the mechanisms by 
which precursor lesions do result in cancerous tumors can offer an opportunity to 
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intervene and prevent disease progression. Further, studying the etiology of cancer 
closer to the time of exposure can allow for more accurate effect measure estimates. 
When outcomes are assessed further from the exposure, it is more difficult to measure 
associations because effect measure estimates tend to be diluted over time. In other 
words, lengthy follow-up, as is often the case with latency periods for cancers, can lead 
to attenuated estimates. Therefore, studying the time period closer to disease onset, 
such as with precursor  lesions, mitigates recall error and loss to follow-up.134 However, 
by studying the precursor lesion of BE versus EA/GCA, a different stage in the cancer 
process from initiation to promotion to progression could be examined. Risk factors for 
BE could be involved in initiation or promotion, while risk factors for EA/GCA could also 
be involved in progression of cancer. This could affect the interpretation of results if an 
association is seen between flavonoids and BE but not EA/GCA, or vice versa, as 
flavonoids may have an effect at different stages of the cancer process.135 
Summary. EA appears to develop from normal mucosal lining through a 
sequence of pathologic events.42 Normal squamous mucosa is thought to be destroyed 
by chronic GERD, which can cause esophageal ulceration followed by BE 
development.130 It is postulated that GCA arises from similar processes,131 but this is 
controversial.128 By studying the precursor lesion of BE, the association between 
flavonoids and the EA/GCA cancer continuum can be examined. Studying BE will also 
help mitigate recall error and loss to follow-up by studying the time period closer to 
disease onset.134 
 
Epidemiology of Barrett’s Esophagus Prevalence 
The incidence and prevalence of Barrett’s esophagus is not known with precision, 
partially because BE can be asymptomatic. As a nonmalignant tumor, BE is considered 
a prevalent condition because individuals can live with BE for years and not be 
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diagnosed. The average age of diagnosis is 63 years, but the estimated median age of 
onset is 40 years.51 However, it is estimated that there are approximately 86,000 new 
cases of BE diagnosed each year.136 
Between 1977 and 1996, newly diagnosed cases of BE increased 800-
3000%.137-139 This drastic increase was attributed to a real increase in incidence, 
increased knowledge of the condition by endoscopists, or both.137-139 Since 1996, newly 
diagnosed cases of BE has increased 150-200%.140,141 This increase is independent of 
the number of gastrointestinal endoscopies that are being performed.107,108 However, 
older studies show that BE was found when endoscopists looked for it. In a Swiss study 
of 4,950 endoscopies conducted between 1963 and 1971, 62 patients (1.25%) had 
BE.142 This is similar to the percentage of new cases of BE diagnosed during routine 
clinical endoscopies (1.5%), suggesting that the incidence of BE has not increased over 
the past 40 years.143  
Several studies have estimated the population prevalence of BE.144-154 However, 
one of the best estimates comes from a study conducted in two Swedish communities of 
3,000 randomly selected adults who underwent endoscopy and biopsy. BE was present 
in 1.6% of the subjects (95% CI: 0.8-2.4). Notably, the prevalence of BE was very similar 
between individuals who reported reflux symptoms and those who did not (2.3 v. 1.2%, 
respectively).144 Using this prevalence estimate, it is estimated that 3.3 million adults 
over 18 years of age in the U.S. have prevalent BE.155 The estimate of BE prevalence 
from the Swedish study is similar to a study of two Italian villages of 1,033 people where 
1.3% were found to have BE. Reflux symptoms were a poor predictor of BE in this study 
as well, as only 53.8% of participants found to have BE reported reflux symptoms.154 
However, a recent study estimated prevalence using modeling techniques to determine 
the prevalence of BE needed to simulate SEER incidence rates for EA. From this model, 
the estimated prevalence for BE in the general U.S. population was 5.6% (95% CI: 5.5-
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5.7).156 Using this prevalence estimate with the 2000 U.S. Census estimates,157 it is 
estimated that 11.7 million adults over 18 years of age in the U.S. have prevalent BE.  
Summary. BE is the only known precursor of EA/GCA,2 whose incidence in the 
U.S. and other Western countries is increasing rapidly.5,8,9,39 Therefore, it is of 
importance to determine the risk factors for BE because of the increasing incidence of 
EA/GCA in the U.S. Specifically, it is of interest to determine if flavonoids can be used as 
a risk reduction strategy for BE. 
 
Barrett’s Esophagus Risk Factors 
Medical Conditions/Clinical Characteristics. GERD. The main risk factor of BE is 
GERD symptoms.51,158-160 Liberman et al. studied the risk of BE with a history of reflux 
symptoms. Individuals with a longer history of reflux symptoms, compared to individuals 
without a history of reflux symptoms, had increased odds of having BE: odds ratio (OR) 
of 3.0 (95% CI, 1.2–8.0) for a 1- to 5-year history, OR of 5.1 (95% CI, 1.7–14.7) for 5- to 
10-year history, and OR of 6.4 (95% CI, 2.4–17.1) for more than 10 years.160  
 Hiatal Hernia. BE occurs more frequently among individuals with a hiatal hernia, 
which is a condition where the stomach protrudes through an opening in the diaphragm 
into the chest cavity.161,162 A recent study of 48 BE patients and 103 controls found 2 cm 
or longer hiatal hernia in 96% of BE patients and 42% of controls, and the authors 
concluded that hiatal hernia likely contributes to the development of BE.162  
Demographic Factors. Non-modifiable risk factors for BE include age,51,146,163 
race,51,164,165 gender,51,146 and low socioeconomic status.166 Age of more than 40 years is 
an independent predictor of BE,163 and the prevalence of BE increases with age until it 
plateaus in 60-69 year olds.146 As with EA and GCA, BE is more common in Caucasians 
and males. In patients undergoing endoscopy in the Clinical Outcomes Research 
Initiative database, suspected BE was detected in 7.8% of Caucasians, 4.8% of 
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Hispanics, 1.3% of Asian-Americans, and 1.1% of African-Americans.155 The 
male:female sex ratio for BE ranges from 1.7:1 to 4:1.51 In a study by Kubo et al., they 
showed that individuals with at least a college education compared to individuals with 
high school or less education had a decreased risk of BE (OR=0.47, 95% CI: 0.27-0.82) 
and individuals with an income of >$75,000 compared to individuals with an income of 
<$50,000 were at a decreased risk of BE (OR=0.68, 95% CI: 0.42-1.11).166 
Epidemiologic Factors. Obesity. Obesity is another risk factor for BE that has 
received attention.51,167,168 In the Study of Reflux Disease, Edelstein et al. showed that 
overweight and obese individuals, compared to normal weight, were at an increased risk 
of BE (adjusted OR=1.6, 95% CI: 0.9-2.8 and 2.6, 95% CI: 1.5-4.4, respectively) and 
individuals with a high, compared to low, waist-to-hip ratio (WHR) were also at an 
increased risk of BE (adjusted OR=2.4, 95% CI: 1.4-3.9). When BMI and waist-to-hip 
ratio were adjusted for each other, the estimate for BMI was more attenuated than the 
estimate for WHR.169 This suggests that central obesity could be more important to the 
development of BE, potentially through hiatal hernia, intragastric pressure promoting 
reflux, or high levels of insulin.170  
Cigarette Smoking. Although cigarette smoking is a risk factor for esophageal 
adenocarcinoma, the association between cigarette smoking and BE is not clear, but 
there is a suggested trend of increasing risk with increasing pack-years of smoking and 
increased risk of BE for current smokers, compared to never smokers (adjusted 
OR=1.27, 95% CI: 0.74-2.17).171 
 Aspirin. Risk reduction factors against these tumors include non-steroidal 
anti-inflammatory drugs (NSAIDs) and other COX-2 inhibitors,172 fruits and 
vegetables,21,26,27 and dietary antioxidants, including vitamin C and vitamin E.173 A 
case-control study conducted in Ireland found that use of NSAIDs or aspirin, at least 
1 year prior to interview, was associated with a decreased risk of BE (OR=0.40, 95% 
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CI: 0.19-0.81 and 0.53, 95% CI: 0.31-0.90, respectively).172  
 Dietary Intake. In the Study of Reflux Disease, researchers showed that 
individuals in the second and third tertile of fruit and vegetable intake had a lower risk 
of BE than individuals in the lowest tertile of intake (adjusted OR=0.40, 95% CI: 0.23-
0.71 and 0.33, 95% CI: 0.17-0.63, respectively).26 In a case-control study conducted 
at Kaiser Permanente Northern California, individuals with high intakes of vitamin C 
or E were found to have a decreased risk of BE (4th versus 1st quartile, adjusted 
OR=0.48, 95% CI: 0.26-0.90 and 0.25, 95% CI: 0.11-0.59, respectively).27 
 Summary. Risk factors for BE include GERD,51,158-160  hiatal hernia,161,162 
age,51,146,163 race,51,164,165 gender,51,146 low socioeconomic status,166 obesity,51,167,168 
and potentially cigarette smoking.171 Risk reduction factors against these tumors 
include non-steroidal anti-inflammatory drugs (NSAIDs) and other COX-2 
inhibitors,172 fruits and vegetables,21,26,27 and dietary antioxidants, including vitamin C 
and vitamin E.173 These risk factors were important to consider when designing the 
directed acyclic graph of the association between flavonoids and BE risk, as these 
are potential confounders or intermediates of this association. 
 
Flavonoids and Barrett’s Esophagus: Biologic Mechanisms  
Few studies have looked at the biological mechanisms of how flavonoids affect 
Barrett’s esophagus. In an in vitro study, mentioned above, researchers looked at BE 
cells and found that Polyphenon E, a flavan-3-ol derived from green tea, inhibited 
growth and down-regulated the expression of cyclin D1 protein in BE cells.95 One 
animal study, also mentioned above, has shown that a synthetic flavone, 
Flavopiridol, reduces the development of BE. In this study, mice were exposed to a 
carcinogen that is known to induce esophageal cancer. Prevalence of BE in 
experimental mice was 7% compared to 26% in control mice (p=0.008).100 
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 Summary. Experimental studies have shown that some classes of flavonoids 
have important chemopreventive effects against BE.95,100 This gives biological 
plausibility to the hypothesis of an inverse association between flavonoid intake and 
BE risk. Demonstration of an association between flavonoids and BE development 
suggests potential to use flavonoids as a risk reduction strategy. 
 
Epidemiology of Flavonoids and Barrett’s Esophagus 
One epidemiological investigation to date has examined the association between dietary 
flavonoid intake and risk of Barrett’s esophagus.174 This case-control study of 151 
Barrett’s esophagus cases from the Veterans Affairs Medical Center in Houston, Texas, 
considered one flavonoid class, isoflavones, and found an inverse association (highest 
versus lowest tertile OR=0.45, 95% CI: 0.25-0.81).174  
Summary. One previous study174 has reported on the association between 
isoflavone intake and BE. However, intake of isoflavone-containing foods in the United 
States is limited. The other five flavonoid classes are found in foods more commonly 
consumed by Americans,175 yet their associations with BE have not been considered. 
 
Barrett’s Esophagus: Natural History 
Although BE patients have a 125-fold greater risk of EA/GCA, the probability that BE 
will develop into adenocarcinoma is still rare – incidence of cancer is 1 out of 227 BE 
patient-years of follow-up.176 Therefore, it is of interest to determine which BE 
patients will progress to EA/GCA. A recent review examined this question and 
discussed the use of chromosome abnormalities as markers of BE that will 
progress.177 One study of note was a cohort of BE patients that were followed for the 
outcome of EA.83 The baseline biopsies were examined for 9p loss of heterozygosity 
(LOH), 17p LOH, DNA content abnormalities (teteraploidy and aneuploidy), TP53 
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mutation, and CDKN2A mutation and methylation. While at 10-years follow-up 
everything except CDKN2A mutation and methylation contributed to EA risk in 
univariate analyses, the chromosome instability panel of 9p LOH, 17p LOH, DNA 
content abnormalities was found to be the best predictor of EA (HR=38.7, 95% CI: 
10.8-138.5) compared to participants with no baseline abnormalities. At 10-years of 
follow-up, 3 of 85 (3.5%) participants without baseline abnormalities developed 
incident EA and 14 of 22 (63.6%) participants with the chromosome instability panel 
of three baseline abnormalities developed EA.83 
 Another characteristic of BE that is related to the risk of developing EA/GCA 
is BE segment length.10 Long-segment BE (LSBE) is defined as specialized intestinal 
metaplasia (SIM) and visible column epithelium greater than or equal to 2 or 3 cm 
(definitions vary).169,178 Similarly, short-segment BE (SSBE) is defined as SIM and 
visible column epithelium less than 2 or 3 cm (definitions vary).169,178 In a study of 
889 patients utilizing the LSBE definition of ≥3 cm, dysplasia or EA/GCA was noted 
in 31% of LSBE and only 10% of SSBE.178 
 Summary. Unfortunately, categorization of BE participants by chromosome 
abnormalities was not possible, as these were not determined for the parent BE 
study. This will be an important categorization for future studies. However, 
categorization of individuals by BE segment length was conducted and allowed 
examination of potentially etiologically distinct subgroups. 
 
Esophageal Squamous Cell Carcinoma and Non-cardia Gastric 
Adenocarcinoma 
 
Esophageal and gastric cardia adenocarcinoma is of particular interest due to rapidly 
increasing incidence in the U.S. and other Western countries3-7 and a highly 
prevalent precursor lesion,144-154 which aids in identifying optimal times along the 
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cancer continuum to target for intervention with specific chemopreventives to 
enhance risk reduction. However, esophageal squamous cell carcinoma (ESCC) and 
non-cardia gastric adenocarcinoma (NCGA) are significant to study because they are 
the most common forms of esophageal and gastric cancer worldwide.8,37 
 
Esophageal Squamous Cell Carcinoma/Non-cardia Gastric Adenocarcinoma  
Risk Factors 
 
ESCC: Medical Conditions/Clinical Characteristics. Squamous Dysplasia. 
Similarly to EA, ESCC has a precursor lesion, squamous dysplasia, which increases 
individuals’ risk of ESCC.179,180 In a study by Wang et al. in a high-risk Chinese 
population with 13 years of follow-up, the risk of ESCC increased along the 
squamous dysplasia continuum, from mild dysplasia [adjusted hazard ratio (HR)=2.9, 
95% CI: 1.6-5.2] to moderate dysplasia (HR=9.8, 95% CI: 5.3-18.3) to severe 
dysplasia (HR=28.3, 95% CI: 15.3-52.3) to carcinoma in situ (HR=34.4, 95% CI: 
16.6-71.4).181 
 Human Papillomavirus (HPV). There is some evidence that HPV may be 
involved in the etiology of ESCC. A review reported that 22.9% and 15.2% of ESCC 
cases were positive for HPV when tested by in situ hybridization and polymerase 
chain reaction, respectively.182 A more recent meta-analysis reported the average 
HPV prevalence in ESCC  cases of 27.7% (95% CI: 23.4-32.0%) by polymerase 
chain reaction; 24.3% (95% CI: 15.9-32.6%) by in situ hybridization; 30.4 (95% CI: 
18.5-42.3%) by immunohistochemistry; 32.2% (95% CI: 15.4-49.0%) by L1 serology; 
and 17.6% (95% CI: 6.1-29.2%) by Southern/slot/dot blot.183 
 ESCC: Epidemiologic Factors. Tobacco and Alcohol. The primary 
modifiable risk factors for ESCC are tobacco and alcohol use. Cigarette use is more 
strongly associated with ESCC than EA.28 The NIH–AARP Diet and Health Study 
investigated the association between cigarette use and ESCC. The risk of ESCC 
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among current smokers was increased almost 10-fold compared to non-smokers 
(HR=9.27, 95% CI: 4.04-21.29).184 In the U.S. Multi-Center Study, researchers found 
a 5-fold increase of ESCC (OR=5.1, 95% CI: 2.8-9.2) for current smokers compared 
to never smokers.67 This study also estimated the risk of ESCC in alcohol users, 
considered as consuming at least one drink per month, more than a year prior to 
diagnosis. Ever drinkers were at a higher risk of ESCC than never drinkers (OR=3.5, 
95% CI: 1.9-6.2).67 It has also been shown that tobacco and alcohol act 
synergistically.28  
 Aspirin. Two risk reduction factors for ESCC that have been consistent in the 
literature are fruit and vegetable intake and non-steroidal anti-inflammatory drug 
(NSAID) use.28 A meta-analysis of the association between NSAID use and ESCC 
found that any use of NSAIDs compared to no use reduced risk of ESCC (OR=0.58, 
95% CI: 0.43-0.78).185  
 Dietary Intake. Most studies conducted have found an inverse association 
between high intake of fruits and vegetables and ESCC.28 The U.S. Multi-Center 
Study showed that increasing total fruit and vegetable intake by one serving per day 
resulted in an OR of 0.90 (95% CI: 0.82-0.99) for ESCC.15 
 ESCC: Demographic Factors. Non-modifiable risk factors for ESCC include 
low socioeconomic status (SES), age, race, and sex.28 In a 1939 case series of 
ESCC, it was noted that ESCC was primarily a cancer found among lower SES.28,186 
For participants in the U.S. Multi-Center Study with an income greater than $75,000 
compared to those with an income of less than $15,000 per year, the OR was 0.2 
(95% CI: 0.1-0.6).67  Age over 60 years is a risk factor for ESCC.187 Unlike EA, ESCC 
has the highest rates among African-American males. Among African-Americans, 
ESCC accounts for approximately 87% of esophageal cancer but only 45% in 
Caucasians.188 Between 1992 and 2005 in SEER 13 data, the male-to-female 
33 
incidence rate ratio was about 2 in Caucasians and 3 in African-Americans. The 
rates for ESCC are over four-fold higher among African-American men compared to 
Caucasian men (rate per 100,000: 9.4 versus 2.1).188 
 NCGA: Medical Conditions/Clinical Characteristics. Helicobacter pylori 
and Gastric Ulcers. NCGA has been associated with H. pylori infection and gastric 
ulcers.189 A recent nested case-control study conducted in Norway found that for 
NCGA the odds ratio was 4.75 (95% CI: 2.56-8.81) for H. pylori positive compared to 
negative.190 The U.S. Multi-Center Study found that gastric ulcers were associated 
with an increased risk of NCGA (OR=2.1, 95% CI 1.4-3.2).191 
 NCGA: Demographic Factors. Non-modifiable risk factors associated with 
non-cardia gastric adenocarcinoma include low socioeconomic status, age, race, and 
sex. Low socioeconomic status has been associated with gastric adenocarcinoma in 
many studies.189 For participants in the U.S. Multi-Center Study with an income 
greater than $75,000 compared to those with an income of less than $15,000 per 
year, the adjusted OR for NCGA was 0.5 (95% CI: 0.2-0.9).67 Risk of NCGA 
increases with age; risk of NCGA is 6-7 times higher among 60-84 years old than 
among 40-59 year olds.192 Similarly to ESCC, the rates of NCGA are highest for 
African-American males. Incidence rates of NCGA are approximately twice as high in 
African-Americans compared to Caucasians [incidence rate ratio (IRR)=2.35, 95% 
CI: 2.25-2.45] and men compared to women (IRR for women versus men=0.56, 95% 
CI: 0.54-0.57).193 
 NCGA: Epidemiologic Factors. Tobacco and Alcohol. While the literature 
has been somewhat inconsistent on the association between NCGA and tobacco 
use,189 the U.S. Multi-Center Study found that current cigarette smokers have an 
increased risk of NCGA compared to non-smokers (OR=1.8, 95% CI: 1.2-2.7).67 
Alcohol consumption is primarily associated with GCA, and there has not been 
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convincing evidence of an association between alcohol and NCGA.67,189,194 
 Aspirin. In a recent meta-analysis of the association between NSAIDs and 
NCGA, researchers found both aspirin (OR=0.64, 95% CI: 0.52-0.80) and other NSAID 
use (OR=0.80, 95% CI: 0.67-0.95) to be risk reduction factors for NCGA.86  
Dietary Intake. Modifiable dietary risk reduction factors for NCGA include fruit 
and vegetable intake and vitamin C intake; dietary risk factors include salted foods and 
nitrates/nitrosamines. While the literature on gastric cancer has consistently shown a risk 
reduction with higher levels of fruit and vegetable intake,189 recent studies differentiating 
between GCA and NCGA have not found strong risk reduction by fruits and vegetables 
for NCGA.14,15 Thus far, vitamin C has been the micronutrient most consistently 
associated with a reduction in risk of gastric cancer.189 In the U.S. Multi-Center Study, 
vitamin C, both from food sources and supplements, was found to decrease the risk of 
NCGA (highest versus lowest quartile OR=0.59, 95% CI: 0.45-0.76 and 0.60, 95%CI: 
0.41-0.88, respectively).91  
Salted Foods. Salt and salted foods have long been associated with gastric 
cancer.189 The U.S. Multi-Center Study found that high sodium intake in the diet 
increased risk for NCGA (highest versus lowest quartile OR=1.46, 95% CI: 1.00–2.15).91 
Nitrites and N-nitroso compounds have been found to carcinogenic in animal 
models.189,195 In the U.S. Multi-Center Study, both meats high in nitrite (adjusted OR for 
increase of 1 serving/day=1.88, 95% CI: 1.24-2.84)15 and diets high in nitrite (highest 
versus lowest quartile OR=1.64, 95% CI: 1.30-2.07) were associated with an increased 
risk of NCGA.91 
 Summary. Risk factors of ESCC include squamous dysplasia,179,180 tobacco 
and alcohol use,67 low SES,28 age,28 race,28 and sex.28 Risk reduction factors for 
ESCC are fruit and vegetable intake and non-steroidal anti-inflammatory drug 
(NSAID) use.28 Risk factors of NCGA include H. pylori and gastric ulcers,189 low 
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SES,67 age,192 race,193 sex,193 cigarette smoking,67 and salted foods.91 Risk reduction 
factors for NCGA include NSAIDs86 and vitamin C intake.189 These risk factors were 
important to consider when designing the directed acyclic graph of the association 
between flavonoids and ESCC and NCGA risk, as these are potential confounders or 
intermediates of this association. 
 
Flavonoids and Esophageal Squamous Cell Carcinoma/Non-cardia Gastric 
Adenocarcinoma: Biologic Mechanisms 
 
All flavonoid classes (anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols, 
and isoflavones) have been directly linked to ESCC or NCGA in laboratory 
experiments, as discussed below. 
Anthocyanidins. In ESCC research, a group from the Ohio State University 
demonstrated that freeze-dried berries (black and red raspberries, blackberries, 
strawberries, blueberries, noni, açaí and wolfberry) inhibited 24-56% of the formation of 
esophageal tumors in rats caused by N-nitrosomethylbenzylamine (NMBA),196,197 which 
has long been long been used to model ESCC in rats. Then they also evaluated two 
anthocyanidin compounds and found that black raspberries inhibited growth, induced 
apoptosis, and controlled gene expression in rat esophageal epithelial cells. 
Researchers found that the anthocyanidins inhibited proliferation, induced apoptosis, 
and down-regulated the expression of cyclooxygenase-2 (COX-2) and nitric oxide 
synthase (iNOS) genes.198 Finally, the group tested various diets in rats, including one 
with black raspberry powder and one rich in anthocyanidins. The diet of black raspberry 
powder and anthocyanidin-rich diet were almost equally effective in preventing NMBA-
induced esophageal cancer in rats, suggesting that anthocyanidins are the main 
chemopreventive in the black raspberry powder.199 
 In gastric cancer research, an in vitro study of gastric cancer cells found that 
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berry juice (mixture of strawberry, raspberry, black currant, red currant, white currant, 
gooseberry, high-bush blueberry, low-bush blueberry, velvet leaf blueberry, 
serviceberry, blackberry, black chokeberry, sea buckthorn, and cranberry) produced 
cell-cycle arrest through down-regulation of cdk4, cdk6, cyclin D1 and cyclin D3 
expression and inhibited TNF-induced activation of COX-2 expression.200 Similarly, 
Shih et al. in an in vitro study of human gastric cells found that anthocyanidins, 
specifically malvidin, inhibited proliferation and induced apoptosis.201 
 Flavan-3-ols. A study using human gastric cancer cells demonstrated that six 
active flavan-3-ols [epicatechin (EC), epigallocatechin (EGC), epigallocatechin 
gallate (EGCg), gallocatechin (GC), epicatechin gallate (ECg), gallocatechin gallate 
(GCg)] had inhibited proliferation of gastric cancer cells. EGCg and GCg had the 
highest levels of antiproliferative activity.202 
 Flavanones. In ESCC studies, another model for ESCC in rats is using N-
methyl-N-amylnitrosamine (MNAN) to produce esophageal tumors. Rats given the 
flavanone hesperidin had a 40% decrease in incident ESCC, compared to the control 
group (45% versus 75%).203  
In an in vitro gastric cancer study, flavanones down-regulate b-catenin/T-cell 
factor (Tcf) transcriptional target gene cyclin D1 through modulation of Tcf activity.204 
The group that conducted this study from Seoul National University also looked at a 
specific flavanone, naringenin, and found that it inhibited b-catenin/Tcf signaling in a 
gastric cancer cell line.205 Another study group also examined naringenin in gastric 
cancer induced by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and saturated sodium 
chloride (S-NaCl) in rats. The researchers found that naringenin has chemopreventive 
action against gastric cancer in rats,206 naringenin could potentially prevents damage of 
cell membranes and gastric mucosa by oxidative damage,207 and up-regulation of 
antioxidants by naringenin might be responsible for the chemopreventive effects seen in 
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rats.208 
 Flavones. In a study of ESCC induced by benzo[a]pyrene (BaP) in human 
esophageal epithelial cells, researchers found that flavones inhibited BaP-induced 
CYP1B1 (an enzyme important in smoking-induced esophageal cancer) 
transcription, showing that flavones might be a potential chemopreventive for 
ESCC.209 The same group that investigated the cytotoxic effects of flavones and 
flavonols in EA also examined these for ESCC. In human ESCC cells, flavones, 
specifically luteolin, apigenin, and chrysin, induced cytotoxicity, which was mediated 
by G(2)/M cell cycle arrest and apoptosis. Of the flavones, luteolin had the most 
cytotoxic potency.210 In a study mentioned above, researchers also tested the 
flavone diosmin and found that it decreased incident MNAN associated ESCC by 
46% (75% versus 29%).203 Another study also examined specific types of flavones, 
including baicalein, baicalin, and luteolin, and found that baicalein and luteolin had 
the strongest anti-proliferative effects against gastric carcinoma.211  
 In gastric cancer research, a study of the flavone nobiletin found that nobiletin 
prevented the dissemination of gastric adenocarcinoma to the peritoneum, which 
happens in the final stages of gastric adenocarcinoma, in mice.212 Another study of 
nobiletin in vitro found that nobiletin had antiproliferative effects, induced apoptosis, 
and down-regulation of the cell cycle in human gastric adenocarcinoma cells.213 The 
flavone acacetin inhibited cellular proliferation and induced apoptosis characterized 
with changes in nuclear morphology, DNA fragmentation, and cell morphology in 
human gastric carcinoma cells.214 The flavone apigenin inhibited growth, clone 
formation, and proliferation of human gastric carcinoma cells.215 Luteolin, a flavone, 
inhibited the growth of human gastric cancer cells.216 Similarly, luteolin and daidzein 
inhibited cell cycle progression at G1 in human gastric carcinoma cells.217 
 Flavonols. In a ESCC study mentioned above, researchers found that 
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flavonols, specifically quercetin, kaempferol, and myricetin, induced cytotoxicity in 
human ESCC cells, which was mediated by G(2)/M cell cycle arrest and apoptosis. 
Of the flavonols, quercetin had the most cytotoxic potency.210 Additionally, 
isorhamnetin, which is a metabolite of quercetin, has been found to inhibit 
proliferation and induce apoptosis in a human ESCC cell line.218 
 Quercetin has been shown to inhibit the growth of malignant human gastric 
cancer cells, suppress DNA synthesis, and block cell cycle progression.219 Another 
study also showed that quercetin inhibited growth and induced apoptosis of human 
gastric carcinoma cells. The mechanism for this is thought to be down-regulation of 
p53 and C-myc protein expression and the up-regulation of p16 expression by 
quercetin.220 
 Isoflavones. In esophageal squamous cell lines, soybean isoflavone was 
shown to induce apoptosis, possibly mediated by down-expression of gene bcl-2 and 
up-expression of gene bax.221 A study of human gastric adenocarcinoma and ESCC 
cells in vitro tested seven isoflavones (biochanin A, daidzein, genistein, genistin, 
prunectin, puerarin, and pseudobaptigenin) for their chemopreventive effects. Gastric 
adenocarcinoma proliferation was strongly inhibited by biochanin A and genistein, 
and ESCC proliferation was moderately suppressed by these isoflavones.222 
 Genistein has been shown to have chemopreventive effects in human gastric 
carcinoma cells; genistein inhibited cell cycle progression at G2-M,217,223 induced 
apoptosis,224,225 inhibited growth223,225 and proliferation,223 decreased cyclin D1 
protein expression,223 and enhanced cyclin B1 and p21(waf/cip1) protein 
expression.223 One study showed that in seven days with the highest dose (20.0 
microg/mL), the growth inhibitory rate was 84.7%.223 In rats with gastric 
carcinogenesis induced by MNNG, genistein increased apoptosis and lowered 
cellular proliferation for gastric cancer.226  
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 Summary. Experimental studies have shown that all classes of flavonoids 
have important chemopreventive effects against ESCC or NCGA. This gives 
biological plausibility to the hypothesis of an inverse association between flavonoid 
intake and ESCC and NCGA incidence and survival among ESCC and NCGA cases. 
Demonstration of an association between flavonoids and incidence of ESCC and 
NCGA or survival among ESCC and NCGA cases suggests potential to use 
flavonoids as a risk reduction strategy for these cancers. 
 
Epidemiology of Flavonoids and Esophageal Squamous Cell Carcinoma/Non-cardia 
Gastric Adenocarcinoma 
 
The European Prospective Investigation into Cancer and Nutrition examined the 
association between flavonoid intake and esophageal and gastric cancer, stratifying 
by histology (i.e., adenocarcinoma versus squamous cell carcinoma for esophageal 
cancer) and anatomic subsite (i.e., cardia versus non-cardia for gastric cancer).103,104 
No associations were found in the main analyses. There was suggestion of total 
flavonoids being associated with decreased risk of gastric cancer in women and 
esophageal cancer in current smokers. When results were stratified by histology or 
anatomic subsite, risk reductions were not detected for ESCC or NCGA possibly due 
to small sample size (ESCC n=176, NCGA n=323).99,100 
 Another recent study to examine the association between ESCC and 
flavonoid intake was by Bobe et al.101 This study examined the effect of total 
flavonoid intake separately for Caucasians and African-Americans (highest versus 
lowest quartile OR=1.19, 95% CI: 0.50-2.81; OR=0.72, 95% CI: 0.35-1.46, 
respectively). The authors found an inverse association among whites between 
ESCC and isoflavones (highest versus lowest quartile OR=0.43, 95% CI: 0.20-0.93). 
This study had a limited sample size (114 Caucasian cases and 218 African-
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American cases of ESCC) to examine this association, though.101 One other study of 
the association between ESCC and total dietary flavonoid intake has been 
conducted in Italy and did not show an association between total flavonoids and 
ESCC (highest versus lowest quintile OR=0.99, 95% CI: 0.55-1.79), but it did shown 
an inverse association between flavanones and ESCC (highest versus lowest 
quintile OR=0.38, 95% CI: 0.23-0.66). This study had a sample size of 304 cases 
and 743 controls.227  
 Another study examined all upper aerodigestive tract cancers (UADC) in 
Uruguay, including esophageal (n=66), oral cavity and pharyngeal (n=33), and larynx 
cancer cases (n=34), and found an association between total flavonoids and UADC 
(highest versus lowest tertile OR=0.3, 95% CI: 0.1-0.5).228 Additionally, a study in 
Shanghai, China, used a nested case-control study to determine the association 
between prediagnostic urinary tea polyphenol markers and risk of esophageal (42 
cases) and gastric cancer (190 cases). Among esophageal and gastric cancers that 
developed four years or more after enrollment, there was an inverse association 
between epigallocatechin positivity, a flavan-3-ol, and esophageal/gastric cancer risk 
(OR=0.58, 95% CI: 0.34-0.98).229 
 The only other study of total dietary flavonoids and gastric adenocarcinoma 
(GA) was conducted by Lagiou et al., mentioned above. This study did not find an 
association between total flavonoids and GA risk, but did find an inverse association 
between one class of flavonoids, flavanones, and GA risk (per one standard 
deviation increase in intake OR=0.55, 95% CI: 0.31-0.96). However, the study 
examined all adenocarcinoma of the stomach and did not consider anatomic 
subsites (i.e., cardia or non-cardia), and it was also limited by small sample size (100 
cases of GA).102 Two other studies examined the association between flavonoids or 
lignans and overall gastric cancer risk.105,230 A study in Mexico City did not find an 
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association between total flavonoids or lignans and gastric cancer risk, but the 
authors did find an inverse association between one type of lignan, 
secoisolariciresinol, and gastric cancer risk (highest versus lowest tertile OR=0.42, 
95% CI: 0.27-0.65).230 The other study was conducted in Sweden and looked at the 
association between quercetin, a flavonol, and gastric adenocarcinoma risk, both by 
cardia and non-cardia type. The study reported an inverse association between 
quercetin and NCGA (highest versus lowest quintile OR=0.57, 95% CI: 0.40-0.83). 
This study included a large sample size (420 cases of NCGA).105 
 Summary. There have been several epidemiologic studies to examine the 
association ESCC or NCGA and flavonoids. With two notable exceptions,105,227 the 
majority of these studies have been limited by small sample size, which can result in 
unstable effect estimates. No previous studies have been conducted examining 
survival among ESCC or NCGA cases in relation to flavonoid intake. 
 
Role of Cell Cycle-Related Genes: Cyclin D1 and P53 
Both cyclin D1 and p53 have roles controlling cell cycle and cancer progression. 
Multiple studies indicate that cyclin D1 and p53 overexpression predict poor ESCC 
prognosis and some studies additionally show that cyclin D1 and p53 could be used 
as independent prognostic factors.231  The U.S. Multi-Center Study found that 91 of 
117 (77.8%) ESCC and 59 of 205 (28.8%) NCGA were positive for cyclin D1.108 In 
this same study, the authors reported 75 of 112 (67.0%) ESCC and 114 of 220 
(51.8%) NCGA overexpressed p53.84  
 An in vivo experiment has suggested that overexpression of cyclin D1 may be 
an early event in the tumorgenesis process for esophageal cancer in rats induced by 
the carcinogen 2,6-dimethylnitrosomorpholine (DMNM), by causing an increase in 
proliferation of esophageal stem cells. In this study, increased p53 expression began 
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at the dysplastic stage of carcinogenesis. It was hypothesized that cyclin D1 is an 
initiating event during metaplasia, and abnormal p53 is required during dysplasia to 
promote the development of esophageal cancer.115  
 Summary. Cyclin D1 and p53 are involved in tumor differentiation, 
proliferation and apoptosis,84,108,109,111,112 and mutations may reflect exposure to 
etiologic factors.84,108,111,112 The association between flavonoids and ESCC or NCGA 
was examined by p53 and cyclin D1 status. Categorizing cases by these markers 
was conducted to examine potentially etiologically distinct subgroups. 
 
Esophageal Squamous Cell Carcinoma/Non-cardia Gastric Adenocarcinoma 
Prognostic Factors 
 
Similar to EA/GCA, ESCC and NCGA are extremely lethal cancers, and there are 
very few factors that contribute to a better prognosis and survival benefit. However, 
several factors that have been explored include age, sex, stage, grade, obesity, 
education, income, cigarette smoking, alcohol use, non-steroidal anti-inflammatory 
drugs (NSAIDs), esophageal cancer type, and perioperative chemotherapy.1,232 
 Demographic Factors. Age has not been shown to have a prognostic impact 
on ESCC or NCGA.1 In the U.S. Multi-Center Study,1 sex, education, and income 
were important non-modifiable prognostic factors for ESCC, but these were not 
shown to have a prognostic impact on NCGA. Women with ESCC had a better 
prognosis than men (adjusted HR=0.61, 95% CI: 0.42-0.88), and individuals with 
higher education (more than high school versus less than high school adjusted 
HR=0.79, 95% CI: 0.59-1.05) and higher income (≥$15,000 versus <$15,000 
adjusted HR=0.74, 95% CI: 0.55-0.99) had better prognosis. It was suggested that 
decreased survival among low income cases may indicate lack of access to medical 
care or death from other comorbidities.1  
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 Epidemiologic Factors. Cigarette smoking did not have a prognostic impact 
on ESCC or NCGA.1 The U.S. Multi-Center Study reported that modifiable factors of 
alcohol consumption and NSAID use had a prognostic impact on ESCC but not 
NCGA.1 Adiposity and weight loss have also been shown to be prognostic factors for 
both ESCC and NCGA.1,124 For ESCC, ever having consumed alcohol (defined as ≥1 
alcoholic drink per month for ≥6 months), compared with never, was associated with 
poorer prognosis (adjusted HR=1.77, 95% CI: 0.93-3.35), and ever using NSAIDs 
(defined as ≥1 tablet of aspirin or non-aspirin NSAIDs per week for ≥6 months), 
compared with never, was associated with better prognosis (adjusted HR=0.79, 95% 
CI: 0.57-1.11).1  
 The survival benefit from adiposity for ESCC and NCGA is complex, with 
overweight individuals generally having the better overall survival compared to 
normal weight and obese individuals. This relationship between weight and survival 
is more complex for ESCC patients. Compared to normal weight participants (BMI 
<25 kg/m2), the adjusted HR for ESCC was 0.90 (95% CI: 0.67-1.20) for overweight 
participants (BMI 25-29.9 kg/m2) and 1.24 (95%CI: 0.70-2.20) for obese participants 
(BMI 30+ kg/m2). Compared to normal weight participants, the unadjusted HR for 
NCGA was 0.68 (95% CI: 0.53-0.87) for overweight participants and 0.77 (95% CI: 
0.53-1.11) for obese participants.1 Pre-treatment weight loss is thought to indicate 
advanced disease. Patients, including both EA and ESCC, with pre-treatment weight 
loss of >10% body weight has been shown to have worse prognosis than those 
without weight loss (HR=0.63, 95% CI: 0.26-1.00).124  
 Medical Conditions/Clinical Characteristics. Histologic type, stage, and 
grade have prognostic importance. Compared with EA, ESCC has a worse prognosis 
(EA versus ESCC HR=0.44, 95% CI: 0.23-0.83).232 As expected, stage is an 
important prognostic factor. Compared with distant stage, the adjusted HRs for 
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regionalized, localized, and unknown stage, respectively, are 0.52 (95% CI: 0.35-
0.77), 0.41 (95% CI: 0.26-0.64), and 0.47 (95% CI: 0.30-0.74) for ESCC and 0.37 
(95% CI: 0.29-0.49), 0.12 (95% CI: 0.08-0.19), and 0.47 (95% CI: 0.29-0.74) for 
NCGA.1 Grade of the tumor did not appear to be as important. Compared to 
poor/undifferentiated tumors, the unadjusted HR for well/moderately differentiated 
tumors was 1.16 (95% CI: 0.85-1.58) for ESCC and 0.68 (95% CI: 0.51-0.89) for 
NCGA.1 Additionally perioperative chemotherapy was associated with better 
prognosis (no chemotherapy versus chemotherapy HR=0.43, 95% CI: 0.24-0.77).232 
History of gastroesophageal reflux disease (GERD; defined as at least once per 
week or 2 years of weekly antacid use) was also associated with poorer prognosis of 
ESCC (adjusted HR=1.41, 95% CI: 1.00-1.99) but not NCGA.1 
 Summary. Prognostic factors of ESCC include sex,1 education,1 income,1 
GERD,1 and histology.232 Prognostic factors for both ESCC and NCGA include 
alcohol consumption,1 NSAID use,1 adiposity,1 weight loss,124 stage,1 and grade.1 
These prognostic factors were important to consider when designing the directed 
acyclic graph of the association between flavonoids and survival among ESCC and 
NCGA cases, as these are potential confounders or intermediates of this association. 
Flavonoids may also reflect the presence of a tumor at a particular stage. The 
association between flavonoids and stage of ESCC or NCGA was conducted to 
examine potentially etiologically distinct subgroups. 
 
Specific Aims 
This dissertation examined the association between flavonoid intake and esophageal 
and gastric tumors along the cancer continuum (normal tissue  precancerous 
conditions  invasive cancer  mortality). This novel approach aided in identifying 
key windows of susceptibility that signified when along the cancer continuum this 
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potential intervention strategy could be implemented in an effort to reduce the high 
disease burden associated with these cancers. Specific aims are as follows. 
 
Specific Aim 1: Determine if flavonoid intake is associated with esophageal and gastric 
cancer incidence.   
Hypothesis: There will be an inverse association between flavonoid intake and 
esophageal/gastric cancer incidence. The association may vary by: (a) the six flavonoid 
classes (anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols, and isoflavones) 
and lignans, because of different foods that contribute to each flavonoid class; and (b) 
tumor subtype. 
Rationale: The incidence of esophageal adenocarcinoma (EA) and gastric cardia 
adenocarcinoma (GCA) has increased 300-575% over the last 30-40 years.3-7 EA/GCA 
also have a highly prevalent precursor lesion (BE),144-154 which will aid in identifying 
optimal times along the EA/GCA cancer continuum to target for intervention with specific 
chemopreventives to enhance risk reduction. However, esophageal squamous cell 
carcinoma (ESCC) and non-cardia gastric adenocarcinoma (NCGA) are significant to 
study because they are the most common forms of esophageal and gastric cancer 
worldwide.8,37  
Few epidemiologic studies to date have analyzed the association between 
esophageal or gastric cancer risk and flavonoid intake. None of these studies found 
associations between total flavonoid or lignan intake and esophageal or gastric cancer. 
However, several studies have found associations between specific flavonoid or lignan 
types, including anthocyanidins,101 flavanones,101,102,227 flavones,102 flavonols 
(overall102,227,233 and quercetin105), isoflavones,101 and lignans (secoisolariciresinol),230 
and esophageal or gastric cancer risk. Experimental studies have supported this 
hypothesis and have shown that flavonoids regulate cell cycle, proliferation, and 
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apoptosis, which have important chemotherapeutic effects against these tumors.29 It will 
be important to examine the associations by anatomic subsite and histologic type of 
cancer (i.e., esophageal adenocarcinoma, gastric cardia adenocarcinoma, esophageal 
squamous cell carcinoma, or non-cardia gastric adenocarcinoma), as these cancer types 
have distinct etiologies.234,235 Cyclin D1 and p53 are involved in tumor differentiation, 
proliferation and apoptosis.84,108,109,111,112 Categorizing cases by these markers, and by 
stage, will be conducted to examine potentially etiologically distinct subgroups 
 
Specific Aim 2: Determine if flavonoid intake is associated with Barrett’s esophagus 
(BE) development.   
Hypothesis: There will be an inverse association between total flavonoid intake 
and BE. It will also be important to consider: (a) the six classes of flavonoids and 
lignans; and (b) BE segment length. 
Rationale: BE is the only known potential precursor of EA/GCA.2 Studying 
precursor lesions, such as BE, can elucidate key risk factors that act early in disease 
onset. Understanding the mechanisms by which precursor lesions develop into cancer 
can offer opportunities to intervene and prevent disease progression.134 This dissertation 
examines the association between flavonoids and BE and esophageal/gastric cancer 
risk, which was innovative because it will be the first study to look at flavonoid intake and 
both precursor and invasive tumors in the continuum of EA/GCA development. 
Laboratory studies report reduced risk of BE when using synthetic flavones.100,236 
In these studies, flavonoids regulated cell cycle, proliferation, and apoptosis. BE 
segment length is a common marker for tumor stage.237,238 Categorizing cases by this 
marker may elucidate the underlying association.     
 
Specific Aim 3: Determine if flavonoid intake is associated with survival among cases of 
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esophageal and gastric cancer.  
Hypothesis: There will be an inverse association between total flavonoid intake 
and survival among cases of esophageal/gastric cancer. It will also be important to 
consider: (a) the six classes of flavonoids and lignans; and (b) tumor subtype. 
Rationale: Esophageal and gastric cancers are two of the most common causes 
of cancer mortality worldwide,33,34 and these cancers have very poor survival prognoses 
(normally less than a year).1 Phase I and II clinical trials are also using synthetic 
flavonoids as chemotherapy drugs, including flavone (Flavopiridol)31 and isoflav-3-ene 
(Phenoxodial),32 to produce cell cycle arrest and inhibit tumor growth in patients with 
metastatic cancer. 
No epidemiologic studies have been conducted to determine the association 
between flavonoid intake and survival in esophageal/gastric cancer cases. However, in 
vitro and in vivo studies have shown flavones induce cytotoxicity and reduce 
dissemination of cancer,210-217 flavonols induce cytotoxicity and inhibit growth and 
progression,210,218-220 and isoflavones induce apoptosis and inhibit proliferation.221-226 
Demonstration of an association between flavonoids and BE development, 
esophageal or gastric cancer incidence or survival among esophageal and gastric 
cancer cases suggests potential to use flavonoids as a risk reduction strategy for these 
tumors. The current study provides important preliminary data for future intervention 
studies (i.e., by determining the most effective class of flavonoids for esophageal and 
gastric cancer risk reduction). This could allow some esophageal and gastric cancer to 
be prevented before individuals develop these deadly cancers or offer support for use of 
flavonoids as novel chemotherapy drugs. 
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Summary 
Esophageal and gastric cancer have very poor survival prognoses (normally less than a 
year),1 and the only known potential precursor of esophageal and gastric cardia 
adenocarcinoma is Barrett’s esophagus (BE).2 Studying precursor lesions, such as BE, 
provides insight into the etiology of cancer by elucidating key risk factors that act early in 
disease onset. However, not all precursor lesions develop into cancer. Therefore, 
understanding the mechanisms by which precursor lesions do result in cancerous 
tumors can offer an opportunity to intervene and prevent disease progression.134 
Epidemiological studies have shown that diets high in fruit and vegetable intake are 
inversely associated with esophageal and gastric cancer and BE.14-28 Flavonoids 
naturally occur in fruits and vegetables and are thought to partially account for the 
decreased risk of  esophageal/gastric cancer and BE in individuals with higher intakes of 
fruits and vegetables.29  Therefore, since an association between fruits and vegetables 
and esophageal/gastric cancer and BE has been reported, it is plausible to evaluate the 
association between flavonoids, esophageal and gastric cancer, and BE to determine if 
flavonoids are associated with risk reduction for these tumors. This dissertation 
investigated the association between flavonoid intake and the esophageal/gastric cancer 
continuum. Demonstration of an association between flavonoids and BE development, 
esophageal or gastric cancer incidence, or survival among esophageal and gastric 
cancer cases suggests potential to use flavonoids as a risk reduction strategy for these 
tumors. This could allow some esophageal and gastric cancer to be prevented before 
individuals develop these deadly cancers or offer support for use of flavonoids as novel 
chemotherapy drugs. 
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CHAPTER 2: METHODS 
 
Overview of Study Methods 
The goals of this dissertation were to determine the associations between intake of dietary 
flavonoids and lignans and the risk of developing Barrett’s esophagus (BE) and esophageal 
and gastric cancer and survival among esophageal and gastric cancer cases. To address 
these goals, existing data from two parent studies – one study of esophageal/gastric cancer 
and one of BE – was used to complete three steps. Step 1: Development of two study-
specific flavonoid databases, one for each parent study [Esophageal and Gastric Cardia 
Adenocarcinoma (EGA) Study and BE Study]. The two parent study-specific food frequency 
questionnaires (FFQs) were linked with the existing flavonoid and lignan databases, utilizing 
weights from the FFQ, to determine flavonoid content of each FFQ line item. Step 2: 
Utilization of the two study-specific flavonoid/lignan databases to estimate flavonoid intake 
for the corresponding participants in the two studies, by using reported serving sizes and 
frequency of intake. Step 3: Estimation of (i) odds ratios for the associations between 
flavonoid/lignan intake and the risk of developing esophageal/gastric cancer and BE and (ii) 
hazard ratios for the association between flavonoid/lignan intake and risk of mortality in 
esophageal/gastric cancer cases. Whether risk varies by flavonoid/lignan type or 
stage/differentiation of the case tumor was also explored. Details of the study methods are 
presented below. 
 
Study Populations 
Existing data was used from two parent studies of esophageal/gastric cancer and BE to 
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determine the association between flavonoids/lignans and the risk of developing esophageal 
and gastric cancer and BE and survival among esophageal and gastric cancer cases.  
 The parent EGA study, as known as the U.S. Multi-Center Study, was a multi-center, 
case-control study conducted in the state of Connecticut, a 15-county area of New Jersey, 
and a three-county area of western Washington state.1 Each of these geographic areas had 
a population-based cancer registry, which were used to identify the cases using rapid 
reporting methods.1  Eligible cases were English-speaking men and women between the 
ages of 30 and 79, who were diagnosed with a primary invasive cancer of the esophagus or 
stomach between the years of 1993 and 1995 [February 1, 1993-January 31, 1995 in 
Connecticut (CT); April 1, 1993-November 30, 1994 in New Jersey (NJ); and March 1, 1993-
February 28, 1995 in Washington state (WA)]. All cases of esophageal or gastric cardia 
adenocarcinoma were recruited (target cases of primary interest). Esophageal squamous 
cell carcinoma and non-cardia gastric adenocarcinoma cases were frequency matched to 
the target cases by geographic location and 5-year age group (CT, NJ, WA), sex (NJ, WA), 
and race (white or other, NJ).1 
 Population-based controls were frequency matched by 5-year age group and sex. 
Control participants 30-64 years of age were identified through random digit dialing (RDD) 
techniques.2 Control participants 65-79 years of age were identified by random sampling of 
Health Care Financing Administration rosters. Current use of RDD may be problematic, but 
the parent EGA study was conducted in 1993-1995. Two recent studies demonstrated that 
RDD contact, cooperation, and response rates were still high until after the mid-1990s.3,4  
 The parent study of BE, also known as the Study of Reflux Disease, was a case-
control study conducted in western Washington state.5 Eligible cases were men and women 
between the ages of 20 and 80 without previously diagnosed BE who were undergoing an 
upper endoscopy for gastroesophageal reflux disease symptoms between the years of 1997 
and 2000. Potentially eligible cases were identified through community gastroenterology 
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clinics. Controls were identified through RDD techniques. The parent BE study was 
conducted between 1997 and 2000, after the response rates began to decline, but the 
investigators concluded that RDD was still a viable option for control recruitment until 2000.5 
 For both parent studies, information on potential risk factors was obtained by a 
structured questionnaire administered face-to-face by a trained interviewer. Information was 
collected on demographics, tobacco and alcohol use, medical conditions, and medications. 
Dietary information was collected via face-to-face interview for the EGA study but by self-
report for the BE study. Written informed consent was obtained for all participants prior to 
the interview.1,5 For the EGA study, the average time between cancer diagnosis and 
interview was 3.7 months when the participant was interviewed and 8.5 months when a 
proxy was interviewed. Average time for interview completion was 130 minutes.1 The time 
between endoscopy and interview for the BE cases was 1-2 months, with the interview 
averaging 45 minutes.5 
 In the EGA study, initial participant selection was based on the state tumor registry 
reports, which were obtained for potentially eligible participants that were diagnosed with 
esophageal adenocarcinoma (EA), gastric cardia adenocarcinoma (GCA), esophageal 
squamous cell carcinoma (ESCC), or non-cardia gastric adenocarcinoma (NCGA). 
Additional potential participants with diagnosed esophageal and gastric cancer classified as 
not otherwise specified (NOS), mixed, undifferentiated, uncertain histologic type, and 
unspecified subsite of the stomach were approached for participation in the study.  
 At the time of the interview, signed medical record release forms were obtained from 
the case participants, in order to retrieve relevant medical records and corresponding 
pathologic specimens for the first primary diagnosis of esophageal or gastric cancer. 
Histologic slides of the diagnostic biopsy were reviewed for more than 99% of cases.1 After 
a systematic review of these materials, the study pathologists (Drs. Heidi Rotterdam for NJ 
and A. Brian West for CT and WA) made the final determination of case eligibility. Cancers 
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were classified using ICD-O codes and histology codes. Eligible EA cases were classified as 
ICD-O6 codes C150.0-150.9 and histologic codes 8140-8381. Eligible GCA cases were 
classified as ICD-O code C151.0 and histologic codes 8140-8381. Eligible ESCC cases 
were classified as ICD-O codes C150.0-150.9 and histologic codes 8050-8082. Eligible 
NCGA cases were classified as ICD-O codes C151.1-151.9 and histologic codes 8140-
8381.  
 Although pathologic specimens were available for review, tumors that involve the 
distal esophagus and gastric cardia (i.e., proximal stomach) are difficult to classify.7 
Therefore, the site of origin was determined by estimating the tumor’s center. For tumors 
where the site of origin could not be determined by H. Rotterdam, A.B. West reviewed the 
records, and vice versa. Disagreements were resolved by consensus. To ensure 
consistency of the diagnoses between pathologists throughout the study period, randomly 
chosen pathology materials were reviewed by both pathologists on a regular basis; the rare 
inconsistencies were resolved by consensus. 
  In the BE study, participants were recruited from individuals undergoing an upper 
endoscopy for gastroesophageal reflux disease (GERD) symptoms. Consenting participants 
had a four-quadrant biopsy specimen collected. Biopsy specimens were evaluated by one of 
three university-based pathologists, who were blinded to the endoscopy findings. Cases 
were defined as those with specialized intestinal metaplasia (SIM) on at least one of the four 
biopsy specimens.5 
Demographics of Study Participants 
Demographic characteristics of the parent studies of EGA and BE have been previously 
published1,5 and are summarized in Table 2.1. For the EGA parent study, the median age at 
diagnosis was 66 years, and the median overall survival times were 9.6 months for EA, 12.8 
months for GCA, 10.7 months for ESCC, and 12.9 months for NCGA. The majority of the 
participants were diagnosed with regional or distant stage tumors. In the BE parent study, 
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the mean age at diagnosis was 55 years. In both parent studies, the majority of participants 
were Caucasian males and cases were less likely to be well educated than controls.  
 
Exposure Assessment 
Dietary information for the EGA study was collected by trained research interviewers during 
structured interviews, utilizing a food frequency questionnaire (FFQ). The FFQ was modified 
from the FFQ developed by investigators at the Fred Hutchinson Cancer Research Center 
(FHCRC)8 and included 104 items.9 Participants in the EGA study were asked to report their 
usual dietary intake in the 3-5 years prior to diagnosis (cases) or interview (controls). 
Completed FFQs were not obtained for 33 cases who had abbreviated interviews because 
of serious illness.9 Face-to-face interviews were conducted for 80.6% (n=554) of eligible EA 
and GCA cases, 74.1% (n=589) of eligible ESCC and NCGA cases, and 70.2% (n=695) of 
eligible controls in the EGA study. The overall response rate for the control participants was 
70.2%, when accounting for the telephone screener response rate of 90.8% for the 51.8% of 
control participants identified through RDD. The primary two reasons for non-participation 
were participant refusal (12% of EA and GCA cases, 17% of ESCC and NCGA cases, and 
23% of controls) and physician refusal for case participants (4% for each group).1  
 The BE study used the standard self-administered FHCRC FFQ, which included 131 
items.8 Participants were asked to report their dietary intake for the year prior to interview. 
The response rates for the parent BE study were 92.8% for eligible cases and 68.7% for 
eligible controls. Completed FFQs were obtained for 88.1% (n=170) of cases and 86.3% 
(n=182) of controls. While there is expected to be some level of reporting error in an FFQ, 
the FHCRC FFQ has been validated by using 4-day food records8 and four 24-hour recalls10 
as criterion instruments.  
 Rapid case ascertainment was conducted in the EGA study. However proxies, 
usually spouses, were interviewed when the cases were too ill or died prior to being 
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interviewed. One-year overall survival is approximately 40% for EA and GCA,11 and overall 
five-year survival is 12.2% and 21.1% for esophageal and gastric cancer diagnosed 
between 1993 and 1995, respectively.12 Next-of-kin proxies were interviewed for 30.9% 
(n=354) of cases and 3.4% (n=24) of controls.1 
 While reliability and validity of proxy versus self-report have not been investigated in 
the parent EGA and BE studies, other studies have examined this issue for a number of 
factors, including dietary intake. For example, next-of-kin proxy recall for fruits and 
vegetables has been shown to be similar to self-report.13,14 For a 5-year recall period, self-
respondents had fair agreement for fruits (κ=0.35) and vegetables (κ=0.31). Any next-of-kin 
respondent had a fair agreement for fruits (κ=0.37) and vegetables (κ=0.20). Spouses had a 
slightly lower correlation for fruits (κ=0.29) but better reporting for vegetables (κ=0.33) than 
overall next-of-kin proxies.13 Another study showed that agreement between next-of-kin and 
colon cancer cases was fair-to-moderate for fruits (κ=0.42) and vegetables (κ=0.45); 
agreement between controls and next-of-kin was similar. The study also found that next-of-
kin response was more highly correlated with self-report when the questionnaire was 
interviewer administered (as was the case in the parent EGA study).14 While the kappa 
coefficients may appear to show low agreement, this is common in nutritional epidemiology. 
For example, a study of the correlation between the FHCRC FFQ and the mean of two, four-
day diet records found Pearson correlation coefficients of 0.31-0.64.15  
 From these previous studies,13,14 it was expected that self-report and proxy-report 
would be similar. However, there was still potential for the agreement between self-report 
and proxy to be dissimilar in this ancillary study. However, in a study of the association 
between micronutrients and esophageal and gastric cancer in the parent EGA study, results 
from analyses excluding versus including proxy data were almost identical.9 Proxies may 
even provide better information than the participants, as the majority of participants were 
older males, and their wives – who were the most likely source of the proxy responses – 
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may have prepared most meals.16,17   
 To develop an expanded flavonoid database, each FFQ was linked on frequency of 
dietary intake and portion size with existing databases of flavonoid intake from the U.S. 
Department of Agriculture (USDA) Database for the Flavonoid Content of Selected Foods18 
and the USDA-Iowa State University Database on the Isoflavone Content of Selected 
Foods.19,20 While these are useful in estimating flavonoid intake, none of the USDA 
databases contain content values for lignans. Therefore, these USDA databases were 
supplemented with available literature on the lignan content of foods.20,21  
 While the USDA databases for flavonoid content were utilized in this ancillary study, 
there is also a European database that includes both flavonoids and lignans, known as the 
Phenol-Explorer. This database was explored for quality by examining: 1) correspondence 
of FFQ line items and foods included in Phenol-Explorer, 2) completeness of flavonoids 
included in the database, and 3) readiness of Phenol-explorer for use. It was determined 
that, at the time of data linkage, the Phenol-Explorer was less complete than the USDA 
databases. Additionally, flavonoid content determined by chromatography and 
chromatography after hydrolysis was not combined in this database. Thus, it was decided 
not to utilize the Phenol-Explorer.22,23 
 There were 91 items from the standard 131-item FHCRC FFQ that contain at least 
one class of flavonoid or lignan (Table 2.2). Some FFQ items represent multiple foods or 
beverages, such as “apples and pears”, rather than a single food or beverage. Therefore, 
the individual foods and beverages from the FFQ item were weighted according to weights 
used by the FHCRC for computation of total energy and nutrient intake. For the parent EGA 
study, the FHCRC was unable to locate records of the weighting scheme that was utilized 
for computation of total energy and nutrient intake from the FFQ. Thus, verification of the 
weighting scheme was done by recreating total energy intake estimates. This was 
accomplished by using a weighting scheme utilized on a similar FHCRC FFQ and examining 
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the correlations between the calculated total energy and the FHCRC computed total energy. 
The Pearson correlation coefficient between the FHCRC total energy variable and the 
calculated total energy variable, without including alcohol, was 0.97. Thus, the weights that 
were used were reasonably close to how the FHCRC originally weighted the FFQ items.  
 To estimate the mean intake of flavonoids among participants in the parent EGA and 
BE studies, the frequency of dietary intake and portion size from the FHCRC FFQ was used. 
For both studies, participants were asked “how often did you eat/drink these foods.” For the 
EGA parent study, participants gave the number of times the food item was consumed per 
day, week, month, or year. Participants were not asked the portion size, so portion size was 
assumed to be a medium serving, which is consistent with the FHCRC procedures. For the 
BE parent study, frequency of dietary intake was categorized as never or less than once per 
month, 1 per month, 2-3 per month, 1 per week, 2 per week, 3-4 per week, 5-6 per week, 1 
per day, or 2+ per day. Then participants were given a definition of medium serving size 
(e.g., for “apples and pears” medium serving size was defined as “1 medium or ½ cup”) and 
asked to report the serving size of the dietary line item they usually ate – small, medium, or 
large.8 
 For example, the FFQ line item of “apples and pears” was assigned a weight of 0.75 
for “apples” and 0.25 for “pears”.24 To calculate the flavonoid intake, the weight assigned to 
each food in the FFQ item was multiplied by the flavonoid content of that food, summed 
across all foods in the FFQ line item, and then multiplied by the number of times consumed 
per day and serving size.20 In this example, 100 grams of apple contains 1.29 mg and pear 
contains 12.18 mg of anthocyanidins.18 A medium serving size of apples or pears was 
estimated as 145 grams. Therefore, if an individual reported consuming one medium serving 
of apples or pears per day, the individual’s daily intake of anthocyanidins from apples and 
pears was calculated as follows:  
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Daily intake of anthocyanidins from apples or pears = 145g apple or pear/day 
* [(0.75 apple weight * 1.29 mg/100g apples) + (0.25 pear weight * 12.18 
mg/100g pears)] = 5.82 mg anthocyanidins/day 
 Recall error may be of concern, given that participants were asked to recall past 
behavior, including usual dietary intake. However, moderate agreement has been shown 
between baseline food intakes and recall of these intakes assessed by a food frequency 
questionnaire 3-10 years later for total energy (r=0.54,25 rs=0.62,
26 and Κ=0.3227) vegetables 
(Κ=0.31),27 and fruits and vegetables (r=0.41).28  
 An additional potential source of error in estimating flavonoid content in foods, 
especially fruits and vegetables, may be associated with the variability of environmental 
conditions, horticultural practices, degree of ripeness, plant variety, storage conditions, 
cooking methods, and industrial processing, which may vary regionally and over time.20,29-33 
To estimate the impact of these potential influences  on the flavonoid content of select 
foods, the USDA Food Composition and Nutrient Data Laboratories determined the 
flavonoid content for over 60 fruits, vegetables, and nuts by sampling foods from four United 
States regions at two times of the year. While this study found variation in flavonoid content 
within and between foods was high, the average flavonoid content was similar to values 
reported in the USDA Database for the Flavonoid Content of Selected Foods.34 
 
Outcome Assessment: Cyclin D1 and P53 Status 
Archived Tumor Block Collection. Tumor blocks with sufficient tissue for 
immunohistochemical (IHC) analyses were collected for 630 (55.1%) and 649 (56.8%) of the 
1130 cancer cases for cyclin D135 and p53,36 respectively. As reported in the parent EGA 
study,35 availability of tumor tissue varied little by tumor subsite, histology, stage at 
diagnosis, or suspected risk factors for these tumor types (age, sex, race, cigarette smoking, 
alcohol intake, BMI, and NSAID use). Additionally, tumor availability did not vary by proxy 
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versus self-report status.  
 Processing and Staining. Cyclin D1. Immunohistochemical techniques were used 
to determine cyclin D1 status, utilizing previously published methods.37,38 In this method, 5-
µm sections from the formalin-fixed, paraffin-embedded tumor sample were deparaffinized, 
hydrated, and placed in a 10 mM citrate buffer (pH 6) and microwaved for antigen retrieval 
for a total of 10 minutes. Blocking serum (horse serum), primary antibody (mouse 
monoclonal IgG2a), and the antihuman cyclin D1 (1:20; Immunotech) were used in the IHC 
analysis. The detection method for cyclin D1 was the Vectastain Elite ABC kit (Vector 
Laboratories, Burlingame, CA); chromogen diaminobenzidine was used and sections 
counterstained with methyl green.35 
 P53. The methods utilized for p53 protein analyses were based on previously 
published methods.39 In this method, dewaxed sections from the formalin-fixed, paraffin-
embedded tumor sample were microwaved for antigen retrieval, utilizing the p53 DO-7 
monoclonal antibody (1:50; DAKO Corp., Santa Barbara, CA).40 Using a 32-minute 
incubation of the primary antibody and avidin-biotin complex immunoperoxidase technique, 
IHC protocol was performed by a Ventana Automated Immunostainer (Ventana Corp., 
Tucson, AZ).41 Slides were stained in multiple batches by the same lab, using positive and 
negative controls to ensure that results were consistent across batches.36 
 Interpretation. Cyclin D1. The study pathologist (Dr. Hanina Hibshoosh) was 
responsible for interpretation of the IHC results, utilizing previously published 
methodology.37,42 A semiquantitative scoring system was used to categorize the nuclear 
staining in esophageal and gastric cancers by considering both staining intensity and 
percentage of positive nuclei. In this system, nuclear staining intensity is a four-level ordered 
categorical variable (0=none, 1=mild, 2=moderate, 3=strong), and the percentage of positive 
cells is a dichotomous variable (negative=none or rare, defined as ≤5% positive cells; 
positive=more than rare, defined as >5% positive cells). The cutoff value for rare cells 
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reflects the level of background staining seen in adjacent normal cells. Cases were 
classified as cyclin D1 positive only if: 1) the staining number was moderate or strong and 2) 
the percentage of positive cells was classified as positive (>5%). If a case did not meet 
these criteria, they were classified as cyclin D1 negative.35 
 P53. Nuclear p53 protein staining was assessed by a study pathologist. Nuclear 
staining percentage was classified using a five-level ordered categorical variable 
(0=negative, 1=<10%, 2=10–50%, 3=51–90%, and 4=>90% cells stained). Cases were 
classified as p53 positive only if: 1) the staining number was moderate or strong and 2) the 
percentage of positive cells was ≥10%. If cases did not meet these criteria, they were 
classified as p53 negative.36 
 
Outcome Assessment: Segment Length 
Tumor Biopsy Collection, Processing, and Staining. Consenting participants in the BE 
study had a four-quadrant biopsy specimen taken from the tubular esophagus just distal to 
the squamocolumnar junction during an endoscopy visit. Tumor biopsies were fixed in zinc 
formaldehyde. Alcain blue stain (pH 2.5) was utilized to assist in establishing the presence 
of specialized intestinal metaplasia (SIM).5  
 Interpretation. Biopsy specimens were evaluated by one of three university-based 
pathologists, who were blinded to the endoscopy findings. Cases were defined as those with 
SIM on at least one of four standard biopsy specimens.5  
 During the endoscopy procedure, physicians recorded the presence (and length) or 
absence of visible columnar epithelium, or visible BE (VBE). This allowed the cases to be 
classified into one of three progressively exclusive groups: 1) SIM (i.e. all cases), 2) SIM and 
VBE (VBE cases), and 3) SIM and VBE greater than 2 centimeters in length [long-segment 
BE (LSBE) cases].5 The first and most inclusive category of all SIM cases adheres to the 
concept of “ultra-short segment BE”.5,43-45 The latter two categories adhere to the BE case 
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definition as put forth by the American College of Gastroenterology.5,46 
 
Outcome Assessment: Vital Status 
In a follow-up of the EGA study, vital status and date of death were determined by the state 
tumor registries, which linked the tumor registry data with the National Death Index.47 
Overall survival time (in months) was calculated from the date of diagnosis until death or last 
follow-up. The maximum follow-up was 90 months. Follow-up ended for western Washington 
state in July 2000, for New Jersey on September 15, 2000, and for Connecticut on October 
28, 2000. At the end of the follow-up period, participants that were still alive were censored. 
The outcome of death was ascertained from all-cause mortality.47 
 
Covariate Assessment 
Covariate information for both parent studies of EGA and BE was collected during the 
structured interviews, which were conducted by trained research interviewers. Directed 
acyclic graphs (DAGs, Figures 2.1-2.5) were utilized as conceptual models to determine 
which variables were evaluated as potential confounders. Variables that were evaluated as 
potential confounders in this ancillary study for risk of developing esophageal/gastric cancer 
include proxy status, income, education, cigarette smoking, alcohol consumption, and body 
mass index (BMI). Variables that were evaluated as potential confounders in this ancillary 
study for esophageal/gastric cancer survival include income, education, cigarette smoking, 
alcohol consumption, BMI, tumor stage, tumor grade, dysphagia, study site, sex, and self-
reported race. The predetermined covariates evaluated as effect measure modifiers were 
cigarette smoking, BMI, and GERD (Tables 2.9-2.11). While the generally accepted model 
for EA is that it develops through GERD and BE,48 not all EA cases report having GERD or 
BE.49 Therefore, there are potentially other pathways to development of EA/GCA that are 
not through GERD or BE. As stated earlier, it is of concern that proxy responses may 
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misclassify exposure or covariate information. However, most validation studies that have 
compared self-report to proxy report have found good concordance for cigarette intake,50,51 
weight and height,50 and dietary recall.13,14  
 Variable assessment and corresponding definitions of covariates for the EGA study 
are as follows.1,9 To assess yearly household income in the parent EGA study, participants 
were asked to look at card showing six levels of income (A. less than $15,000; B. $15,000-
$29,999; C. $30,000-49,999; D. $50,000-74,999; E. $75,000-$99,999; F. $100,000 or more) 
and state the letter that best describes the total household income during the last calendar 
year. Education was categorized as <12 years, 12 years, vocational school, some college, 
college graduate, and graduate school. To be considered a cigarette smoker, participants 
had to have smoked at least 100 cigarettes or more in his/her lifetime. Participants who 
were considered smokers were then asked the intensity of use (number of cigarettes/day) 
and duration. Alcohol consumption was assessed by asking the participant to report 
consumption patterns for beer, wine, and liquor separately for anytime one year or more 
prior to the interview. A never drinker was defined as having less than one drink per month. 
Beer, wine, and liquor were combined to form an overall consumption variable for alcohol. 
BMI (weight in kg/height in m2) was assessed by asking the participant what his/her height 
and their usual adult weight (i.e., the most common weight during adulthood) one year prior 
to diagnosis (cases) or interview (controls). Energy intake (kcal/day) was assessed using the 
Fred Hutchinson Cancer Research Center (FHCRC) food frequency questionnaire (FFQ), 
with kilocalories from alcohol included. The data from the FFQ was double-entered at the 
study site and then sent to FHCRC to be analyzed for energy and nutrient intake. Energy 
intake was calculated by summing the kilocalories for each food item consumed during the 
reported year and then the kilocalories were averaged over the year. Self-reported race was 
categorized as white and other.  
 Variables5,52 evaluated as potential confounders in this ancillary study of BE 
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development include income, education, BMI, self-reported race, cigarette smoking, and 
total energy intake. Income (less than $45,000, 45,000-74,999, 75,000 or more), cigarette 
smoking, and total energy intake (kcal/day) were assessed in a similar manner to the parent 
EGA study. Education was categorized as high school or less, technical school, and college 
or more. To calculate BMI (kg/m2) in the parent BE study, interviewers measured 
participant’s height and weight at the time of the participant interview using established 
protocols.53 As with the EGA study, cigarette smoking and BMI were also be evaluated as a 
potential effect measure modifiers. Participants were additionally asked to self-report their 
race (white, black or African, Asian, American Indian/Eskimo, other/unknown).  
 
Study Design 
Barrett’s esophagus and esophageal and gastric cancer are rare diseases; therefore a case-
control study is the most efficient study design. Two possible alternative designs for this 
study would be to 1) conduct a cohort study of Barrett’s esophagus patients to analyze the 
exposure of dietary flavonoids and the outcome of esophageal or gastric cardia 
adenocarcinoma (EA/GCA) or 2) conduct a cohort study of gastroesophageal reflux disease 
(GERD) patients to analyze the exposure of dietary flavonoids and the outcome of BE. 
However, these study designs are inefficient. Although BE patients have a 125-fold greater 
risk of EA/GCA, the probability that BE will develop into adenocarcinoma is still rare – 
incidence of cancer is 1 out of 227 BE patient-years of follow-up.54 Similarly, only 10-15% of 
GERD patients develop BE.55 Therefore, using a cohort design to study these aims would be 
an incredibly time-intensive and expensive method to study esophageal and gastric cancer 
and BE. This ancillary study is a practical and cost-efficient use of resources because the 
dietary and confounder data has been previously collected.  
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Results from Previous Analyses 
Published results using the dietary data from both parent studies have shown that diets high in 
fruit and vegetable intake are inversely associated with esophageal/gastric cancer and Barrett’s 
esophagus (BE).52,56  In the EGA parent study, adjusted odds ratios (OR) were calculated based 
on increasing fruit/vegetable intake by one serving per day. Total fruit and vegetable intake was 
associated with decreased risk of incident esophageal adenocarcinoma (OR=0.88, 95% CI: 
0.82-0.95) and esophageal squamous cell carcinoma (OR=0.90, 95% CI: 0.82-0.99). Results 
were near null for gastric cardia adenocarcinoma (OR=0.97, 95% CI: 0.90-1.03) and non-cardia 
gastric adenocarcinoma (OR=0.99, 95% CI: 0.93-1.05).56 In the parent BE study, adjusted ORs 
were calculated based on tertiles of fruit/vegetable intake. Participants in the highest tertile of 
combined fruit and vegetable intake had lower risk of developing BE (OR=0.39, 95% CI: 0.21-
0.75) as compared with participants in the lowest tertile of fruit/vegetable intake.52  
 
Statistical Analysis 
The first aim of this ancillary study was to determine if flavonoid/lignan intake is associated with 
esophageal/gastric cancer incidence, utilizing existing data from the EGA study collected as part 
of a multi-center, population-based case-control study conducted in Connecticut, New Jersey, 
and western Washington state.1 The second aim was to determine if flavonoid/lignan intake is 
associated with Barrett’s esophagus (BE) development, using existing data from the BE study, a 
community-based case-control study conducted in western Washington state.5 The third aim 
was to determine if flavonoid/lignan intake is associated with survival among esophageal/gastric 
cancer cases, utilizing existing follow-up data from the EGA study. For all three aims, the effects 
for total flavonoid intake were estimated, as well as the effects for each of the six classes of 
flavonoids (anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols, and isoflavones). 
Lignans were considered separately for all three aims due to the substantial differences in the 
foods and beverages that contribute to lignans as compared with each class of flavonoid. 
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Demonstration of an association between flavonoids and BE development, esophageal or 
gastric cancer incidence or survival among esophageal and gastric cancer cases suggests 
potential to use flavonoids as a risk reduction strategy for these tumors. This could allow some 
esophageal and gastric cancer to be prevented before individuals develop these deadly cancers 
or offer support for use of flavonoids as novel chemotherapy drugs. 
 Details of the statistical analyses are discussed below. 
  
Data Management/Quality Control 
The EGA parent study was a multi-site study in Connecticut, New Jersey, and western 
Washington state. Since esophageal and gastric cancers remain relatively rare, the study 
included data collection efforts from multiple centers to ensure an adequate sample size 
within the given time frame for the study (1993-1995). The principal investigators [PIs; Drs. 
Marilie Gammon (NJ), Harvey Risch (CT), and Thomas Vaughan (WA)] of this study 
collaborated closely together to ensure that the study methods and the same questionnaire 
were implemented at each study site so the data could be compiled for the planned 
analyses. The BE parent study was conducted in western Washington state by a PI (T. 
Vaughan) from the EGA parent study. Therefore, data collection and management have 
been performed in similar ways for both studies.57 
 Data for both parent studies were collected during a structured paper-based 
interview conducted by trained research interviewers at the participant’s home or another 
requested location. Participant responses were double entered into a computerized 
database to ensure that there were minimal entry errors. Discrepancies in data entry were 
resolved by referencing the original interview document. After the data from the food 
frequency questionnaire was entered, it was sent to the Fred Hutchinson Cancer Research 
Center to be analyzed for micro- and macronutrient intake, along with total energy intake.57 
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Descriptive Analysis for the Ancillary Study 
Data analysis began with an examination of the data distributions of the exposure, outcome, 
and covariates, using tables and histograms. For the EGA ancillary study analysis, the 
frequency (n) and relative frequency (%) of case-control status, flavonoid intake, proxy 
status, race, age, gender, body mass index (BMI), cigarette smoking, alcohol consumption, 
socioeconomic status (SES), total energy intake, and geographic site, were assessed using 
tabular methods. In the BE ancillary study analysis, the frequency and relative frequency 
was assessed for the following covariates: case-control status, flavonoid intake, race, age, 
gender, BMI, SES, and total energy intake. For both analyses, age, BMI, cigarette smoking, 
alcohol consumption, flavonoid intake, and total energy intake were assessed as continuous 
measures using histograms and descriptive statistics including the mean, median, standard 
deviation, range, and skewness. 
 
Exposure Variable Construction 
After linking the flavonoid and lignan databases with the FFQ, the flavonoid and lignan intakes 
were continuous variables. Flavonoid intake was categorized as deciles, quintiles, and quartiles, 
based on the distribution of overall and sex-specific intake (Tables 2.3 and 2.4) among the 
controls (logistic regression) or all cases (survival analysis).17 Results were similar; therefore, 
only the overall quartiles are presented. By using multiple categories, no assumptions are made 
about the dose-response relationship. However, finer divisions of extreme categories were also 
considered to extend the examination of a dose-response relationship. Categorical analysis also 
constrained any undue influence from outlying observations. However, a crudely categorized 
variable may not account for the full effect of the variable, leading to residual confounding. Thus, 
the exposure variable was examined as a continuous variable and a quartiled categorical 
variable.17 In addition to examining total flavonoid intake, continuous and categorical forms of 
the six flavonoid classes (anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols, and 
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isoflavones) and lignans were constructed for analysis. Examination of flavonoid intake utilizing 
restricted quadratic splines was also performed (Figures 2.6 and 4.1). Both categorization and 
spline models produced consistent results for the main analysis; however, the categorized 
results for quartiles were more stable. Therefore, only results for categorized quartiles are 
reported. Tests for linear trends utilized the original continuous flavonoid values in mg/day. All p-
values were 2-sided. 
 
Analysis to Address Specific Aim 1 
To determine if flavonoid intake was associated with risk of esophageal and gastric cancer 
incidence, unordered polytomous unconditional logistic regression was used to calculate 
odds ratios (ORs), as an estimate of relative risk, and 95% confidence intervals (CIs) for 
esophageal adenocarcinoma (EA), gastric cardia adenocarcinoma (GCA), esophageal 
squamous cell carcinoma (ESCC), and non-cardia gastric adenocarcinoma (NCGA) as 
distinct outcomes (Table 3.3). Polytomous logistic regression allows simultaneous 
estimation of risk. All models for the outcomes of esophageal and gastric cancer included 
the following matching variables: geographic site (CT, NJ, WA), age (continuous), sex (male, 
female), and race (white, other). Confounders and effect measure modifiers were chosen 
using a priori knowledge of the relationships between the exposure, outcome, and potential 
confounders (Figure 2.1-2.2):58 proxy status (proxy, non-proxy), income (evaluated as 
<$15,000, $15,000-29,999, $30,000-49,999, $50,000-74,999, or ≥$75,000 and <$15,000, 
≥$15,000), education (evaluated as <high school, high school, technical school/some 
college, >college and <high school, >high school), cigarette smoking (evaluated as 
ever/never, continuous pack-years, and continuous cigarettes/day), alcohol consumption 
(evaluated as ever/never and continuous for beer, wine, and liquor), and BMI (evaluated as 
continuous and as categorized, <25, 25-29.9, or ≥30 kg/m2). 
 To further determine if there is an association between flavonoid intake and 
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esophageal and gastric cancer subtypes, cyclin D1 and p53 status and tumor stage were 
used. Unordered polytomous unconditional logistic regression was used for each tumor (EA, 
GCA, ESCC, and NCGA) to calculate odds ratios and 95% confidence intervals for the 
association between flavonoids and cyclin D1+ tumors (compared to controls) and cyclin 
D1- tumors (compared to controls), adjusting for matching factors and potential 
confounders. This analysis was repeated to determine the association between flavonoids 
and p53 status (p53+/p53-) and tumor stage (localized, regional, and distant). The case-only 
odds ratio, or ratio of the odds ratios, was calculated to assess etiologic heterogeneity. The 
case-only OR equals 1 if there are homogeneous subgroups.58 These analyses are shown 
in Tables 2.5-2.7. 
 
Analysis to Address Specific Aim 2 
To determine if flavonoid intake is associated with BE development, conditional and 
unconditional logistic regression was used to calculate odds ratios and 95% confidence 
intervals (Tables 2.8 and 4.3). All models for the outcome of BE included the matching 
variables age (continuous) and sex (male, female). Potential covariates included58 BMI 
(evaluated as continuous and as dichotomous, <25 or ≥25 kg/m2), race (white, other), 
income (<$45,000, ≥$45,000-74,999, ≥$75,000), education (≤high school, technical school, 
≥college), and cigarette smoking (ever/never). 
 To further determine if there was an association between BE and flavonoids, 
segment length was used. Unconditional logistic regression was used to calculate ORs and 
95% CIs for progressively more exclusive groups of SIM, VBE, and LSBE cases, adjusting 
for matching factors and potential confounders (Table 4.4). Additionally, an analysis was 
conducted examining exclusive groups of SIM (i.e., no visible columnar epithelium on 
endoscopy), VBE (i.e., visible columnar epithelium ≤2 cm), and LSBE (i.e., visible columnar 
epithelium >2 cm). The results utilizing exclusive groups and progressively more exclusive 
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groups were similar; however, the ORs for the exclusive groups were unstable due to small 
sample sizes (data not shown).  
 
Logisitic Regression Analyses for Specific Aims 1 and 2 
Since the outcomes for both analyses in specific aims 1 and 2 were dichotomous and the 
relationship between the outcome and predictor was non-linear, logistic regression was 
appropriate. Assumptions were made that the outcomes were statistically independent 
because there were no repeated events and the residual variation is binomially distributed; 
this assumption of logistic regression is rarely violated. To model continuous or ordinal 
variables, such as flavonoids, the first check was to ensure that they have a linear 
relationship with the logit form of the outcome. As they do not satisfy this assumption, these 
predictors were modeled with indicator variables.59 
 Covariates considered as potential confounders or effect measure modifiers for this 
analysis were chosen using a priori knowledge of the relationships between the exposure, 
outcome, and potential confounders (Figure 2.1-2.3).58  First, to ensure that the assumption 
of multiplicativity was satisfied, effect measure modification was assessed between 
flavonoids and predetermined covariates (i.e., cigarette smoking and BMI, for both analyses, 
and GERD, for the EGA analysis; Tables 2.9-2.13) using likelihood ratio tests to compare 
regression models that included a multiplicative term to models without that term.59  Then, 
potential confounders were assessed using backward elimination with multivariate models. If 
the elimination of a variable changed the log odds ratio by more than 10%, the variable was 
considered a confounder.58 
  
Analysis to Address Specific Aim 3 
To determine if flavonoid intake is associated with survival among esophageal and gastric 
cancer cases, Kaplan-Meier curves were constructed to examine flavonoids as a univariate 
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predictor of survival and Cox proportional hazard regression analysis was used to calculate 
multivariable hazard ratios (HRs) and 95% confidence intervals for EA, GCA, ESCC, and 
NCGA as distinct outcomes. The proportional hazards (PH) assumption was evaluated 
through use of Kaplan-Meier curves and an interaction term between exposure and follow-
up time. The PH assumption was not observed to be violated. Potential confounders58 for 
the survival analysis included the same variables listed above in the logistic regression 
analysis as well as study site (WA, NJ, CT), age (continuous), sex (male/female), tumor 
stage (localized, regional, distant, and unknown), tumor grade (well/moderate, 
poor/undifferentiated, and not determined), and dysphagia (yes/no) (Figures 2.4 and 2.5).58 
  
Total Energy Intake 
Total energy intake was included in all models for specific aims 1-3.17 Generally, total energy 
intake is adjusted for in nutrient models because absolute intake of a specific nutrient is 
almost always positively correlated with total energy intake. Additionally, energy intake may 
confound relationships between specific nutrients and the outcome of interest.17 However, 
some nutrients may not be positively correlated with total energy and total energy may not 
be associated with disease. Individuals with implausible reporting of total energy intake were 
explored in the main analyses in two ways: 1) an a priori implausible definition of <500 or 
>4,000 kcal/day for women and <800 or >5,000 kcal/day for men and 2) an empirical 
approach of excluding individuals with reported total energy intake in the upper and lower 
1% and 2.5%.17 As the results from exclusion of participants based on implausible energy 
intake were similar between the a priori definition and the empirical approach, the a priori 
definition was utilized for excluding participants. The standard multivariate model, which 
includes a term for nutrient and total energy intake, was used for energy adjustment. This 
approach models nutrient intake in relation to the outcome when energy is held constant.  
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Sensitivity Analysis 
The main exposure of interest (flavonoids) was calculated from a food frequency questionnaire 
(FFQ), and some degree of misclassification due to recall error and proxy response was 
expected. Therefore, care was taken when interpreting the study results, and several analyses 
were conducted to determine the robustness of the study results. For the EGA study, an 
analysis restricting the data to participants who were interviewed directly (excluding all of the 
dietary data obtained in proxy interviews) was undertaken (Tables 2.14 and 2.15). The effect 
estimates were consistent with the overall analysis, which included proxy-report and self-report; 
therefore, proxy responses were included to increase power. 
 Collinearity was assessed using the residual model, where the main exposure variable in 
the logistic regression models is energy-adjusted flavonoid intake.17 A few challenges of the 
residual model include negative residuals, which can be difficult to interpret.17 As the results 
obtained from the standard multivariate and residual models were similar, only the results from 
the standard multivariate model were reported to ease interpretation of the study results (Tables 
2.16 and 2.17).  
 The multivariate nutrient density model, where the main exposure variable in the logistic 
regression models is flavonoid intake per 1000 kilocalories, was also utilized as a sensitivity 
analysis. This model is often highly correlated with the residual model. If energy intake is 
associated with the outcome, an association could be introduced by using the nutrient density 
model. The multivariate nutrient density model addresses the problem of confounding by total 
energy by adding total energy intake as additional covariate in the model.60 This model may be 
particularly advantageous if body size (and therefore total energy intake) varies greatly among 
study participants, as the standard multivariate and residual models imply that nutrient intake 
increments have the same effect in a small participant (with low levels of energy intake) and a 
large participant (with high levels of energy intake) (Tables 2.16 and 2.17).17 However, results 
were similar between the multivariate nutrient density and standard multivariate models. Thus, 
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only the standard multivariate model is reported. 
 Another sensitivity analysis was conducted excluding the anthocyanidin value for 
bananas. The USDA Flavonoid Database assigns a value of 7.39 mg/100 g of banana for 
anthocyanidins,18 which is controversial.61,62   
All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC). 
 
Statistical Power 
Power calculations are shown in Table 2.18 for risk of developing esophageal adenocarcinoma 
(EA), gastric cardia adenocarcinoma (GCA), esophageal squamous cell carcinoma (ESCC) and 
non-cardia gastric adenocarcinoma (NCGA) as separate outcomes and Barrett’s esophagus 
(BE). The sample size used for power calculations was based on the number of individuals with 
a food frequency questionnaire (FFQ) available. For the parent EGA study, participants with a 
FFQ available were: 282 EA cases, 255 GCA cases, 206 ESCC cases, 352 NCGA cases, and 
687 controls. For the parent BE study, participants with a FFQ available were: 170 BE cases 
and 182 controls. Power was computed by overall sample size and non-proxy sample size for 
the EGA study. In this study, proxies were utilized for 30.2% of case interviews (30.9% of EA, 
25.9% of GCA, 34.5% of ESCC, and 30.1% of NCGA) and 3.4% of control interviews. In Table 
2.18, power calculations are shown for survival among cases of EA, GCA, ESCC, and NCGA as 
separate outcomes. 
The goal of specific aim 1 was to determine if flavonoid intake was associated with risk 
of esophageal and gastric cancer incidence. Power to detect an association between flavonoids 
(dichotomous or quartiled) and esophageal or gastric cancer types as separate outcomes was 
determined using a 2-sided likelihood ratio chi-square test with a sample size of 255 cases and 
687 controls and α=0.05. This study had 96% power to detect an OR of 0.45 for the association 
between quartiled flavonoids and esophageal or gastric cancer. This effect estimate was similar 
to the association between anthocyanidins and EA incidence reported by Bobe et al. (OR=0.47). 
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As shown in Table 2.18, excluding proxies did not substantially alter power.  
The goal of specific aim 2 was to determine if flavonoid intake was associated with 
Barrett’s esophagus development. Power to detect an association between flavonoids 
(dichotomous or tertiled) and BE was determined using a 2-sided likelihood ratio chi-square test 
with sample size of 170 BE cases and 182 controls and α=0.05. This study had 84% power to 
detect an OR of 0.45 for the association between tertiled flavonoids and BE. The expected OR 
for the association between flavonoids and BE was anticipated to be stronger than the OR for 
flavonoids and EA or GCA63 or fruit/vegetable intake and BE (OR=0.39).52,64,65 
The goal of specific aim 3 was to determine if flavonoid intake was associated with 
survival among esophageal and gastric cancer cases. Power to detect an association between 
flavonoids (dichotomous or quartiles) and esophageal or gastric cancer types as separate 
outcomes was determined using a 2-sided log-rank test with a sample size of 255 cases, 
α=0.05, 7.5 years of follow-up, 86% events, and 5% loss. This study had 96% power to detect 
an OR of 0.45 for the association between quartiled flavonoids and survival among esophageal 
or gastric cancer cases. Excluding proxies did not substantially alter power, as shown in Table 
2.18. 
All power analyses were conducted in SAS version 9.2 (SAS Institute, Cary, NC). 
 
Strengths and Weaknesses 
The study approach was carefully developed to enhance study interpretation and mitigate 
the negative impact of any study limitations, which have been discussed throughout the 
study methods. Below, a brief review of the study approach is presented. 
 The major advantage of this study design is consideration of flavonoid intake across 
the cancer continuum – from precursor lesion, to invasive cancer, and finally mortality 
among cancer cases. This approach is novel – no other epidemiologic studies have 
considered the cancer continuum in relation to flavonoid intake. It is also biologically 
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plausible to consider this approach, because experimental data indicate that flavonoids may 
influence cancer development differently along the cancer continuum.66,67 Finally this study 
is significant because these cancers have a high fatality rate,47 and thus identification of a 
risk reduction strategy is a priority. 
 Data interpretation was enhanced because the study draws upon data from two 
parent studies of EGA and BE that are population- or community-based. This type of design 
enhances external validity. 
 Limitations of the study are that both study populations are primarily Caucasian and 
male, which limits external validity. However, rates of EA and GCA are highest among white 
males.68-71 Therefore, the study results are still generalizable to the majority of the 
population who are at higher risk for developing EA and GCA.  
 There is also possible selection bias in both parent studies from refusal to 
participate, potentially due to race or socioeconomic status (SES). However, in the parent 
EGA study, New Jersey was the only center to recruit African-Americans and the refusal 
rates were equivalent between races.57 In both parent studies, the distribution of SES 
included both high-income and low-income individuals.  
 In the parent EGA study, there was additional selection bias of those individuals who 
died before they could be recruited. When this happened, the next-of-kin (usually a spouse), 
was recruited when possible. Two studies on the reliability of dietary recall among self-
respondents and next-of-kin respondents showed that recall of dietary information was 
similar in both self-respondents and next-of-kin respondents.13,14 
 Another important consideration is that this study utilized dietary intake data that was 
collected as part of a FFQ. While some level of reporting error in a FFQ is expected, the 
FHCRC FFQ has been validated using 4-day food records8 and four 24-hour recalls10 as 
criterion instruments. Further, to date, no other studies of BE52,72,73 or EA/GCA56,72,74-81 have 
used an alternative to the FFQ to assess dietary intake. Thus, to overcome the limitations of 
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the FFQ, we would have to conduct a new study, probably a cohort study, which would be a 
far less cost effective strategy with which to test our hypothesis by employment of multiple 
alternative dietary assessment methods repeatedly over time. Additionally, despite rapidly 
increasing incidence rates in Western countries, esophageal and gastric tumors remain 
relatively rare. Thus a case-control study remains the best strategy for identifying risk factors 
for these tumors. In a case-control approach, the goal is to assess usual adult exposures 
prior to diagnosis, which are likely to better reflect the etiologic window of exposure for 
cancer. However, the use of currently measured flavonoid biomarkers is of limited 
usefulness in epidemiologic studies, because of the variation in absorption profiles, with 
maximum concentrations reached between 0.5-9 hours after dietary intake.18,82-85 To capture 
exposures over time, these alternatives would have to be repeated, which is not feasible in a 
cohort study.  
 Finally, multiple comparisons are a potential problem in this study looking at eight 
exposures (total flavonoids, six flavonoid classes, and lignans) and nine outcomes 
(development of BE, EA, GCA, ESCC, and NCGA, and survival among cases of EA, GCA, 
ESCC, and NCGA). Qualitative comparisons were made and care was taken in the 
interpretation of the results to not over interpret a result that could be due to multiple 
comparisons. 
 In sum, the strength and innovation of the study is that it is the first study to examine 
dietary flavonoid intake along the continuum of EA/GCA development. This approach is 
enhanced by utilizing population-based and community-based data. The major limitations 
that complicated data interpretation include the reliance on dietary data that was collected 
using a FFQ and the use of proxy data. However, for the latter issue, sensitivity analyses 
were conducted to assess the influence of this concern on the study results. Finally, this 
study is significant because there is potential to use flavonoids as a risk reduction strategy 
for these tumors. 
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Summary 
In the United States and many other Western countries, incidence of esophageal and gastric 
cardia adenocarcinoma (EA/GCA) is rapidly increasing, and Barrett’s esophagus (BE) is the 
only known potential precursor.86 Studying precursor lesions, such as Barrett’s esophagus, 
provides insight into the etiology of cancer by elucidating key risk factors that act early in 
disease onset. However, not all precursor lesions develop into cancer. Therefore, understanding 
the mechanisms by which precursor lesions do result in cancerous tumors can offer an 
opportunity to intervene and reduce the risk of disease progression. The goals of this 
dissertation were to investigate the potential association between flavonoid intake and 
esophageal and gastric cancer and BE as an ancillary study of two parent studies. The main 
exposure of interest (flavonoids) was calculated from a food frequency questionnaire, and some 
degree of misclassification due to recall error and proxy responses was possible. Therefore, 
care was taken when interpreting the study results; several analyses were conducted to explore 
the robustness of the results. Demonstration of an association between flavonoids and BE 
development, esophageal and gastric cancer incidence or survival among esophageal and 
gastric cancer cases suggests potential to use flavonoids as a risk reduction strategy for these 
tumors. This could allow some esophageal and gastric cancer to be prevented before 
individuals develop these deadly cancers or offer support for use of flavonoids as novel 
chemotherapy drugs. 
 
 
 
 Table 2.1. Distribution of Demographic Characteristics Among Case and Control Participants in the Parent EGA and BE Studies. 
 Esophageal and Gastric Cardia Adenocarcinoma Study   Barrett’s Esophagus Study 
 
 
 
Characteristic 
 
Control 
Participants 
Esophageal 
Adeno-
carcinoma 
Gastric Cardia 
Adeno-
carcinoma 
Esophageal 
Squamous 
Cell 
Carcinoma 
Non-cardia 
Gastric Adeno-
carcinoma 
  
 
 
Characteristic 
 
Control 
Participants 
Barrett’s 
Esophagus 
n=695 n=293 n=261 n=221 n=368  n=211 n=193 
Age 
   <57 
   57-64 
   65-71 
   >71 
 
179 (25.8) 
178 (25.6) 
176 (25.3) 
162 (23.3) 
 
76 (25.9) 
48 (16.4) 
79 (27.0) 
90 (30.7) 
 
65 (24.9) 
56 (21.5) 
71 (27.2) 
69 (26.4) 
 
34 (15.4) 
53 (24.0) 
74 (33.5) 
60 (27.2) 
 
65 (17.7) 
61 (16.6) 
93 (25.3) 
149 (40.5) 
 
Age 
   20-39 
   40-49 
   50-59 
   60-80 
 
31 (14.7) 
53 (25.1) 
64 (30.3) 
63 (29.9) 
 
27 (14.0) 
49 (25.4) 
57 (29.5) 
60 (31.1) 
Sex 
   Male 
   Female 
 
555 (79.9) 
140 (20.1) 
 
245 (83.6) 
48 (16.4) 
 
223 (85.4) 
38 (14.6) 
 
176 (79.6) 
45 (20.4) 
 
254 (69.0) 
114 (31.0) 
 
Sex 
   Male 
   Female 
 
133 (63.0) 
78 (37.0) 
 
118 (61.1) 
75 (38.8) 
Race 
   White 
   Black 
   Other 
 
646 (93.0) 
34 (4.9) 
15 (2.2) 
 
289 (98.6) 
2 (0.7) 
2 (0.7) 
 
252 (96.6) 
4 (1.5) 
5 (1.9) 
 
168 (76.0) 
48 (21.7) 
5 (2.3) 
 
307 (83.4) 
36 (9.8) 
25 (6.8) 
 
Race 
   White 
   Black 
   Other 
 
192 (91.0) 
5 (2.4) 
14 (6.6) 
 
172 (89.1) 
3 (1.6) 
18 (9.3) 
Education 
   ≤ High School 
   Technical  
   College+ 
 
308 (44.3) 
175 (25.2) 
212 (30.5) 
 
158 (53.9) 
78 (26.6) 
57 (19.5) 
 
141 (54.0) 
61 (23.4) 
59 (22.6) 
 
155 (70.1) 
38 (17.2) 
28 (12.7) 
 
225 (61.1) 
81 (22.0) 
61 (16.6) 
 
Education 
   ≤ High School 
   Technical  
   College+ 
 
42 (19.9) 
9 (4.2) 
160 (75.8) 
 
49 (25.4) 
9 (4.7) 
135 (70.0) 
Income, US $ 
   <15,000 
   15,000-29,999 
   30,000-49,999 
   50,000-74,000 
   >75,000 
 
93 (13.4) 
177 (25.5) 
175 (25.2) 
126 (18.1) 
124 (17.8) 
 
60 (20.5) 
87 (29.7) 
69 (23.5) 
42 (14.3) 
35 (11.9) 
 
41 (15.7) 
81 (31.0) 
65 (24.9) 
37 (14.2) 
37 (14.2) 
 
71 (32.1) 
75 (33.9) 
56 (25.3) 
9 (4.1) 
10 (4.5) 
 
87 (23.6) 
15 (4.1) 
100 (27.2) 
46 (12.5) 
20 (5.4) 
 
Income, US $ 
   < 45,000 
   45,000-74,999 
   75,000+ 
   Unknown 
 
61 (28.9) 
68 (27.0) 
77 (36.5) 
16 (7.6) 
 
 
57 (29.5) 
56 (29.0) 
61 (31.6) 
19 (9.8) 
 
Geographic 
Center 
   Connecticut 
   New Jersey 
   Washington 
 
206 (29.6) 
333 (47.9) 
156 (22.5) 
 
80 (27.3) 
138 (47.1) 
75 (25.6) 
 
82 (31.4) 
113 (43.3) 
66 (25.3) 
 
83 (37.6) 
99 (44.8) 
39 (17.7) 
 
117 (31.8) 
172 (46.7) 
79 (21.5) 
 
Geographic 
Center 
   Washington 
       
 
211 (100.0) 
 
 
193 (100.0) 
 
Tumor Stage 
   Localized 
   Regional 
   Distant 
   Unknown 
   Missing 
 
 
76 (25.9) 
72 (24.6) 
83 (28.3) 
62 (21.2) 
0 
 
34 (13.0) 
120 (46.0) 
70 (26.8) 
37 (14.2) 
0 
 
50 (22.6) 
82 (37.1) 
40 (18.1) 
49 (22.2) 
0 
 
70 (19.1) 
161 (43.9) 
104 (28.3) 
29 (7.9) 
3 
 
Tumor Length* 
   SIM 
   VBE 
   LSBE 
 
 
 
193 (100.0) 
97 (50.3) 
54 (28.0) 
 
9
6
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Table 2.2. Fred Hutchinson Cancer Research Center Food Frequency Questionnaire Items 
That Contain at Least One Class of Flavonoid. 
 
Apples and Pears 
Apricots (fresh, canned, dried) 
Avocado and guacamole, including added to mixed dishes 
Bacon, breakfast sausage, and scrapple 
Bananas 
All other beans, such as baked, lima beans, black-eyed peas and chili without meat 
Bean soups, such as pea, lentil, black bean, potajes 
Beer 
Black tea 
Broccoli 
Regular burrito and enchilada 
Doughnuts, cakes, pastries, Pop-Tarts®, and pan dulce 
Cantaloupe, orange melon, muskmelon, mango and papaya 
Carrots, including mixed dishes with carrots 
Cauliflower, cabbage, sauerkraut and Brussels sprouts 
Cold cereal 
Milk on cereal (cold and cooked) 
Chili with meat and beans 
Chocolate candy and candy bars 
Coffee 
Milk, cream, or creamer in coffee and tea 
Coleslaw 
Cooked greens, such as spinach, mustard greens, turnip greens, collards 
Cookies 
Tomatoes cooked, tomato sauce, salsa and salsa picante 
Corn and hominy 
Cream soups such as chowders, potato, tomato, cheese, ajiaco 
Crispy quesadilla 
Dark breads, including dark bagels, rolls, pita bread, and English muffins 
Other dried fruit, such as raisins or prunes 
Eggs 
Flauta and crispy rolled tacos 
Butter, margarine or oil, on bread or tortillas 
Fat added when cooking beans, rice, vegetables, and potatoes 
Fat used to deep-fry, pan fry, or sauté 
Butter, margarine, sour cream, oils, or other fat added to vegetables, beans, rice, and potatoes, after 
cooking 
Fried chicken 
French fries, fried potatoes, fried rice, fried cassava and fritters 
Orange juice and grapefruit juice 
Tomatoes, fresh or juice 
Gravies made with meat drippings and white sauce 
Green tea 
Green peppers, green chilies, jalapenos, and green chili salsa 
Lettuce and plain lettuce salad 
Hot dogs, chorizo, and other sausage such as bratwurst 
Hard candy, jam, jelly, honey, or syrup 
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(Table 2.2. continued) 
Ice cream 
Low-fat or non-fat frozen desserts, such as frozen yogurt, sherbet, ice milk, and low-fat milkshakes 
Low-fat pizza 
Macaroni and cheese, lasagna, or noodles with a cream sauce 
All other melon, such as honeydew 
Menudo and tortilla soup 
Milk, all types (including canned and soy) not on cereal 
Mixed lettuce or spinach salad with vegetables such as carrots or tomatoes 
Cooked cereal and grits 
Onions and leeks, including in cooking 
Oranges, grapefruit and tangerines (not juice) 
Any other fruit, such as fruit cocktail, berries, grapes, applesauce, pineapple 
Other soups such as chicken noodle 
Other fruit juices such as apple grape 
Other potatoes, cassava, and yucca (boiled, baked, or mashed) 
Pancakes and waffles 
Peaches, nectarines and plums (fresh or canned) 
Peanut butter, peanuts, other nuts and seeds 
Green or English Peas 
All other pies, fried pastries, pastelitos and fruit empanadas 
Pizza 
Potato, macaroni, or pasta salads made with mayonnaise or oil 
Pudding, custard, and flan 
Pumpkin and sweet potato pie 
Red peppers and red chilies  
Rice, grains and plain noodles 
Refried beans 
Soft quesadilla 
Soft taco and enchilada baked without oil 
Spaghetti or other noodles with tomato sauce (and no meat) 
Spaghetti or other noodles with meat sauce 
Stew, pot pie and casseroles with meat or chicken 
Green or string beans 
Strawberries and kiwi 
Summer squash, zucchini, nopales, and okra 
Sweet potatoes and yams 
Taco and tostada 
Tamales, with or without meat 
Tofu and textured vegetable products 
Canned tuna, tuna salad, and tuna casserole 
Vegetables soups 
Watermelon and red melon 
White breads, including bagels, rolls, pita bread, and English muffins 
Wine 
Winter squash, such as acorn, butternut, pumpkin 
 
 
 
 Figure 2.1. Directed Acyclic Graph (DAG) of Potential Confounders of the Association Between Dietary Flavonoid Intake and 
Esophageal/Gastric Cardia Adenocarcinoma Development Risk. - - - Denotes a pathway that may not be present for all EA/GCA 
cases. 
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 Figure 2.2. Directed Acyclic Graph (DAG) of Potential Confounders of the Association Between Dietary Flavonoid Intake and 
Esophageal Squamous Cell Carcinoma and Non-cardia Gastric Adenocarcinoma Development Risk.  
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 Figure 2.3. Directed Acyclic Graph (DAG) of Potential Confounders of the Association Between Dietary Flavonoid Intake and 
Barrett’s Esophagus Development Risk. - - - Denotes a pathway that may not be present for all BE cases. 
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 Figure 2.4. Directed Acyclic Graph (DAG) of Potential Confounders of the Association Between Dietary Flavonoid Intake and 
Survival Among Cases of Esophageal/Gastric Cardia Adenocarcinoma. - - - Denotes a pathway that may not be present for all 
EA/GCA cases. 
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 Figure 2.5. Directed Acyclic Graph (DAG) of Potential Confounders of the Association Between Dietary Flavonoid Intake and 
Survival Among Cases of Esophageal Squamous Cell Carcinoma/Non-cardia Gastric Adenocarcinoma.  
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Table 2.3. Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for the Association 
Between Flavonoid and Lignan Intake and Risks of Esophageal and Gastric Cancer, U.S. Multi-
Center Study: Connecticut, New Jersey, and Western Washington State, 1993-1995. 
 
  
 
  
Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Women’s intake  
(mg/day)
2
 
Men’s intake  
(mg/day)
2
 
Controls 
(N=662) 
Cases 
(N=274) OR (95% CI) 
Cases 
(N=248) OR (95% CI) 
Total Flavonoids  
        0-63.73    0-63.91 166 84 1.00 59 1.00 
   63.74-104.32    63.92-96.36 165 52 0.59 (0.39, 0.90) 59 0.99 (0.65, 1.53) 
   104.33-304.96    96.37-191.03 166 53 0.59 (0.39, 0.90) 59 1.00 (0.65, 1.54) 
   ≥304.97    ≥191.04 165 85 0.96 (0.66, 1.42) 71 1.23 (0.81, 1.88) 
   P for trend
3
  
  
0.61 
 
0.07 
Anthocyanidins  
     
   0-7.57    0-7.11 165 99 1.00 67 1.00 
   7.58-11.25    7.12-11.87 166 69 0.63 (0.43, 0.93) 70 1.00 (0.66, 1.49) 
   11.26-18.14    11.88-19.08 166 59 0.53 (0.35, 0.79) 60 0.85 (0.56, 1.30) 
   ≥18.15    ≥19.09 165 47 0.43 (0.28, 0.65) 51 0.72 (0.46, 1.11) 
   P for trend
3
  
  
0.06 
 
0.91 
Flavan-3-ols  
     
   0-9.70    0-10.55 166 76 1.00 58 1.00 
   9.71-18.85    10.56-22.16 165 59 0.69 (0.46, 1.04) 51 0.80 (0.52, 1.25) 
   18.86-215.10    22.17-101.85 165 56 0.65 (0.42, 0.98) 69 1.08 (0.71, 1.66) 
   ≥215.11    ≥101.86 166 83 1.02 (0.69, 1.51) 70 1.19 (0.78, 1.81) 
   P for trend
3
  
  
0.32 
 
0.07 
Flavanones  
     
   0-13.22    0-10.74 165 91 1.00 61 1.00 
   13.23-39.40    10.75-34.47 166 64 0.70 (0.47, 1.03) 57 0.92 (0.60, 1.40) 
   39.41-51.14    34.48-48.75 166 61 0.65 (0.44, 0.97) 56 0.96 (0.62, 1.47) 
    ≥51.15    ≥48.76 165 58 0.61 (0.41, 0.92) 74 1.25 (0.82, 1.90) 
   P for trend
3
  
  
0.003 
 
0.82 
Flavones  
     
   0-1.39    0-1.25 165 84 1.00 59 1.00 
   1.40-1.90    1.26-1.88 166 55 0.61 (0.40, 0.92) 55 0.87 (0.56, 1.33) 
   1.91-2.53    1.89-2.62 165 60 0.67 (0.45, 1.01) 65 1.03 (0.67, 1.57) 
   ≥2.54    ≥2.63 166 75 0.81 (0.54, 1.21) 69 1.06 (0.69, 1.63) 
   P for trend
3
  
  
0.81 
 
0.15 
Flavonols  
     
   0-8.07    0-8.32 165 84 1.00 51 1.00 
   8.08-12.55    8.33-11.99 166 51 0.59 (0.39, 0.89) 65 1.28 (0.83, 1.97) 
   12.56-20.80    12.00-17.58 165 64 0.72 (0.48, 1.07) 56 1.10 (0.71, 1.71) 
   ≥20.81    ≥17.59 166 75 0.77 (0.52, 1.14) 76 1.35 (0.88, 2.08) 
   P for trend
3
  
  
0.71 
 
0.10 
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(Table 2.3. continued) 
  
 
  
Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Women’s intake  
(mg/day)
2
 
Men’s intake  
(mg/day)
2
 
Controls 
(N=662) 
Cases 
(N=274) OR (95% CI) 
Cases 
(N=248) OR (95% CI) 
Isoflavones  
        0-0.24    0-0.27 166 49 1.00 38 1.00 
   0.25-0.37    0.28-0.42 165 50 0.95 (0.60, 1.50) 62 1.48 (0.93, 2.36) 
   0.38-0.52    0.43-0.59 166 78 1.39 (0.89, 2.18) 69 1.51 (0.93, 2.43) 
   ≥0.53    ≥0.60 165 97 1.72 (1.08, 2.74) 79 1.66 (1.00, 2.73) 
   P for trend
3
  
  
0.07 
 
0.17 
Lignans  
     
   0-0.043    0-0.045 166 69 1.00 50 1.00 
   0.044-0.062    0.046-0.062 165 76 0.96 (0.64, 1.43) 61 1.10 (0.71, 1.71) 
   0.063-0.081    0.063-0.082 166 56 0.64 (0.42, 0.98) 68 1.15 (0.74, 1.77) 
   ≥0.082    ≥0.083 165 73 0.78 (0.52, 1.19) 69 1.07 (0.69, 1.67) 
   P for trend
3
  
  
0.26 
 
0.63 
 
  
 
Esophageal  
Squamous  
Cell Carcinoma 
Other Gastric  
Adenocarcinoma 
Women’s intake  
(mg/day)
2
 
Men’s intake  
(mg/day)
2
 
Cases 
(N=191) OR (95% CI) 
Cases 
(N=341) OR (95% CI) 
Total Flavonoids  
       0-63.73    0-63.91 48 1.00 80 1.00 
   63.74-104.32    63.92-96.36 36 0.66 (0.39, 1.09) 86 1.02 (0.69, 1.50) 
   104.33-304.96    96.37-191.03 62 1.11 (0.70, 1.78) 84 0.95 (0.64, 1.40) 
   ≥304.97    ≥191.04 45 0.84 (0.52, 1.37) 91 1.04 (0.71, 1.54) 
   P for trend
3
  
 
0.42 
 
0.50 
Anthocyanidins  
    
   0-7.57    0-7.11 69 1.00 93 1.00 
   7.58-11.25    7.12-11.87 52 0.66 (0.42, 1.03) 89 0.92 (0.63, 1.33) 
   11.26-18.14    11.88-19.08 34 0.40 (0.24, 0.65) 94 0.91 (0.63, 1.33) 
   ≥18.15    ≥19.09 36 0.43 (0.26, 0.70) 65 0.65 (0.44, 0.98) 
   P for trend
3
  
 
0.11 
 
0.10 
Flavan-3-ols  
    
   0-9.70    0-10.55 45 1.00 70 1.00 
   9.71-18.85    10.56-22.16 36 0.74 (0.44, 1.24) 98 1.41 (0.96, 2.09) 
   18.86-215.10    22.17-101.85 65 1.24 (0.78, 1.99) 79 1.06 (0.71, 1.60) 
   ≥215.11    ≥101.86 45 0.93 (0.57, 1.53) 94 1.26 (0.85, 1.87) 
   P for trend
3
  
 
0.68 
 
0.36 
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(Table 2.3. continued) 
  
 Esophageal  
Squamous  
Cell Carcinoma 
Other Gastric  
Adenocarcinoma 
Women’s intake  
(mg/day)
2
 
Men’s intake  
(mg/day)
2
 
Cases 
(N=191) OR (95% CI) 
Cases 
(N=341) OR (95% CI) 
Flavanones  
       0-13.22    0-10.74 61 1.00 87 1.00 
   13.23-39.40    10.75-34.47 47 0.73 (0.46, 1.15) 84 0.98 (0.67, 1.43) 
   39.41-51.14    34.48-48.75 45 0.62 (0.39, 0.99) 81 0.85 (0.58, 1.25) 
    ≥51.15    ≥48.76 38 0.50 (0.31, 0.82) 89 0.93 (0.64, 1.37) 
   P for trend
3
  
 
0.002 
 
0.36 
Flavones  
    
   0-1.39    0-1.25 70 1.00 96 1.00 
   1.40-1.90    1.26-1.88 51 0.71 (0.46, 1.11) 86 0.93 (0.64, 1.36) 
   1.91-2.53    1.89-2.62 29 0.36 (0.22, 0.60) 70 0.77 (0.52, 1.13) 
   ≥2.54    ≥2.63 41 0.55 (0.34, 0.90) 89 1.03 (0.70, 1.53) 
   P for trend
3
  
 
0.02 
 
0.98 
Flavonols  
    
   0-8.07    0-8.32 56 1.00 81 1.00 
   8.08-12.55    8.33-11.99 34 0.59 (0.36, 0.97) 97 1.16 (0.80, 1.69) 
   12.56-20.80    12.00-17.58 41 0.74 (0.46, 1.20) 85 1.02 (0.69, 1.50) 
   ≥20.81    ≥17.59 60 0.89 (0.56, 1.41) 78 0.90 (0.61, 1.34) 
   P for trend
3
  
 
0.70 
 
0.92 
Isoflavones  
    
   0-0.24    0-0.27 32 1.00 62 1.00 
   0.25-0.37    0.28-0.42 53 1.34 (0.80, 2.25) 87 1.49 (0.99, 2.24) 
   0.38-0.52    0.43-0.59 56 1.17 (0.69, 2.01) 96 1.68 (1.10, 2.56) 
   ≥0.53    ≥0.60 50 0.84 (0.47, 1.49) 96 1.67 (1.07, 2.62) 
   P for trend
3
  
 
0.11 
 
0.37 
Lignans  
    
   0-0.043    0-0.045 66 1.00 84 1.00 
   0.044-0.062    0.046-0.062 48 0.66 (0.42, 1.04) 93 1.10 (0.75, 1.60) 
   0.063-0.081    0.063-0.082 42 0.51 (0.31, 0.82) 100 1.16 (0.79, 1.70) 
   ≥0.082    ≥0.083 35 0.39 (0.23, 0.64) 64 0.75 (0.49, 1.14) 
   P for trend
3
  
 
0.0003 
 
0.13 
1
Adjusted for age (continuous), sex, race (white, other), geographic center (Connecticut, New Jersey, 
Washington), cigarette smoking (ever/never), dietary energy intake (kilocalories, continuous). 
2Sex-
specific quartiles. 3P-value for trend for continuous variable. 
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Table 2.4. Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for the Association 
Between Flavonoid and Lignan Intake and Barrett’s Esophagus, Study of Reflux Disease, 
Western Washington State, 1997-2000. 
 
 
 
 
 
 
 
Women (mg/day) Men (mg/day)   
Controls 
(N=183)   
Cases 
(N=170)   OR (95% CI)2 
Total Flavonoids 
 
         0-58.64    0-37.61 
 
46 
 
49 
  
   58.65-100.80    37.62-60.71 
 
45 
 
33 
 
0.82 (0.43, 1.59) 
   100.81-198.70    60.72-146.89 
 
46 
 
50 
 
1.29 (0.70, 2.39) 
   ≥198.71    ≥146.90 
 
46 
 
38 
 
0.97 (0.51, 1.86) 
   P for trend3 
 
 
     
Anthocyanidins 
 
 
     
   0-7.04    0-5.70 
 
46 
 
62 
  
   7.05-13.13    5.71-9.37 
 
46 
 
38 
 
0.54 (0.30, 0.99) 
   13.14-22.21    9.38-17.00 
 
46 
 
34 
 
0.47 (0.25, 0.88) 
   ≥22.22    ≥17.01 
 
45 
 
36 
 
0.60 (0.32, 1.14) 
   P for trend3 
 
 
     
Flavan-3-ols 
 
 
     
   0-12.50    0-8.31 
 
45 
 
45 
  
   12.51-27.05    8.32-15.60 
 
46 
 
22 
 
0.51 (0.25, 1.02) 
   27.06-148.91    15.61-68.59 
 
45 
 
60 
 
1.63 (0.88, 3.00) 
   ≥148.92    ≥68.60 
 
47 
 
43 
 
1.09 (0.58, 2.07) 
   P for trend3 
 
 
     
Flavanones 
 
 
     
   0-5.37    0-3.38 
 
46 
 
60 
  
   5.38-15.79    3.39-11.21 
 
46 
 
38 
 
0.69 (0.37, 1.27) 
   15.80-30.52    11.22-25.18 
 
45 
 
37 
 
0.68 (0.37, 1.26) 
   ≥30.53    ≥25.19 
 
46 
 
35 
 
0.70 (0.37, 1.32) 
   P for trend3 
 
 
     
Flavones 
 
 
     
   0-1.09    0-1.24 
 
45 
 
40 
  
   1.10-1.87    1.25-1.93 
 
47 
 
38 
 
0.90 (0.47, 1.73) 
   1.88-2.41    1.94-3.00 
 
45 
 
50 
 
1.33 (0.69, 2.54) 
   ≥2.42    ≥3.01 
 
46 
 
42 
 
0.98 (0.50, 1.92) 
   P for trend3 
 
 
     
Flavonols 
 
 
     
   0-7.78    0-6.89 
 
46 
 
54 
  
   7.79-12.00    6.90-9.65 
 
45 
 
39 
 
0.76 (0.41, 1.43) 
   12.01-15.23    9.66-14.04 
 
46 
 
30 
 
0.56 (0.29, 1.09) 
   ≥15.24    ≥14.05 
 
46 
 
47 
 
0.94 (0.50, 1.77) 
   P for trend3 
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(Table 2.4. continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Adjusted for age (continuous), sex, body mass index (continuous), and kilocalories 
(continuous). 2Sex-specific quartiles. 3P-value for trend for continuous variable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Women (mg/day) Men (mg/day)   
Controls 
(N=183)   
Cases 
(N=170)   OR (95% CI)2 
Isoflavones 
 
         0-0.21    0-0.28 
 
46 
 
41 
  
   0.22-0.49    0.29-0.54 
 
46 
 
55 
 
1.19 (0.64, 2.24) 
   0.50-0.98    0.55-1.16 
 
46 
 
36 
 
0.78 (0.40, 1.51) 
   ≥0.99    ≥1.17 
 
45 
 
38 
 
0.77 (0.39, 1.52) 
   P for trend3 
 
 
     
Lignans 
 
 
     
   0-0.036    0-0.032 
 
46 
 
55 
  
   0.037-0.052    0.034-0.051 
 
45 
 
49 
 
0.84 (0.46, 1.56) 
   0.053-0.076    0.052-0.067 
 
47 
 
29 
 
0.46 (0.23, 0.93) 
   ≥0.077    ≥0.068 
 
45 
 
37 
 
0.62 (0.31, 1.23) 
   P for trend3     
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Figure 2.6. Restricted Quadratic Spline Graph of the Unadjusted Odds Ratios (represented by 
the solid line) and 95% Confidence Intervals (represented by the dotted lines) of the Association 
Between Total Flavonoid Intake and Esophageal and Gastric Cardia Adenocarcinoma, U.S. 
Multi-Center Study: Connecticut, New Jersey, and Western Washington State, 1993-1995. 
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Figure 2.6A: Esophageal Adenocarcinoma 
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Figure 2.6B: Esophageal Adenocarcinoma 
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Figure 2.6C: Esophageal Adenocarcinoma 
0.1
1.0
10.0
0 50 100 150 200 250
O
d
d
s
 R
a
ti
o
 
Total Flavonoids (mg/day) 
Decial knots: 30, 41, 52, 64, 77, 104, 175, 260, 471 
Reference: 23 
Figure 2.6D: Gastric Cardia Adenocarcinoma 
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Figure 2.6E: Gastric Cardia Adenocarcinoma 
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Figure 2.6F: Gastric Cardia Adenocarcinoma 
 Table 2.5. Adjusted1 Odds Ratios for Cyclin D1 Positive (+) and Cyclin D1 Negative (-) Esophageal and Gastric Cancer in Relation to 
Total Flavonoid Intake by Tumor Type, U.S. Multi-Center Study: Connecticut, New Jersey, and Western Washington State, 1993-
1995. 
 
        Cyclin D1+ Cases   Cyclin D1- Cases   
Ratio of the ORs  
(95% CI) Tumor type and  
intake (mg/day)   
Controls 
(N=662)   
Cases 
(N=266)   OR (95% CI)2   
Cases 
(N=333)   OR (95% CI)2   
Esophageal Adenocarcinoma 
           0-63.81 
 
166 
 
14 
 
1.00 
 
25 
 
1.00 
  
   ≥63.82 
 
496 
 
64 
 
1.39 (0.74, 2.62) 
 
50 
 
0.53 (0.31, 0.91) 
 
2.70 (1.22, 5.99) 
Gastric Cardia Adenocarcinoma 
         0-63.81 
 
166 
 
13 
 
1.00 
 
22 
 
1.00 
  
   ≥63.82 
 
496 
 
39 
 
0.91 (0.46, 1.80) 
 
68 
 
1.00 (0.58, 1.72) 
 
0.79 (0.33, 1.86) 
Esophageal Squamous Cell Carcinoma 
           0-63.81 
 
166 
 
13 
 
1.00 
 
8 
 
1.00 
  
   ≥63.82 
 
496 
 
69 
 
1.47 (0.76, 2.84) 
 
17 
 
0.61 (0.24, 1.53) 
 
2.63 (0.85, 8.11) 
Non-Cardia Gastric Adenocarcinoma 
           0-63.81 
 
166 
 
11 
 
1.00 
 
32 
 
1.00 
  
   ≥63.82   496  
43 
 
1.12 (0.54, 2.30) 
 
111 
 
1.00 (0.63, 1.59) 
 
1.01 (0.44, 2.32) 
1
Adjusted for age (continuous), sex, race (white, other), geographic center (Connecticut, New Jersey, Washington), cigarette smoking 
(ever/never), dietary energy intake (kilocalories, continuous). 
2
Odds ratio (95% confidence interval).  
 
 
 
 
 
 
 
1
1
2
 
 Table 2.6. Adjusted1 Odds Ratios for P53 Positive (+) and P53 Negative (-) Esophageal and Gastric Cancer in Relation to Total 
Flavonoid Intake by Tumor Type, U.S. Multi-Center Study: Connecticut, New Jersey, and Western Washington State, 1993-1995. 
 
        P53+ Cases   P53- Cases   
Ratio of the ORs  
(95% CI) Tumor type and  
intake (mg/day)   
Controls 
(N=662)   
Cases 
(N=389)   OR (95% CI)2   
Cases 
(N=225)   OR (95% CI)2   
Esophageal Adenocarcinoma 
           0-63.81 
 
166 
 
33 
 
1.00 
 
14 
 
1.00 
  
   ≥63.82 
 
496 
 
84 
 
0.75 (0.47, 1.20) 
 
32 
 
0.60 (0.30, 1.19) 
 
1.09 (0.49, 2.42) 
Gastric Cardia Adenocarcinoma 
          0-63.81 
 
166 
 
25 
 
1.00 
 
10 
 
1.00 
  
   ≥63.82 
 
496 
 
73 
 
0.99 (0.59, 1.65) 
 
32 
 
0.90 (0.42, 1.93) 
 
1.23 (0.49, 3.07) 
Esophageal Squamous Cell Carcinoma 
           0-63.81 
 
166 
 
10 
 
1.00 
 
15 
 
1.00 
  
   ≥63.82 
 
496 
 
57 
 
1.52 (0.73, 3.14) 
 
18 
 
0.36 (0.16, 0.79) 
 
5.60 (1.80, 17.46) 
Non-Cardia Gastric Adenocarcinoma 
           0-63.81 
 
166 
 
19 
 
1.00 
 
25 
 
1.00 
  
   ≥63.82   496  
88 
 
1.27 (0.73, 2.21) 
 
79 
 
0.94 (0.56, 1.58) 
 
1.24 (0.61, 2.51) 
1
Adjusted for age (continuous), sex, race (white, other), geographic center (Connecticut, New Jersey, Washington), cigarette smoking 
(ever/never), dietary energy intake (kilocalories, continuous). 
2
Odds ratio (95% confidence interval).  
 
 
  
 
 
 
 
 
 
 
1
1
3
 
 Table 2.7. Adjusted1 Odds Ratios for Esophageal and Gastric Cancer Stage2 in Relation to Total Flavonoid Intake by Tumor Type, 
U.S. Multi-Center Study: Connecticut, New Jersey, and Western Washington State, 1993-1995. 
 
    Localized Regional Distant Ratio of 
Localized/Distant 
(95% CI) 
Tumor type and  
intake (mg/day) 
Controls 
(N=662) 
Cases 
(N=217) OR (95% CI)
3
 
Cases 
(N=404) OR (95% CI)
3
 
Cases 
(N=271) OR (95% CI)
3
 
Esophageal Adenocarcinoma 
         0-63.81 166 31 1.00 24 1.00 15 1.00 
 
   ≥63.82 496 42 0.33 (0.20, 0.57) 46 0.61 (0.35, 1.06) 60 1.36 (0.74, 2.53) 0.31 (0.14, 0.70) 
Gastric Cardia Adenocarcinoma 
         0-63.81 166 8 1.00 24 1.00 17 1.00 
 
   ≥63.82 496 23 0.88 (0.37, 2.08) 90 1.22 (0.73, 2.02) 51 1.04 (0.57, 1.90) 0.78 (0.25, 2.43) 
Esophageal Squamous Cell Carcinoma 
         0-63.81 166 10 1.00 19 1.00 7 1.00 
 
   ≥63.82 496 35 1.06 (0.49, 2.30) 53 0.81 (0.45, 1.48) 26 0.98 (0.40, 2.40) 1.09 (0.32, 3.76) 
Non-Cardia Gastric Adenocarcinoma 
         0-63.81 166 17 1.00 42 1.00 17 1.00 
 
   ≥63.82 496 51 0.87 (0.48, 1.60) 106 0.77 (0.51, 1.18) 78 1.44 (0.81, 2.54) 0.67 (0.31, 1.46) 
1
Adjusted for age (continuous), sex, race (white, other), geographic center (Connecticut, New Jersey, Washington), cigarette smoking 
(ever/never), dietary energy intake (kilocalories, continuous). 
2
ORs not estimated for unknown cancer stage. 
3
Odds ratio (95% confidence 
interval).  
 
 
  
 
 
 
 
1
1
4
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Table 2.8. Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) from Conditional 
Logistic Regression Models for the Association Between Flavonoid and Lignan Intake and 
Barrett’s Esophagus, Study of Reflux Disease, Western Washington State, 1997-2000. 
 
Variable and  
intake (mg/day)   
Controls 
(N=155)   
Cases 
(N=144)   OR 
 
95% CI 
Total Flavonoids 
      
 
   0-42.38 
 
38 38 1.00  
   42.39-75.36 
 
39  32  1.05 0.48, 2.29 
   75.37-166.98 
 
38  42  1.34 0.65, 2.75 
   ≥166.99 
 
40  32  1.13 0.52, 2.47 
   P for trend2 
 
    0.80  
Anthocyanidins 
 
      
   0-6.12 
 
39  53  1.00  
   6.13-9.82 
 
37  20  0.26 0.11, 0.61 
   9.83-18.26 
 
39  40  0.62 0.31, 1.23 
   ≥18.27 
 
40  31  0.59 0.26, 1.31 
   P for trend2 
 
    0.94  
Flavan-3-ols 
 
      
   0-9.50 
 
37  39  1.00  
   9.51-17.35 
 
38  18  0.40 0.16, 0.97 
   17.36-107.34 
 
42  60  1.49 0.75, 2.97 
   ≥107.35 
 
38  27  0.91 0.42, 1.98 
   P for trend2 
 
    0.56  
Flavanones 
 
      
   0-3.80 
 
36  45  1.00  
   3.81-12.90 
 
40  34  0.69 0.30, 1.58 
   12.91-29.64 
 
38  36  0.79 0.38, 1.62 
   ≥29.65 
 
41  29  0.72 0.35, 1.49 
   P for trend2 
 
    0.26  
Flavones 
 
      
   0-1.15 
 
39  30  1.00  
   1.16-1.88 
 
36  32  1.16 0.51, 2.63 
   1.89-2.82 
 
39  43  1.62 0.74, 3.54 
   ≥2.83 
 
41  39  1.32 0.63, 2.76 
   P for trend2 
 
    0.62  
Flavonols 
 
      
   0-6.99 
 
39  44  1.00  
   7.00-10.86 
 
36  36  1.07 0.54, 2.12 
   10.87-14.89 
 
42  25  0.74 0.36, 1.53 
   ≥14.90 
 
38  39  1.21 0.57, 2.58 
   P for trend2 
 
    0.77  
Isoflavones 
 
      
   0-0.24 
 
39  32  1.00  
   0.25-0.52 
 
38  49  1.44 0.67, 3.12 
   0.53-1.16 
 
42  32  0.75 0.35, 1.61 
   ≥1.17 
 
36  31  0.68 0.27, 1.72 
   P for trend2 
 
    0.25  
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Variable and  
intake (mg/day)   
Controls 
(N=155)   
Cases 
(N=144)   OR 
 
95% CI 
Lignans 
 
      
   0-0.033 
 
38  45  1.00  
   0.034-0.051 
 
40  43  0.72 0.36, 1.45 
   0.052-0.070 
 
41  25  0.40 0.17, 0.93 
   ≥0.071 
 
36  31  0.59 0.26, 1.31 
   P for trend2      0.33  
1
Adjusted for age (continuous), sex, body mass index (continuous), and dietary energy intake 
(kilocalories, continuous). 
2
P-value for trend for continuous variable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2.9. Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for Effect Measure Modification2 Between Total Flavonoid 
Intake and Body Mass Index (BMI) and Esophageal and Gastric Cancer, U.S. Multi-Center Study: Connecticut, New Jersey, and 
Western Washington State, 1993-1995. 
 
 
 Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Non-Cardia  
Gastric  
Adenocarcinoma 
Total 
Flavonoids 
Controls 
(N=662) 
Cases 
(N=274) 
OR (95% CI) 
Cases 
(N=248) 
OR (95% CI) 
Cases 
(N=191) 
OR (95% CI) 
Cases 
(N=341) 
OR (95% CI) 
Overall 662 274 1.02 (0.97, 1.07) 248 0.97 (0.90, 1.04) 191 1.05 (0.99, 1.11) 341 1.01 (0.96, 1.07) 
   BMI <25 325 96 1.07 (0.99, 1.16) 98 1.02 (0.93, 1.12) 119 1.09 (1.00, 1.19) 173 1.04 (0.94, 1.15) 
   BMI ≥25 337 178 1.25 (0.91, 1.72) 150 0.73 (0.49, 1.09) 72 1.67 (1.16, 2.39) 168 1.95 (1.37, 2.80) 
1
Adjusted for age (continuous), sex, race (white, other), geographic center (Connecticut, New Jersey, Washington), cigarette smoking 
(ever/never), body mass index (<25, ≥25 kg/m
2
), and dietary energy intake (kilocalories, continuous). 
2
Likelihood ratio test (LRT) for continuous 
total flavonoid intake (per 100 mg/day) and dichotomized BMI (<25 versus ≥25 kg/m
2
): χ
2
=4.357, d.f.=4, pint=0.36; LRT for continuous flavonoid 
intake (per 100 mg/day) and continuous BMI (kg/m
2
): χ
2
=2.725, d.f.=4, pint=0.60.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
1
7
 
 Table 2.10. Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for Effect Measure Modification2 Between Total 
Flavonoid Intake and Cigarette Smoking and Esophageal and Gastric Cancer, U.S. Multi-Center Study: Connecticut, New Jersey, 
and Western Washington State, 1993-1995. 
 
 
 Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Non-Cardia  
Gastric  
Adenocarcinoma 
Total 
Flavonoids 
Controls 
(N=662) 
Cases 
(N=274) 
OR (95% CI)† 
Cases 
(N=248) 
OR (95% CI)† 
Cases 
(N=191) 
OR (95% CI)† 
Cases 
(N=341) 
OR (95% CI)† 
Overall 662 274 1.02 (0.97, 1.07) 248 0.97 (0.90, 1.04) 191 1.05 (1.00, 1.11) 341 1.02 (0.96, 1.08) 
   Never Smoker 237 61 1.07 (0.96, 1.18) 52 0.85 (0.61, 1.19) 16 1.08 (0.95, 1.22) 96 1.05 (0.92, 1.18) 
   Ever Smoker 425 213 1.73 (1.18, 2.52) 196 4.64 (2.18, 9.87) 175 2.19 (1.40, 3.42) 244 1.96 (1.28, 3.00 
1
Adjusted for age (continuous), sex, race (white, other), geographic center (Connecticut, New Jersey, Washington), cigarette smoking 
(ever/never), and dietary energy intake (kilocalories, continuous). 
2
Likelihood ratio test (LRT) for continuous total flavonoid intake (per 100 mg/day) 
and dichotomized cigarette smoking (ever/never): χ
2
=1.907, d.f.=4, pint=0.75; LRT for continuous flavonoid intake (per 100 mg/day) and continuous 
cigarette smoking duration (years): χ
2
=1.900, d.f.=4, pint=0.75.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
1
8
 
 Table 2.11. Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for Effect Measure Modification2 Between Total 
Flavonoid Intake and Gastroesophageal Reflux Disease and Esophageal and Gastric Cancer, U.S. Multi-Center Study: Connecticut, 
New Jersey, and Western Washington State, 1993-1995. 
 
 
 Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Non-Cardia  
Gastric  
Adenocarcinoma 
Total 
Flavonoids 
Controls 
(N=662) 
Cases 
(N=274) 
OR (95% CI)† 
Cases 
(N=248) 
OR (95% CI)† 
Cases 
(N=191) 
OR (95% CI)† 
Cases 
(N=341) 
OR (95% CI)† 
Overall 662 274 1.02 (0.97, 1.07) 248 0.97 (0.90, 1.05) 191 1.05 (1.00, 1.11) 341 1.02 (0.96, 1.08) 
   No GERD  473 123 0.96 (0.89, 1.03) 153 0.97 (0.89, 1.05) 154 1.04 (0.98, 1.12) 211 1.01 (0.93, 1.09) 
   GERD 189 151 1.23 (0.88, 1.72) 95 0.52 (0.33, 0.82) 37 1.47 (1.03, 2.11) 130 2.88 (2.03, 4.08) 
1
Adjusted for age (continuous), sex, race (white, other), geographic center (Connecticut, New Jersey, Washington), cigarette smoking 
(ever/never), and dietary energy intake (kilocalories, continuous). 
2
Likelihood ratio test (LRT) for continuous total flavonoid intake (per 100 mg/day) 
and dichotomized GERD (yes/no): χ
2
=7.143, d.f.=4, pint=0.13.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
1
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Table 2.12. Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for Effect Measure 
Modification2 Between Total Flavonoid Intake and Body Mass Index (BMI) and Barrett’s 
Esophagus, Study of Reflux Disease, Western Washington State, 1997-2000. 
 
Total Flavonoids  
per 100 mg/dayb   
Controls 
(N=183)   
Cases 
(N=170)   OR 
 
95% CI 
Overall 
 
183  170  1.03 0.86, 1.23 
   BMI <25 
 
57  33  1.08 0.80, 1.47 
   BMI ≥25 
 
126  137  1.81 0.89, 3.65 
1
Adjusted for age (continuous), sex, body mass index (<25, ≥25 kg/m
2
), and dietary energy intake 
(kilocalories, continuous). 
2
Likelihood ratio test (LRT) for continuous total flavonoid intake (per 100 
mg/day) and dichotomized BMI (<25 versus ≥25 kg/m
2
): χ
2
=0.155, d.f.=1, pint=0.69; LRT for continuous 
flavonoid intake (per 100 mg/day) and continuous BMI (kg/m
2
): χ
2
=0.298, d.f.=1, pint=0.59.  
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Table 2.13. Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for Effect Measure 
Modification2 Between Total Flavonoid Intake and Cigarette Smoking and Barrett’s Esophagus, 
Study of Reflux Disease, Western Washington State, 1997-2000. 
 
Total Flavonoids  
per 100 mg/dayb   
Controls 
(N=183)   
Cases 
(N=170)   OR 
 
95% CI 
Overall 
 
183  170  1.04 0.87, 1.25 
   Never Smoker 
 
94  61  1.06 0.80, 1.41 
   Ever Smoker 
 
89  109  2.17 1.20, 3.90 
1
Adjusted for age (continuous), sex, body mass index (continuous), cigarette smoking (ever/never), and 
dietary energy intake (kilocalories, continuous). 
2
Likelihood ratio test (LRT) for continuous total flavonoid 
intake (per 100 mg/day) and dichotomized cigarette smoking (ever/never): χ
2
=0.035, d.f.=1, pint=0.85; 
LRT for continuous flavonoid intake (per 100 mg/day) and continuous cigarette smoking (pack-years): 
χ
2
=2.126, d.f.=1, pint=0.14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2.14. Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for the Association Between Flavonoid and Lignan 
Intake Among Non-proxy Incident Esophageal and Gastric Cancers, U.S. Multi-Center Study: Connecticut, New Jersey, and Western 
Washington State, 1993-1995. 
 
    
Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Non-Cardia  
Gastric  
Adenocarcinoma 
Variable and  
intake (mg/day) 
Controls 
(N=643) 
Cases 
(N=190) OR (95% CI) 
Cases 
(N=182) OR (95% CI) 
Cases 
(N=128) OR (95% CI) 
Cases 
(N=241) OR (95% CI) 
Total Flavonoids 
            0-63.81 161 69 1.00 36 1.00 31 1.00 56 1.00 
   63.82-97.90 162 33 0.46 (0.28, 0.74) 45 1.21 (0.73, 1.99) 22 0.65 (0.35, 1.19) 56 0.99 (0.64, 1.54) 
   97.91-217.35 158 33 0.45 (0.28, 0.73) 41 1.09 (0.65, 1.82) 41 1.19 (0.69, 2.07) 59 1.04 (0.66, 1.62) 
   ≥217.36 162 55 0.81 (0.52, 1.25) 60 1.74 (1.07, 2.82) 34 0.99 (0.56, 1.74) 70 1.15 (0.75, 1.77) 
   P for trend
2
 
  
0.86 
 
0.03 
 
0.97 
 
0.38 
Anthocyanidins 
         
   0-7.21 159 71 1.00 47 1.00 47 1.00 66 1.00 
   7.22-11.53 162 48 0.62 (0.40, 0.96) 51 1.03 (0.65, 1.63) 37 0.68 (0.41, 1.14) 64 0.89 (0.58, 1.35) 
   11.54-18.47 162 36 0.43 (0.27, 0.70) 42 0.80 (0.49, 1.31) 22 0.34 (0.19, 0.62) 61 0.78 (0.50, 1.20) 
   ≥18.48 160 35 0.43 (0.27, 0.70) 42 0.81 (0.50, 1.31) 22 0.36 (0.20, 0.65) 50 0.67 (0.43, 1.04) 
   P for trend
2
 
  
0.32 
 
0.64 
 
0.07 
 
0.13 
Flavan-3-ols 
         
   0-10.29 160 53 1.00 38 1.00 32 1.00 50 1.00 
   10.30-22.00 164 45 0.71 (0.44, 1.13) 35 0.78 (0.47, 1.31) 19 0.54 (0.29, 1.02) 72 1.40 (0.90, 2.17) 
   22.01-130.69 157 37 0.59 (0.36, 0.97) 54 1.20 (0.73, 1.95) 43 1.23 (0.71, 2.13) 47 0.96 (0.60, 1.54) 
   ≥130.70 162 55 0.99 (0.63, 1.55) 55 1.39 (0.86, 2.25) 34 0.97 (0.55, 1.70) 72 1.35 (0.87, 2.08) 
   P for trend
2
 
  
0.48 
 
0.03 
 
0.76 
 
0.31 
Flavanones 
         
   0-11.57 161 71 1.00 40 1.00 39 1.00 56 1.00 
   11.58-34.95 163 47 0.65 (0.42, 1.00) 42 1.02 (0.63, 1.68) 32 0.80 (0.47, 1.37) 58 1.04 (0.67, 1.61) 
   34.96-49.52 160 39 0.56 (0.36, 0.89) 43 1.15 (0.70, 1.88) 34 0.81 (0.47, 1.39) 59 1.02 (0.66, 1.59) 
   ≥49.53 159 33 0.47 (0.29, 0.76) 57 1.48 (0.92, 2.40) 23 0.48 (0.27, 0.87) 68 1.10 (0.71, 1.70) 
   P for trend
2
 
  
0.0001 
 
0.40 
 
0.02 
 
0.82 
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 (Table 2.14. continued)  
 
  
Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Non-Cardia  
Gastric  
Adenocarcinoma 
Variable and  
intake (mg/day) 
Controls 
(N=643) 
Cases 
(N=190) 
OR (95% CI) 
Cases 
(N=182) 
OR (95% CI) 
Cases 
(N=128) 
OR (95% CI) 
Cases 
(N=241) 
OR (95% CI) 
Flavones 
         
   0-1.29 157 62 1.00 40 1.00 50 1.00 65 1.00 
   1.30-1.90 164 33 0.47 (0.29, 0.76) 41 0.91 (0.55, 1.49) 35 0.63 (0.38, 1.06) 65 0.95 (0.63, 1.45) 
   1.91-2.62 160 42 0.62 (0.39, 0.99) 47 1.06 (0.65, 1.73) 18 0.27 (0.15, 0.51) 49 0.70 (0.45, 1.10) 
   ≥2.63 162 53 0.74 (0.47, 1.16) 54 1.16 (0.71, 1.89) 25 0.42 (0.24, 0.76) 62 0.94 (0.61, 1.47) 
   P for trend
2
 
  
0.83 
 
0.10 
 
0.008 
 
0.82 
Flavonols 
         
   0-8.31 163 62 1.00 37 1.00 40 1.00 62 1.00 
   8.32-12.16 160 31 0.49 (0.30, 0.79) 45 1.18 (0.72, 1.94) 17 0.40 (0.21, 0.74) 60 0.96 (0.63, 1.48) 
   12.17-17.81 160 42 0.65 (0.41, 1.02) 38 1.00 (0.60, 1.67) 27 0.68 (0.39, 1.19) 58 0.95 (0.62, 1.46) 
   ≥17.82 160 55 0.80 (0.51, 1.25) 62 1.52 (0.94, 2.45) 44 0.94 (0.56, 1.58) 61 0.92 (0.60, 1.43) 
   P for trend
2
 
  
0.78 
 
0.04 
 
0.65 
 
0.94 
Isoflavones 
         
   0-0.27 158 34 1.00 22 1.00 25 1.00 36 1.00 
   0.28-0.41 160 31 0.78 (0.45, 1.34) 46 1.70 (0.97, 3.00) 33 1.01 (0.55, 1.85) 64 1.83 (1.13, 2.96) 
   0.42-0.59 165 55 1.27 (0.76, 2.12) 56 1.84 (1.04, 3.26) 41 1.16 (0.63, 2.13) 73 2.21 (1.35, 3.62) 
   ≥0.60 160 70 1.54 (0.90, 2.63) 58 1.77 (0.97, 3.25) 29 0.61 (0.31, 1.22) 68 1.97 (1.16, 3.34) 
   P for trend
2
 
  
0.06 
 
0.21 
 
0.14 
 
0.30 
Lignans 
         
   0-0.045 159 52 1.00 32 1.00 46 1.00 59 1.00 
   0.046-0.063 160 53 0.87 (0.55, 1.36) 39 1.04 (0.62, 1.77) 33 0.67 (0.40, 1.15) 61 1.07 (0.69, 1.66) 
   0.064-0.082 163 34 0.51 (0.31, 0.84) 59 1.49 (0.90, 2.45) 26 0.46 (0.26, 0.81) 70 1.14 (0.74, 1.77) 
   ≥0.083 161 51 0.70 (0.44, 1.11) 52 1.19 (0.71, 1.98) 23 0.37 (0.20, 0.67) 51 0.82 (0.52, 1.31) 
   P for trend
2
 
  
0.41 
 
0.30 
 
0.002 
 
0.42 
1
Adjusted for age (continuous), sex, race (white, other), geographic center (Connecticut, New Jersey, Washington), cigarette smoking 
(ever/never), dietary energy intake (kilocalories, continuous). 
2
P-value for trend for continuous variable. 
1
2
3
 
 Table 2.15. Adjusted1 Hazard Ratios (HR) and 95% Confidence Internals (CI) for Flavonoid and Lignan Intake and Overall Mortality 
Among Non-proxy Esophageal and Gastric Cancer Cases by Tumor Type, U.S. Multi-Center Study: Connecticut, New Jersey, and 
Western Washington State, 1993–1995 through 2000. 
 
 
Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Non-Cardia  
Gastric  
Adenocarcinoma 
Variable and  
intake (mg/day) 
Cases 
(N=190) 
HR (95% CI) 
Cases 
(N=182) 
HR (95% CI) 
Cases 
(N=128) 
HR (95% CI) 
Cases 
(N=238) 
HR (95% CI) 
Total Flavonoids 
        
   0-62.35 69 1.00 35 1.00 30 1.00 54 1.00 
   62.36-103.39 36 1.18 (0.76, 1.85) 50 1.44 (0.88, 2.34) 27 1.45 (0.81, 2.59) 64 1.15 (0.74, 1.78) 
   103.40-253.24 41 1.23 (0.80, 1.90) 46 1.01 (0.62, 1.65) 41 1.03 (0.60, 1.77) 58 0.78 (0.49, 1.24) 
   ≥253.25 44 0.78 (0.49, 1.22) 51 1.08 (0.65, 1.79) 30 1.03 (0.58, 1.82) 62 1.08 (0.71, 1.65) 
   P for trend
2
 
 
0.02 
 
0.98 
 
0.29 
 
0.65 
Anthocyanidins 
        
   0-6.23 61 1.00 34 1.00 41 1.00 50 1.00 
   6.24-10.11 42 0.88 (0.55, 1.40) 52 0.96 (0.60, 1.54) 38 0.78 (0.46, 1.33) 63 1.46 (0.93, 2.28) 
   10.12-16.23 43 0.78 (0.50, 1.22) 42 0.88 (0.53, 1.46) 24 1.48 (0.83, 2.63) 58 1.41 (0.88, 2.26) 
   ≥16.24 44 0.82 (0.53, 1.29) 54 0.74 (0.45, 1.22) 25 0.88 (0.51, 1.52) 67 1.25 (0.79, 1.98) 
   P for trend
2
 
 
0.25 
 
0.35 
 
0.77 
 
0.63 
Flavan-3-ols 
        
   0-10.90 56 1.00 39 1.00 34 1.00 53 1.00 
   10.91-26.67 45 1.00 (0.65, 1.56) 39 0.77 (0.46, 1.28) 23 1.24 (0.68, 2.26) 74 1.43 (0.92, 2.20) 
   26.68-210.51 44 1.19 (0.77, 1.85) 55 0.89 (0.56, 1.40) 41 0.87 (0.51, 1.48) 47 0.98 (0.61, 1.60) 
   ≥210.52 45 0.93 (0.59, 1.45) 49 0.75 (0.46, 1.22) 30 1.03 (0.59, 1.81) 64 1.33 (0.86, 2.05) 
   P for trend
2
 
 
0.02 
 
0.92 
 
0.25 
 
0.60 
Flavanones 
        
   0-8.63 63 1.00 35 1.00 32 1.00 46 1.00 
   8.64-32.94 52 1.01 (0.67, 1.54) 46 1.36 (0.81, 2.27) 37 1.10 (0.63, 1.92) 62 0.78 (0.49, 1.24) 
   34.95-49.00 41 1.57 (1.02, 2.41) 42 1.57 (0.95, 2.60) 35 1.36 (0.78, 2.38) 61 0.87 (0.54, 1.39) 
   ≥49.01 34 0.91 (0.55, 1.48) 59 1.01 (0.62, 1.64) 24 2.00 (1.06, 3.79) 69 0.71 (0.45, 1.12) 
   P for trend
2
 
 
0.40 
 
0.76 
 
0.36 
 
0.65 
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  (Table 2.15. continued) 
 
  Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Non-Cardia  
Gastric  
Adenocarcinoma 
Variable and  
intake (mg/day) 
Cases 
(N=190) 
HR (95% CI) 
Cases 
(N=182) 
HR (95% CI) 
Cases 
(N=128) 
HR (95% CI) 
Cases 
(N=238) 
HR (95% CI) 
Flavones 
        
   0-1.20 60 1.00 31 1.00 45 1.00 49 1.00 
   1.21-1.81 30 0.76 (0.46, 1.26) 45 1.26 (0.76, 2.11) 33 1.56 (0.95, 2.56) 73 0.93 (0.61, 1.43) 
   1.82-2.64 49 0.84 (0.55, 1.28) 52 1.05 (0.63, 1.74) 26 0.92 (0.52, 1.63) 57 0.87 (0.55, 1.40) 
   ≥2.65 51 0.79 (0.51, 1.21) 54 0.94 (0.56, 1.58) 24 0.94 (0.54, 1.66) 59 0.91 (0.57, 1.45) 
   P for trend
2
 
 
0.08 
 
0.69 
 
0.20 
 
0.44 
Flavonols 
        
   0-8.16 59 1.00 35 1.00 39 1.00 59 1.00 
   8.17-12.30 36 1.21 (0.75, 1.94) 49 1.62 (0.99, 2.67) 19 0.76 (0.40, 1.45) 62 0.83 (0.54, 1.30) 
   12.31-19.34 53 1.18 (0.78, 1.80) 44 1.16 (0.70, 1.94) 33 0.68 (0.40, 1.16) 60 1.16 (0.76, 1.76) 
   ≥19.35 42 0.80 (0.50, 1.27) 54 1.06 (0.64, 1.75) 37 0.85 (0.51, 1.42) 57 0.92 (0.60, 1.41) 
   P for trend
2
 
 
0.01 
 
0.42 
 
0.66 
 
0.52 
Isoflavones 
        
   0-0.31 46 1.00 40 1.00 35 1.00 53 1.00 
   0.32-0.46 32 0.73 (0.44, 1.21) 38 1.32 (0.80, 2.19) 40 0.88 (0.52, 1.48) 66 1.61 (1.02, 2.54) 
   0.47-0.62 52 0.67 (0.42, 1.06) 52 0.97 (0.58, 1.62) 29 1.12 (0.63, 1.99) 60 1.04 (0.64, 1.68) 
   ≥0.63 60 0.77 (0.47, 1.25) 52 1.26 (0.75, 2.13) 24 0.89 (0.48, 1.67) 59 1.20 (0.71, 2.01) 
   P for trend
2
 
 
0.50 
 
0.21 
 
0.75 
 
0.63 
Lignans 
        
   0-0.044 50 1.00 32 1.00 42 1.00 57 1.00 
   0.045-0.060 52 0.83 (0.54, 1.28) 34 1.46 (0.83, 2.55) 35 0.71 (0.41, 1.22) 56 1.33 (0.84, 2.09) 
   0.061-0.079 34 0.89 (0.54, 1.47) 55 1.32 (0.80, 2.19) 26 0.55 (0.31, 0.97) 72 1.13 (0.74, 1.72) 
   ≥0.080 54 0.69 (0.44, 1.08) 61 1.17 (0.71, 1.93) 25 0.51 (0.29, 0.90) 53 1.16 (0.73, 1.86) 
   P for trend
2
 
 
0.28 
 
0.90 
 
0.07 
 
0.88 
1
Adjusted for stage (localized, regional, distant, unknown) and dietary energy intake (kilocalories, continuous). 
2
P-value for trend of continuous 
variable. 
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 Table 2.16. Sensitivity Analysis of Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for the Association Between Total 
Flavonoid Intake and Esophageal and Gastric Cancer, U.S. Multi-Center Study: Connecticut, New Jersey, and Western Washington 
State, 1993-1995. 
 
 
 
Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Non-Cardia  
Gastric  
Adenocarcinoma 
Total 
Flavonoids 
Controls 
(N=662) 
Cases 
(N=274) 
OR (95% CI) 
Cases 
(N=248) 
OR (95% CI) 
Cases 
(N=191) 
OR (95% CI) 
Cases 
(N=341) 
OR (95% CI) 
Standard Multivariate Model (flavonoid mg/day) 
      
   0-63.81 165 83 1.00 59 1.00 48 1.00 80 1.00 
   63.82-97.90 166 54 0.62 (0.41, 0.93) 60 1.00 (0.65, 1.54) 35 0.64 (0.38, 1.07) 84 1.01 (0.69, 1.49) 
   97.91- 
   217.35 
165 57 0.64 (0.42, 0.97) 54 0.90 (0.58, 1.41) 61 1.11 (0.69, 1.77) 78 0.92 (0.62, 1.37) 
   ≥217.36 166 80 0.92 (0.63, 1.37) 75 1.32 (0.87, 2.00) 47 0.87 (0.53, 1.41) 99 1.08 (0.73, 1.58) 
   P for trend
2
  
 
0.61 
 
0.07 
 
0.42 
 
0.50 
Nutrient Density Model (flavonoid mg/1000 kcal) 
      
   0-30.62 165 86 1.00 69 1.00 56 1.00 79 1.00 
   30.63-48.95 166 59 0.70 (0.47, 1.05) 54 0.84 (0.55, 1.28) 41 0.81 (0.50, 1.30) 83 1.05 (0.71, 1.55) 
   48.96- 
   102.90 
165 51 0.66 (0.43, 1.01) 51 0.88 (0.57, 1.36) 55 1.27 (0.80, 2.01) 74 0.97 (0.65, 1.45) 
   ≥102.91 166 78 1.00 (0.67, 1.48) 74 1.30 (0.86, 1.96) 39 0.84 (0.51, 1.37) 105 1.22 (0.83, 1.80) 
   P for trend
2
   0.98  0.10  0.21  0.70 
Residual Model (energy-adjusted flavonoid intake) 
      
   <-133.68 166 84 1.00 62 1.00 53 1.00 77 1.00 
   -133.69-    
   -103.40 
165 58 0.69 (0.46, 1.03) 57 0.96 (0.63, 1.47) 36 0.69 (0.42, 1.14) 86 1.09 (0.74, 1.60) 
   -103.41- 
   14.64 
166 51 0.62 (0.41, 0.94) 55 0.95 (0.62, 1.47) 55 1.14 (0.72, 1.81) 77 0.99 (0.67, 1.47) 
   ≥14.65 165 81 0.98 (0.66, 1.44) 74 1.31 (0.87, 1.99) 47 0.89 (0.56, 1.44) 101 1.17 (0.80, 1.71) 
   P for trend
2
   0.61  0.07  0.42  0.50 
1
Adjusted for age (continuous), sex, race (white, other), geographic center (Connecticut, New Jersey, Washington), cigarette smoking 
(ever/never), dietary energy intake (kilocalories, continuous). 
2
P-value for trend for continuous variable.
1
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Table 2.17. Sensitivity Analysis of Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals 
(CI) for the Association Between Total Flavonoid Intake and Barrett’s Esophagus, Study of 
Reflux Disease, Western Washington State, 1997-2000. 
 
Total Flavonoids   
Controls 
(N=183)   
Cases 
(N=170)   OR 
 
95% CI 
Standard Multivariate Model  
   (flavonoid mg/day) 
      
 
   0-42.38 
 
46 
 
44 
 
1.00  
   42.39-75.36 
 
46 
 
41 
 
1.10 0.59, 2.08 
   75.37-166.98 
 
45 
 
46 
 
1.37 0.73, 2.58 
   ≥166.99 
 
46 
 
39 
 
1.09 0.56, 2.11 
   P for trend2 
 
    
0.81  
Nutrient Density Model  
   (flavonoid mg/1000 kcal) 
 
     
 
   0-27.47 
 
45  48  1.00  
   27.48-49.02 
 
47  36  0.83 0.44, 1.57 
   49.03-110.97 
 
46  54  1.23 0.67, 2.27 
   ≥110.98 
 
45  32  0.84 0.43, 1.66 
   P for trend2 
 
    0.39  
Residual Model  
   (energy-adjusted flavonoid intake) 
 
      
   <-79.39 
 
46  50  1.00  
   -79.40--46.88 
 
46  35  0.76 0.41, 1.38 
   -46.89-38.00 
 
46  50  1.06 0.59, 1.90 
   ≥38.01 
 
45  35  0.75 0.40, 1.39 
   P for trend2      0.90  
1Adjusted for age (continuous), sex, body mass index (continuous), and kilocalories 
(continuous). 2P-value for trend for continuous variable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2.18. Power Calculations for Risk of Esophageal and Gastric Tumors Development and Survival Among Esophageal and 
Gastric Cancer Cases for Dichotomous (2 level), Quartiled (4 level) or Tertiled (3 level) Exposures. 
 
 
EA, GCA, ESCC, or NCGA 
Incidence 
 Survival among EA, GCA, ESCC, or NCGA Cases  BE Development 
 
Overall  Non-proxy  Overall  Non-proxy  Overall 
Exposure Levels: 2 4  2 4  2 4  2 4  2 3 
Minimum Detectable 
Odds/Hazard Ratio 
              
0.40 1.00 0.99  1.00 0.96  1.00 0.98  1.00 0.93  0.99 0.92 
0.45 1.00 0.96  1.00 0.90  1.00 0.95  0.99 0.86  0.95 0.84 
0.50 1.00 0.90  0.98 0.81  1.00 0.90  0.97 0.77  0.89 0.74 
0.55 0.98 0.81  0.94 0.69  0.98 0.80  0.92 0.65  0.79 0.61 
0.60 0.93 0.68  0.85 0.56  0.93 0.68  0.82 0.53  0.66 0.49 
0.65 0.83 0.54  0.72 0.43  0.84 0.55  0.69 0.41  0.52 0.37 
0.70 0.68 0.40  0.56 0.32  0.69 0.41  0.54 0.30  0.38 0.27 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
1
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CHAPTER 3: DIETARY INTAKE OF FLAVONOIDS AND ESOPHAGEAL AND GASTRIC 
CANCER: INCIDENCE AND SURVIVAL IN THE UNITED STATES (U.S.) 
 
Introduction 
Over the last two decades, esophageal and gastric cardia adenocarcinomas have been among 
the most rapidly increasing cancer types in the United States (U.S.) and other Western 
countries.1,2 Esophageal and gastric cardia adenocarcinoma are often considered as one 
clinical entity because they are both epithelial cancers originating in or near the 
gastroesophageal junction, have similar 5-year survival rates of approximately 26%, and have 
comparable survival decrements according to tumor stage.3 Still, esophageal squamous cell 
carcinoma and other (non-cardia) gastric adenocarcinoma are the most common forms of 
esophageal and gastric cancer worldwide. In addition to geographic variation, these four cancer 
types have differing risk factors.4,5 Thus, considering them as distinct entities will help to 
elucidate the underlying etiology.   
Epidemiologic studies have shown that diets high in fruits and vegetables are inversely 
associated with risk of esophageal and gastric cancer incidence.6-8 Flavonoids, which are a 
group of bioactive polyphenolic compounds naturally occurring in fruits, vegetables, and 
beverages of plant origin, have been hypothesized to account at least partially for such risk 
reductions.9 Experimental studies have supported this hypothesis. For example, freeze-dried 
berries, which are high in anthocyanidins, inhibited 24-56% of esophageal tumor multiplicity 
(average number of tumors per esophagus) and 8-21% of esophageal tumor incidence in rats 
caused by N-nitrosomethylbenzylamine (NMBA) compared to controls.10 Additionally, 
Flavopiridol, a synthetic flavone, has been studied in Phase I and II clinical trials in patients with 
metastatic gastric cancer.11 Lignans are another group of polyphenolic compounds that have 
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anti-inflammatory and pro-apoptotic effects, antioxidant properties, and promote cell cycle 
arrest.12  
Recent epidemiological investigations conducted in the United States,13 Greece,14 
Italy,15,16 Europe,17,18 Sweden,19 China,20 and Mexico21 have analyzed associations between 
flavonoid or lignan intake and esophageal or gastric cancer incidence. Decreased risk of 
esophageal or gastric cancer incidence has been seen with specific classes of flavonoids and 
lignans: anthocyanidins,13 flavanones,13-15 flavones,14 flavonols (overall14-16 and quercetin19), 
isoflavones,13 and lignans (secoisolariciresinol).21 However, no epidemiologic studies to date 
have examined associations between flavonoid intake and survival among individuals 
diagnosed with esophageal or gastric cancer. Clarification of whether total flavonoids, or specific 
flavonoid classes, influence the incidence of these tumor subtypes or survival once diagnosed 
would provide empirical support for developing potential risk reduction strategies utilizing these 
compounds.  
In this population-based study, we investigated whether intakes of total flavonoids, 
including specific flavonoid classes, and lignans are associated with: (i) risk of esophageal or 
gastric cancer incidence; and (ii) survival among individuals diagnosed with esophageal or 
gastric cancer. For both aims, we consider associations for all four cancer types separately. 
 
Methods 
To conduct this ancillary study, we built upon the resources from the U.S. Multi-Center Study, a 
population-based investigation conducted in the state of Connecticut [CT, Principal Investigator 
(PI): HA Risch], a 15-county area of New Jersey (NJ, PI: MD Gammon), and a three-county 
area of western Washington state (WA, PI: TL Vaughan), which was initiated as a case-control 
study22 and then continued as a follow-up study to determine vital status among the cases.23  
This study was approved by all Institutional Review Boards of the participating institutions.   
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 Study Population. The three geographic areas (CT, NJ, and WA) each had a 
population-based cancer registry, which was used to identify the cases through rapid 
reporting methods. Eligible case participants were English-speaking men and women 
between the ages of 30 and 79 years, diagnosed with a first primary invasive esophageal or 
stomach cancer between 1993 and 1995. The parent study goal was to recruit all individuals 
newly diagnosed with esophageal or gastric cardia adenocarcinoma (which were considered 
the target case participants), while participants with esophageal squamous cell carcinoma or 
non-cardia gastric adenocarcinoma were frequency matched to the target case participants 
by geographic location and 5-year age group (CT, NJ, WA), sex (NJ, WA), and race (white 
or other, NJ). Final determination of case participant eligibility and classification was made 
by study pathologists (Drs. Heidi Rotterdam at Columbia University for NJ and A. Brian West 
at New York University for CT and WA) after review of medical records and pathology 
specimens.22 
 Population-based control participants were frequency matched to the target case 
participants by 5-year age group and sex. Control participants 30-64 years of age were 
identified using a modified Waksberg random digit dialing technique.24 Control participants 
65-79 years of age were identified by random sampling of Health Care Financing 
Administration rosters (now Centers for Medicare and Medicaid Services).22  
Study participants included 293 persons with esophageal adenocarcinoma and 261 with 
gastric cardia adenocarcinoma (80.6% of eligible target case participants), 221 with esophageal 
squamous cell carcinoma and 368 with other gastric adenocarcinoma (74.1% of eligible 
comparison case participants), and 695 population control participants (74.1% of eligible control 
participants).22 The 93.4% of participants with dietary intake information (see Exposure 
Assessment below) are the focus of the current study, and the distribution of the demographic 
characteristics of this subsample did not differ substantially from those of all study participants25 
and are shown in Table 3.5. Males comprised 83.9% of target cases, 72.9% of comparison 
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cases, and 79.8% of controls; 98.1% of target cases, 83.3% of comparison cases, and 93.2% of 
controls were white; and 78.4% of target cases, 66.0% of comparison cases, and 79.2% of 
controls had more than a high school education.  
 Exposure Assessment. Information on demographic factors, tobacco and alcohol 
use, intake of other beverages (e.g., coffee and tea), medical history, medication use, and 
occupational history was obtained by a structured questionnaire administered face-to-face 
by trained interviewers. Despite efforts to recruit and interview participants rapidly, proxy 
interviews were required for 29.6% of target case participants, 32.2% of comparison case 
participants, and 3.4% of control participants. We analyzed the data both including and 
excluding proxy interviews and the results were consistent (data not shown), therefore we 
present the analysis including the proxy data. The average time between cancer diagnosis 
and interview for cases was 3.7 months for self-report and 8.5 months for proxy-report. 
Interviews averaged 130 minutes. Written informed consent was obtained from each 
participant prior to the interview.22  
 Dietary data were collected by interviewers using a 104-item food frequency 
questionnaire (FFQ)25 modified from one developed and validated by investigators at the 
Fred Hutchinson Cancer Research Center (FHCRC).26 Participants were asked to report 
usual dietary intake for the 3-5 years prior to diagnosis (case participants) or interview 
(control participants). Completed FFQs were not obtained for 33 participants who provided 
only abbreviated interviews. Estimated total energy intake of <500 or >4,000 kilocalories/day 
for women and <800 or >5,000 kilocalories/day for men were considered implausible or 
unrealistic intake values, thereby excluding 61 case and 28 control participants.27 Final 
numbers of participants included in this study were 274 with esophageal adenocarcinoma, 
248 with gastric cardia adenocarcinoma, 191 with esophageal squamous cell carcinoma, 
and 341 with other gastric adenocarcinoma cases, and 662 control participants. 
 Assessment of Dietary Flavonoid Intake. A study-specific flavonoid database was 
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created based on values from the 2011 U.S. Department of Agriculture (USDA) Database 
for the Flavonoid Content of Selected Foods28 and the 2008 USDA-Iowa State University 
Database on the Isoflavone Content of Selected Foods29 and supplemented with lignan 
content data (i.e., secoisolariciresinol and matairesinol) from foods consumed by a North 
American population.30 Using FFQ reported frequencies of dietary intakes, intake of total 
flavonoids and six classes of flavonoids (anthocyanidins, flavan-3-ols, flavanones, flavones, 
flavonols, and isoflavones) and lignans were estimated using the study-specific flavonoid 
database for 81 food and beverage items that contained measureable amounts of 
flavonoids. 
 When FFQ items represented groups of foods or beverages, the individual foods and 
beverages were weighted based on usual population consumption. For example, the FFQ 
item of “apples and pears” was assigned weights of 0.75 for “apples” and 0.25 for “pears”. 
Flavonoid intake was calculated by multiplying the weight assigned to each food in the FFQ 
item was multiplied by the flavonoid content of that food, summing across all foods in the 
FFQ item, and then multiplying by the number of times consumed per day. For example, 100 
grams of apple contains 1.29 mg and pears contain 12.18 mg of anthocyanidins. A serving 
size of apples or pears was estimated as 145 grams. Therefore, if an individual reported 
consuming one serving of apples or pears per day, the individual’s daily intake of 
anthocyanidins from apples and pears was calculated as 145g apple or pear/day * [(0.75 
apple weight * 1.29 mg/100g apples) + (0.25 pear weight * 12.18 mg/100g pear)] = 5.82 mg 
anthocyanidins/day. 
 Outcome Assessment. In follow-up of the Multi-Center study, vital status and date of 
death were determined by linking state tumor registry data with the National Death Index.23 
Overall survival time (in months) was calculated from the date of diagnosis until death or last 
follow-up, with a maximum follow-up of 90 months, ending in 2000. Median survival time 
was 9.6 months for the study participants diagnosed with esophageal adenocarcinoma, 12.8 
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months for those with gastric cardia adenocarcinoma, 10.7 months for esophageal 
squamous cell carcinoma, and 12.9 months for other gastric adenocarcinoma. At the end of 
follow-up, participants who were still alive were considered censored. The outcome was 
death from any cause.23  
 Statistical Analysis. All analyses were conducted using SAS version 9.2 (SAS 
Institute, Cary, NC). All p-values are two-sided. 
 Case-control Analysis. Polytomous unconditional logistic regression was used to 
calculate odds ratios (ORs) and their 95% confidence intervals (CIs) for the association 
between flavonoid/lignan intake and the risk of incidence for the four tumor types 
(esophageal adenocarcinoma, gastric cardia adenocarcinoma, esophageal squamous cell 
carcinoma, and other gastric adenocarcinoma) in comparison with control participants. 
Effect measure modification by cigarette smoking (evaluated as ever/never and continuous 
years of duration), usual adult body mass index (BMI, based on usual adult weight, 
evaluated as continuous and as dichotomized, <25 and ≥25 kg/m2), and gastroesophageal 
reflux disease (yes/no) was assessed using likelihood ratio statistics to compare regression 
models with and without a multiplicative term.31 There was no evidence for effect 
modification by any of these variables (p≥0.05) on the association between flavonoid intake 
and esophageal or gastric cancer.  
 Potential confounders31 for the case-control analysis included proxy status (proxy, 
non-proxy), income (evaluated as <$15,000, $15,000-29,999, $30,000-49,999, $50,000-
74,999, or ≥$75,000 and <$15,000 or ≥$15,000), education (evaluated as <high school, high 
school, technical school/some college, or ≥college and <high school or ≥high school), 
cigarette smoking (evaluated as ever/never, continuous pack-years, and continuous 
cigarettes/day), alcohol consumption (evaluated as ever/never and continuous for beer, 
wine, and liquor), and BMI (evaluated as continuous and as categorized, <25, 25-29.9, or 
≥30 kg/m2). If the log odds ratio changed by ≥10% due to variable elimination, the variable 
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was considered a confounder and remained in the model;31 only cigarette smoking met this 
criterion. Total energy intake was included for adjustment as an a priori confounder.32 Thus, 
all final logistic regression models include cigarette smoking (ever/never), kilocalories 
(continuous), and the frequency matching factors of site (CT, NJ, WA), age (continuous), 
sex (male, female), and race (white, black, other). 
 Survival Analysis. Kaplan-Meier curves were constructed to examine flavonoids as a 
univariate predictor of survival, and Cox proportional hazard regression analysis was used 
to calculate adjusted hazard ratios (HRs) and their 95% confidence intervals for the 
association between flavonoid/lignan intake and mortality for each tumor type as distinct 
outcomes. The proportional hazards assumption was tested utilizing an interaction with 
log(time) in models with confounders, and it was not observed to be violated. 
 Potential confounders31 for the survival analysis included the same covariates listed 
above in the case-control analysis, as well as study site (WA, NJ, CT), age (continuous), sex 
(male/female), tumor stage (localized, regional, distant, and unknown), tumor grade 
(well/moderate, poor/undifferentiated, and not determined), and dysphagia (yes/no). 
Variables remained in the adjusted model if they were significant predictors of survival 
(p<0.05);31 only stage met this criterion. Total energy intake was included as an a priori 
confounder.32 Thus, all final proportional hazard models included tumor stage and 
kilocalories (continuous). 
 Examination of Linear Trend. Flavonoid intake was categorized as quartiles, based 
on the distribution of intake among the controls (logistic regression) or all cases (survival 
analysis).27 To examine trends, we evaluated flavonoid intake with restricted quadratic 
splines as well as linear trends in continuous flavonoid values (mg/day).  
 Sensitivity Analysis. For anthocyanidins, a value of 7.39 mg/100 g of banana is 
assigned in the USDA Flavonoid Database.28 However, this value is controversial.33 Thus, 
we conducted sensitivity analyses that excluded this value (Tables 3.6-3.9).  
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Results 
As shown in Table 3.1, control participants consumed on average similar amounts of total 
flavonoids (median=97.09 mg/day) as case participants (esophageal adenocarcinoma 
median=96.89; gastric cardia adenocarcinoma median=104.27; esophageal squamous cell 
carcinoma median=108.97; other gastric adenocarcinoma median=101.32 mg/day). Flavan-3-
ols were the largest contributor to total flavonoid intake in this study population, and control 
participants consumed less flavan-3-ols than esophageal, gastric cardia, and other gastric 
adenocarcinoma case participants. 
Table 3.2 lists the major sources of flavonoids and lignans in the reported food items of 
the control participants. For total flavonoids, black tea provided 55.8% (105.11 mg/day) of mean 
intake, orange/grapefruit juice 14.2% (26.75 mg/day), and wine 4.5% (8.46 mg/day). Black tea 
was a source of flavan-3-ols, flavonols, and lignans. Orange/grapefruit juice provided 
flavanones, flavonols, isoflavones, and lignans. Wine was a source of anthocyanidins, flavan-3-
ols, flavanones, flavones, flavonols, and lignans.   
As shown in Table 3.3, intake of dietary anthocyanidins, for which wine, bananas and 
fruit juice were the major dietary sources, was inversely associated with risk of incidence for all 
tumor types. Comparing the highest versus lowest quartile of anthocyanidin intake, decreased 
risks were shown for incident esophageal adenocarcinoma (OR=0.43, 95% CI: 0.29-0.66, 
ptrend=0.06) and squamous cell carcinoma (OR=0.43, 95% CI: 0.26-0.70, ptrend=0.11). More 
modest decreased risks were shown between anthocyanidin intake and incident gastric cardia 
(OR=0.71, 95% CI: 0.46-1.10) and other gastric adenocarcinoma (OR=0.70, 95% CI: 0.47-
1.03).  
For all other flavonoid types, the associations with incident esophageal and gastric 
cancers were less consistent. For example, as also shown in Table 3.3, dietary flavanone intake 
was inversely associated only with risk of incident esophageal adenocarcinoma (OR=0.56, 95% 
CI: 0.37-0.85, ptrend=0.003) and squamous cell carcinoma (OR=0.48, 95% CI: 0.29-0.78, 
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ptrend=0.002). Dietary flavone intake was only inversely associated with the risk of esophageal 
squamous cell carcinoma incidence (OR=0.55, 95% CI: 0.34-0.89, ptrend=0.02). Dietary lignan 
intake was also associated with a pronounced reduced risk of esophageal squamous cell 
carcinoma incidence (OR=0.38, 95% CI: 0.23-0.63, ptrend=0.0003) and more modestly 
associated with risk of incident esophageal adenocarcinoma (OR=0.75, 95% CI: 0.49-1.13) and 
other gastric adenocarcinoma (OR=0.73, 95% CI: 0.48-1.11).  
As also shown in Table 3.3, we observed a modest inverse association between dietary 
intake of isoflavones, for which coffee, chili, and white bread were the major dietary sources, 
and risk of esophageal squamous cell carcinoma incidence (OR=0.72, 95% CI: 0.40-1.29); in 
contrast, a positive association was observed for isoflavones in relation to all other tumor types. 
Similarly, we observed a modest positive association for dietary flavonol intake with gastric 
cardia adenocarcinoma incidence, but not other tumor types. Little or no consistent association 
was observed between total flavonoid intake or flavan-3-ols, which accounted for 64.6% of total 
flavonoid intake among controls, and any tumor types.  
As presented in Table 3.4, anthocyanidin intake was associated with a decreased risk of 
mortality among gastric cardia adenocarcinoma cases (highest versus lowest quartile HR=0.63, 
95% CI: 0.42-0.95, ptrend=0.25) and with more modest decreased risk of mortality among 
esophageal adenocarcinoma case participants (HR=0.87, 95% CI: 0.60-1.26). Dietary lignan 
intake was associated with decreased risk of mortality for esophageal squamous cell carcinoma 
case participants (HR=0.58, 95% CI: 0.37-0.92, ptrend=0.07) and with a modest decreased risk of 
mortality for esophageal adenocarcinoma case participants (HR=0.78, 95% CI: 0.54-1.14). 
Flavanone intake was associated with decreased risk of mortality only for other gastric 
adenocarcinoma case participants (HR=0.66, 95% CI: 0.46-0.93, ptrend=0.18). Anthocyanidin, 
lignan, and flavanone intake were associated with little or no decreased risk of mortality for the 
other tumor types.  
As also presented in Table 3.4, isoflavone (HR=0.75, 95% CI: 0.49-1.13) and flavone 
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intake (HR=0.83, 95% CI: 0.58-1.19) were associated with modest decreased risk of mortality 
for esophageal adenocarcinoma cases. Similar associations were also noted for flavan-3-ol 
intake and gastric cardia adenocarcinoma cases (HR=0.71, 95% CI: 0.48-1.05), while little or no 
association was seen among the other tumor types. Little or no association was seen between 
isoflavones, flavones, flavan-3-ols and the other tumors types for risk of mortality. Additionally, 
total flavonoid or flavonol intake was associated with little or no decreased risk of mortality for 
any tumor type.   
A sensitivity analysis that excluded the anthocyanidin value for bananas did not 
substantially alter our results for esophageal or gastric cancer incidence or survival (Tables 3.6-
3.9).    
 
Discussion 
This is the first population-based study, to our knowledge, to examine associations between 
dietary flavonoid intake and survival among esophageal and gastric cancer cases. In our 
analysis, the highest intake quartile of anthocyanidins was associated with a 37% and 13% 
decreased risk of mortality for gastric cardia and esophageal adenocarcinoma cases, 
respectively. The highest intake quartile of lignans was associated with a 42% and 22% 
decreased risk of mortality for esophageal squamous cell carcinoma and adenocarcinoma 
cases, respectively. The highest intake quartile of flavanones was associated with a 34% 
decreased risk of mortality for other gastric adenocarcinoma cases, and the highest quartile of 
flavan-3-ol intake was associated with a 29% decreased risk of mortality for gastric cardia 
adenocarcinoma cases. We also found the highest intake quartile of flavones and isoflavones 
associated with 17 and 25% decreased risk of mortality for esophageal adenocarcinoma cases, 
respectively.   
Additionally, we observed a 25-30% risk reduction for the association between the 
highest intake quartile of anthocyanidins and the risk of gastric cardia adenocarcinoma 
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incidence and for the associations between the highest intake quartile of anthocyanidins and 
lignans and the risk of other gastric adenocarcinoma incidence. We observed approximately 30-
60% risk reductions for the associations between the highest intake quartile of anthocyanidins 
and flavanones and the risk of esophageal adenocarcinoma incidence; similar risk reductions 
were noted for the associations between the highest intake quartiles of anthocyanidins, 
flavanones, flavones, isoflavones, and lignans in relation to esophageal squamous cell 
carcinoma. 
Our findings are consistent with previous epidemiologic studies that have reported 
inverse associations between anthocyanidin intake and risk of esophageal adenocarcinoma 
incidence,13 and with flavanone16, 18 and isoflavone13 intake in relation to risk of esophageal 
squamous cell carcinoma incidence. Previous studies, but not our study reported here, also 
have noted inverse associations between: flavonols and risk of esophageal squamous cell 
carcinoma incidence;15 flavonols,14,16 flavanones,14  flavones,14 and lignans 
(secoisolariciresinol)21 and risk of gastric adenocarcinoma (i.e., cardia and non-cardia) 
incidence; and flavonols (quercetin) and risk of gastric cardia adenocarcinoma incidence.19  
Observed differences between these previous studies and our own could partially be due to 
considering gastric adenocarcinoma as a combined entity and not according to anatomic 
subsite, examining single flavonoids and not classes of flavonoids, differences in study 
populations and dietary patterns across studies, or chance.   
In the present study, notable risk reductions were observed for the associations between 
anthocyanidins and risk of esophageal cancer incidence, regardless of histologic subtype. 
However, in animal studies, results for anthocyanidins as chemopreventive agents are not 
consistent across histologic subtypes (i.e., squamous cell carcinoma vs. adenocarcinoma). 
Multiple experimental studies have shown that anthocyanidin-rich black raspberries have 
chemopreventive properties in N-nitrosomethylbenzylamine-induced tumors in rats (esophageal 
squamous cell carcinoma rodent model).10 In a study of esophagoduodenal anastomosis, a 
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rodent model for reflux-induced esophageal adenocarcinoma, freeze-dried black raspberries 
were not effective in chemoprevention of esophageal adenocarcinoma.34 However, interim 
clinical trial results for Barrett’s esophagus, a potential precursor of esophageal 
adenocarcinoma, found reduced markers of oxidative stress in Barrett’s esophagus patients 
consuming anthocyanidin-rich freeze-dried black raspberries.35  
A previous study, based on data from the same parent study as our own, found a 
modest inverse association between fruit and vegetable intake and the risk of incidence for both 
histologic subtypes of esophageal cancer.7 As flavonoids are concentrated in fruits and 
vegetables,36 the association between flavonoids and esophageal or gastric cancer incidence 
may reflect diets with greater consumption of such foods or a healthy lifestyle in general. The 
parent study assessed many lifestyle factors, including cigarette smoking, alcohol intake, and 
BMI (as a measure of adiposity), individually22 and through the use of pattern analyses.7  
Cigarette smoking was the only covariate among these that influenced our findings and was 
adjusted for in the final models. Thus, lifestyle seems unlikely to account for our results. 
When estimating flavonoid content in food, particularly fruits and vegetables, potential 
sources of error include plant varieties, degree of ripeness, storage conditions, distance 
transported to market, environmental factors affecting plant growth, horticultural practices, 
industrial processing, and cooking methods, which may vary over time and by geographic 
region.28,29,36 Therefore, the foods utilized to create the nutrient database estimates may differ 
from the actual food sources reportedly consumed by this study population.28-30 To estimate the 
potential impact of such influences, the USDA Food Composition and Nutrient Data 
Laboratories sampled over 60 fruits, vegetables, and nuts from four U.S. regions at two times of 
the year and estimated the flavonoid content. Values reported in the USDA databases were 
similar to average flavonoid content determined in this study, although high variability of 
flavonoid content was seen within and between foods.37 Additionally, the FFQ line item for wine 
did not distinguish between red and white, which have different flavonoid concentrations.28 In 
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our study reported here, weights of 50% for red and 50% for white were assigned. However, 
individuals often preferentially drink red or white wine, and thus, individual estimates of flavonoid 
types for which wine is a source may be misclassified. 
Bioavailability of flavonoid compounds is another potential source of error when 
estimating the amount of flavonoid intake necessary to reduce risk of esophageal or gastric 
cancer. However, little is known about flavonoid absorption in the gastrointestinal tract, 
metabolism of flavonoids varies by individual, and the degree to which flavonoids might have 
direct effects on epithelial surfaces as they traverse the esophagus and stomach is unclear.38 
Additionally, absorption profiles of flavonoids vary, with maximum concentrations reached 
between 0.5-9 hours after dietary intake.39 Thus, serum flavonoid biomarkers may not be highly 
correlated with usual adult dietary intake, which can vary seasonally and for other reasons, and 
which for cancer studies is the target exposure. While such variation in estimating 
representative dietary flavonoid intakes and bioavailability may be a study limitation, this issue 
would apply to greater or lesser degrees to all studies reliant on nutritional databases to 
estimate dietary intake.27 
Patients with gastroesophageal reflux disease or Barrett’s esophagus are recommended 
to omit foods that are mechanically or chemically irritating, including some flavonoid-rich foods 
(e.g., coffee, tea, alcohol, citrus, tomatoes, chocolate, peppers, and onions).40 While the FFQ 
assessed dietary habits 3-5 years prior to diagnosis, esophageal adenocarcinoma patients may 
already have symptoms prior to diagnosis, causing their usual diet to change, or perhaps, 
reporting of past diet could be influenced by current dietary habits. However, the foods that are 
irritating vary by individual;41 thus, we are unable to estimate how such potential changes in diet 
would have affected our flavonoid intake values. Additionally, a dietary study showed that 
intakes of fruits, vegetables, and alcohol did not differ by symptomatic gastroesophageal reflux 
disease status.42 While it is unknown if gastroesophageal reflux disease or Barrett’s esophagus 
are necessary precursors of esophageal adenocarcinoma,43 it is still possible that associations 
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observed in case-control studies between flavonoid intake and risk of esophageal 
adenocarcinoma are due to reverse causation. However, examining the comparison case group 
of esophageal squamous cell carcinoma we see similar associations, with the exception of 
isoflavones. Thus, it seems unlikely that our observed associations are completely due to 
reverse causation.    
FFQ responses for the 3-5 years prior to diagnosis are assumed to reflect usual adult 
diet, both pre- and post-diagnosis. Whether such time period, even assessed accurately, 
reflects intakes during the time relevant to esophageal and gastric cancer development is 
unknown. However, because all existing studies conducted among esophageal and gastric 
cancer patients have relied on a FFQ,6,44-46 one would need to conduct a cohort study and 
employ multiple alternative dietary assessment methods over time to overcome limitations of 
existing studies. Such an alternative study design would be very inefficient, because the lifetime 
risk of esophageal or gastric cancer in the general U.S. population is less than one percent.47 
Similarly for the survival analyses, potential changes in dietary intake after diagnosis may be a 
relevant exposure but we were not able to assess this from the data available. 
Our study FFQ did not assess dietary supplement use of flavonoids; however, it is 
unlikely that use of flavonoid-rich supplements was widespread during this study time period. In 
the early 1990s, clinical studies of flavonoid supplements began;48 however, Ginkgo biloba 
extract, EGb 761, was not patented in the U.S. until 1995,49 which is after completion of 
participant interviews in our parent study.22   
The issues of multiple comparisons needs to be considered when discussing the study 
results, as there were 64 comparisons within the main analyses, given we considered 8 
exposures and 8 outcomes. Thus, there is a possibility that some statistically significant results 
arose due to chance. Adjusting for multiple comparisons would reduce the likelihood of 
detecting a false positive association, but would reduce power for detecting a true association if 
one exists. Instead, we chose to focus on associations based on biologic plausibility and 
 
 
150 
consistency with published results;27,50 we also gave more credence to results that were 
consistent across the continuum of cancer development. For example, in the current study, we 
noted inverse associations for both incidence and survival for esophageal adenocarcinoma in 
relation to anthocyanidin intake.  
In summary, our population-based findings suggest that dietary intake of some types of 
flavonoids, particularly anthocyanidins, may lower the risk of esophageal and gastric cancer 
incidence and may potentially enhance survival. In contrast, total dietary flavonoid intake does 
not appear to be inversely associated with these tumors in our study population. This is the first 
epidemiologic study to examine the association of flavonoids and lignans with survival among 
esophageal and gastric cancer cases, and one of few studies to examine these compounds in 
associations with the risk of incident esophageal and gastric cancer by tumor type. Thus, further 
research is needed before definite conclusions can be made about the chemopreventive role of 
dietary flavonoids and lignans on esophageal and gastric cancer incidence and survival. 
 
 
 
 
 
Table 3.1. Mean Intakes (mg/day) of Flavonoids and Lignans Among Case and Control Participants, U.S. Multi-Center Study, 
Connecticut, New Jersey, and Western Washington State: 1993-1995. 
  
  
Controls 
(N=662) 
Esophageal Adenocarcinoma  
(N=274) 
Gastric Cardia Adenocarcinoma  
(N=248) 
  Mean 
Standard 
Deviation Range Mean 
Standard 
Deviation Range Mean 
Standard 
Deviation Range 
Total Flavonoids 188.31 240.76 0.77-2182.23 198.19 245.12 8.45-2199.36 219.90 270.10 5.85-1753.52 
   Anthocyanidins 14.78 11.84 0-83.18 13.34 16.60 0.09-166.59 15.50 16.31 0.41-127.54 
   Flavan-3-ols 121.61 229.64 0.29-2064.10 138.10 234.35 1.07-2063.16 150.53 256.87 0.68-1650.30 
   Flavanones 34.93 27.00 0-231.14 29.42 24.46 0.004-125.24 35.04 24.99 0.02-113.73 
   Flavones 2.07 1.16 0-7.56 2.09 1.39 0-12.50 2.26 1.39 0.17-8.40 
   Flavonols 14.46 9.41 0.36-78.60 14.70 9.68 2.22-72.82 16.04 10.63 3.18-67.17 
   Isoflavones 0.47 0.29 0.02-2.81 0.54 0.33 0.03-2.82 0.53 0.31 0.07-1.99 
Lignans 0.068 0.032 0.011-0.286 0.069 0.039 0.014-0.304 0.073 0.036 0.016-0.247 
  
Esophageal Squamous Cell Carcinoma  
(N=191) 
Other Gastric Adenocarcinoma  
(N=341) 
  Mean 
Standard 
Deviation Range Mean 
Standard 
Deviation Range 
Total Flavonoids 182.98 206.29 7.13-1098.55 219.20 322.57 7.05-2796.17 
   Anthocyanidins 13.51 14.88 0.12-97.54 13.32 9.78 0.42-67.98 
   Flavan-3-ols 121.54 198.64 0.68-1037.81 154.01 307.90 0.93-2467.85 
   Flavanones 29.85 26.08 0-227.42 34.47 26.77 0.06-226.64 
   Flavones 1.86 1.26 0.02-6.75 2.02 1.16 0.02-8.01 
   Flavonols 15.74 10.41 1.85-55.62 14.90 11.36 3.34-98.33 
   Isoflavones 0.49 0.27 0.05-1.67 0.49 0.28 0.03-2.24 
Lignans 0.061 0.032 0.011-0.210 0.065 0.030 0.010-0.266 
 
 
 
1
5
1
 
 
 
 
Table 3.2. Major Sources of Flavonoids and Lignans Among a Population-based Sample of Control Participants Without Esophageal 
or Gastric Cancer With Information on Dietary Intake, U.S. Multi-Center Study: Connecticut, New Jersey, and Western Washington 
State, 1993-1995. 
 
Flavonoid/Phytoestrogen Class Representative Flavonoids Main FFQ Line Item Sources (%) 
Total Flavonoids 
 
Black tea (55.8), orange/grapefruit  
   juice (14.2), wine (4.5) 
   Anthocyanidins Cyanidin, Delphinidin, Malvidin,  
   Pelargonidin, Peonidin, Petunidin 
Wine (29.1), banana (13.7), fruit juice  
   (10.6), other fruit (fruit cocktail,  
   grapes, pineapple, blueberries,  
   applesauce) (9.0), apples (7.5),  
   pies (6.0), bean soup (5.9) 
   Flavan-3-ols (+)-Catechin, (+)-Catechin-3-gallate,  
   (-)-Epicatechin, (-)-Epicatechin-3-gallate,  
   (-)-Epigallocatechin, (-)-Epigallocatechin- 
   3-gallate, (+)-Gallocatechin,  
   (+)-Gallocatechin-3-gallate, Theaflavin,  
   Theaflavin-3-gallate, Theaflavin-3’-gallate,  
   Theaflavin-3,3’-digallate, Thearubigins 
Black tea (83.7), beer (3.2), green  
   tea (3.1), wine (2.0) , apples (1.9),  
   bananas (1.4) 
   Flavanones Eriodictyol, Hesperetin, Naringenin Orange/grapefruit juice (75.4),  
   oranges (21.5), wine (1.8) 
   Flavones Apigenin, Luteolin Pizza (27.5), Wine (13.0), Celery (8.3),  
   vegetable soup (7.8), mixed salad (7.8),  
   cream soups (7.0), chicken noodle 
   soup (5.4) 
   Flavonols Isorhamnetin, Kaempferol, Myricetin,  
   Quercetin 
Black tea (22.9), onions (10.5), beer (9.2),  
   apples (8.1), wine (5.9), mixed  
   salad (5.9) 
   Isoflavones Daidzein, Genistein, Glycitein Coffee (36.8), chili (17.4), white  
   bread (10.8), cake (8.4), fried  
   chicken (5.1), sausage (4.5) 
Lignans Matairesinol, Secoisolariciresinol Coffee (34.8), orange juice (13.4),  
   wine (10.3), black tea (5.0), onions (3.5) 
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Table 3.3. Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for Associations Between Flavonoid and Lignan Intake 
and Esophageal and Gastric Cancer Incidence by Tumor Type, U.S. Multi-Center Study: Connecticut, New Jersey, and Western 
Washington State, 1993-1995. 
 
 
  
Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Other Gastric  
Adenocarcinoma 
Variable and  
intake (mg/day) 
Controls 
(N=662) 
Cases 
(N=274) OR (95% CI)
2
 
Cases 
(N=248) OR (95% CI)
2
 
Cases 
(N=191) OR (95% CI)
2
 
Cases 
(N=341) OR (95% CI)
2
 
Total Flavonoids 
         
   0-63.81 165 83 1.00 59 1.00 48 1.00 80 1.00 
   63.82-97.90 166 54 0.62 (0.41, 0.93) 60 1.00 (0.65, 1.54) 35 0.64 (0.38, 1.07) 84 1.01 (0.69, 1.49) 
   97.91-217.35 165 57 0.64 (0.42, 0.97) 54 0.90 (0.58, 1.41) 61 1.11 (0.69, 1.77) 78 0.92 (0.62, 1.37) 
   ≥217.36 166 80 0.92 (0.63, 1.37) 75 1.32 (0.87, 2.00) 47 0.87 (0.53, 1.41) 99 1.08 (0.73, 1.58) 
   P for trend
3
 
  
0.61 
 
0.07 
 
0.42 
 
0.50 
Anthocyanidins 
         
   0-7.21 166 98 1.00 67 1.00 67 1.00 92 1.00 
   7.22-11.53 165 69 0.65 (0.45, 0.96) 67 0.98 (0.65, 1.47) 51 0.68 (0.43, 1.06) 89 0.91 (0.63, 1.32) 
   11.54-18.47 165 59 0.54 (0.36, 0.81) 63 0.91 (0.60, 1.38) 37 0.44 (0.27, 0.72) 91 0.89 (0.61, 1.29) 
   ≥18.48 166 48 0.43 (0.29, 0.66) 51 0.71 (0.46, 1.10) 36 0.43 (0.26, 0.70) 69 0.70 (0.47, 1.03) 
   P for trend
3
 
  
0.06 
 
0.91 
 
0.11 
 
0.10 
Flavan-3-ols 
         
   0-10.29 165 75 1.00 59 1.00 45 1.00 71 1.00 
   10.30-22.00 166 61 0.72 (0.48, 1.09) 50 0.77 (0.50, 1.20) 37 0.78 (0.47, 1.30) 101 1.45 (0.99, 2.14) 
   22.01-130.69 165 56 0.65 (0.43, 1.00) 69 1.05 (0.69, 1.61) 62 1.24 (0.77, 2.00) 68 0.98 (0.65, 1.48) 
   ≥130.70 166 82 1.02 (0.69, 1.51) 70 1.17 (0.77, 1.78) 47 0.98 (0.60, 1.59) 101 1.30 (0.88, 1.92) 
   P for trend
3
 
  
0.32 
 
0.07 
 
0.68 
 
0.36 
Flavanones 
         
   0-11.57 166 91 1.00 62 1.00 61 1.00 89 1.00 
   11.58-34.95 165 61 0.67 (0.45, 1.00) 54 0.86 (0.56, 1.33) 45 0.70 (0.44, 1.11) 80 0.92 (0.63, 1.35) 
   34.96-49.52 165 69 0.75 (0.50, 1.10) 59 1.01 (0.66, 1.55) 49 0.69 (0.43, 1.10) 83 0.86 (0.59, 1.27) 
   ≥49.53 166 53 0.56 (0.37, 0.85) 73 1.23 (0.81, 1.87) 36 0.48 (0.29, 0.78) 89 0.88 (0.60, 1.28) 
   P for trend
3
 
  
0.003 
 
0.82 
 
0.002 
 
0.36 
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(Table 3.3. continued) 
    
Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Other Gastric  
Adenocarcinoma 
Variable and  
intake (mg/day) 
Controls 
(N=662) 
Cases 
(N=274) OR (95% CI)
2
 
Cases 
(N=248) OR (95% CI)
2
 
Cases 
(N=191) OR (95% CI)
2
 
Cases 
(N=341) OR (95% CI)
2
 
Flavones 
         
   0-1.29 165 82 1.00 60 1.00 71 1.00 95 1.00 
   1.30-1.90 166 58 0.67 (0.45, 1.00) 55 0.87 (0.57, 1.34) 51 0.70 (0.45, 1.09) 87 0.92 (0.64, 1.34) 
   1.91-2.62 166 59 0.68 (0.45, 1.02) 62 0.98 (0.64, 1.50) 28 0.34 (0.20, 0.57) 72 0.77 (0.52, 1.13) 
   ≥2.63 165 75 0.84 (0.56, 1.25) 71 1.09 (0.71, 1.67) 41 0.55 (0.34, 0.89) 87 1.01 (0.69, 1.50) 
   P for trend
3
 
  
0.81 
 
0.15 
 
0.02 
 
0.98 
Flavonols 
         
   0-8.31 166 86 1.00 52 1.00 56 1.00 82 1.00 
   8.32-12.16 165 49 0.56 (0.37, 0.85) 64 1.24 (0.81, 1.91) 33 0.59 (0.36, 0.98) 94 1.16 (0.80, 1.69) 
   12.17-17.81 166 61 0.67 (0.45, 1.00) 53 1.01 (0.65, 1.57) 39 0.70 (0.43, 1.14) 79 0.96 (0.65, 1.41) 
   ≥17.82 165 78 0.80 (0.54, 1.18) 79 1.42 (0.93, 2.17) 63 0.97 (0.62, 1.53) 86 0.98 (0.67, 1.46) 
   P for trend
3
 
  
0.71 
 
0.10 
 
0.70 
 
0.92 
Isoflavones 
         
   0-0.27 165 47 1.00 36 1.00 34 1.00 65 1.00 
   0.28-0.41 166 51 0.98 (0.61, 1.55) 64 1.55 (0.97, 2.49) 50 1.12 (0.67, 1.89) 90 1.45 (0.97, 2.17) 
   0.42-0.59 166 83 1.51 (0.97, 2.37) 73 1.62 (1.00, 2.63) 59 1.18 (0.69, 2.00) 97 1.68 (1.10, 2.56) 
   ≥0.60 165 93 1.65 (1.02, 2.65) 75 1.56 (0.93, 2.60) 48 0.72 (0.40, 1.29) 89 1.50 (0.96, 2.37) 
   P for trend
3
 
  
0.07 
 
0.17 
 
0.11 
 
0.37 
Lignans 
         
   0-0.045 165 70 1.00 50 1.00 67 1.00 87 1.00 
   0.046-0.063 166 75 0.91 (0.61, 1.36) 61 1.06 (0.69, 1.65) 47 0.64 (0.40, 1.01) 92 1.09 (0.75, 1.59) 
   0.064-0.082 165 57 0.65 (0.42, 0.99) 70 1.17 (0.76, 1.81) 42 0.50 (0.31, 0.82) 98 1.11 (0.76, 1.63) 
   ≥0.083 166 72 0.75 (0.49, 1.13) 67 1.01 (0.65, 1.58) 35 0.38 (0.23, 0.63) 64 0.73 (0.48, 1.11) 
   P for trend
3
 
  
0.26 
 
0.63 
 
0.0003 
 
0.13 
1
Adjusted for age (continuous), sex, race (white, other), geographic center (Connecticut, New Jersey, Washington), cigarette smoking 
(ever/never), dietary energy intake (kilocalories, continuous). 
2
Odds ratio (95% confidence interval). 
3
P-value for trend for continuous variable. 
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Table 3.4. Adjusted1 Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Flavonoid and Lignan Intake and Overall Mortality in 
Esophageal and Gastric Cancer Cases by Tumor Type, U.S. Multi-Center Study: Connecticut, New Jersey, and Western Washington 
State, 1993-1995 through 2000. 
 
Variable and  
intake (mg/day) 
Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Other Gastric  
Adenocarcinoma 
Cases 
(N=274) HR (95% CI)
2
 
Cases 
(N=248) HR (95% CI)
2
 
Cases 
(N=191) HR (95% CI)
2
 
Cases 
(N=338) HR (95% CI)
2
 
Total Flavonoids 
           0-62.35 83 1.00 57 1.00 47 1.00 76 1.00 
   62.36-103.39 60 1.37 (0.95, 1.98) 66 1.05 (0.71, 1.54) 42 1.26 (0.81, 1.97) 95 1.01 (0.71, 1.42) 
   103.40-253.24 65 1.39 (0.97, 1.98) 60 0.79 (0.54, 1.17) 61 0.92 (0.60, 1.40) 77 0.72 (0.50, 1.05) 
   ≥253.25 66 0.98 (0.68, 1.41) 65 0.88 (0.59, 1.32) 41 0.91 (0.58, 1.44) 90 0.99 (0.70, 1.39) 
   P for trend
3
 
 
0.11 
 
0.80 
 
0.11 
 
0.90 
Anthocyanidins 
        
   0-6.23 83 1.00 52 1.00 57 1.00 70 1.00 
   6.24-10.11 61 0.93 (0.65, 1.35) 64 0.76 (0.51, 1.12) 52 0.77 (0.50, 1.18) 86 1.27 (0.89, 1.82) 
   10.12-16.23 67 0.88 (0.62, 1.26) 66 0.80 (0.54, 1.18) 41 1.46 (0.94, 2.26) 89 1.22 (0.84, 1.76) 
   ≥16.24 63 0.87 (0.60, 1.26) 66 0.63 (0.42, 0.95) 41 1.01 (0.66, 1.56) 93 1.14 (0.80, 1.63) 
   P for trend
3
 
 
0.14 
 
0.25 
 
0.94 
 
0.55 
Flavan-3-ols 
        
   0-10.90 80 1.00 61 1.00 47 1.00 75 1.00 
   10.91-26.67 62 0.92 (0.64, 1.32) 53 0.69 (0.46, 1.04) 46 1.68 (1.08, 2.62) 102 1.33 (0.94, 1.87) 
   26.68-210.51 66 1.20 (0.84, 1.72) 71 0.78 (0.54, 1.13) 56 0.97 (0.63, 1.50) 70 0.96 (0.66, 1.39) 
   ≥210.52 66 0.93 (0.65, 1.33) 63 0.71 (0.48, 1.05) 42 1.09 (0.69, 1.74) 91 1.22 (0.87, 1.73) 
   P for trend
3
 
 
0.11 
 
0.94 
 
0.10 
 
0.80 
Flavanones 
        
   0-8.63 81 1.00 55 1.00 50 1.00 77 1.00 
   8.64-32.94 66 0.96 (0.67, 1.38) 60 1.12 (0.75, 1.69) 54 0.95 (0.61, 1.47) 83 0.70 (0.49, 1.00) 
   34.95-49.00 71 1.40 (0.99, 1.98) 57 1.24 (0.83, 1.86) 48 1.05 (0.67, 1.63) 87 0.74 (0.52, 1.05) 
   ≥49.01 56 1.15 (0.79, 1.68) 76 0.90 (0.61, 1.33) 39 1.24 (0.76, 2.03) 91 0.66 (0.46, 0.93) 
   P for trend
3
 
 
0.05 
 
0.50 
 
0.80 
 
0.18 
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(Table 3.4. continued) 
Variable and  
intake (mg/day) 
Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Other Gastric  
Adenocarcinoma 
Cases 
(N=274) HR (95% CI)
2
 
Cases 
(N=248) HR (95% CI)
2
 
Cases 
(N=191) HR (95% CI)
2
 
Cases 
(N=338) HR (95% CI)
2
 
Flavones 
        
   0-1.20 79 1.00 46 1.00 64 1.00 74 1.00 
   1.21-1.81 52 0.97 (0.66, 1.41) 63 1.03 (0.68, 1.56) 48 1.23 (0.82, 1.84) 100 0.88 (0.63, 1.24) 
   1.82-2.64 73 0.89 (0.63, 1.26) 70 0.95 (0.63, 1.44) 39 0.88 (0.56, 1.38) 80 0.88 (0.61, 1.26) 
   ≥2.65 70 0.83 (0.58, 1.19) 69 0.86 (0.56, 1.31) 40 1.00 (0.64, 1.54) 84 0.97 (0.67, 1.39) 
   P for trend
3
 
 
0.04 
 
0.54 
 
0.17 
 
0.62 
Flavonols 
        
   0-8.16 79 1.00 50 1.00 55 1.00 79 1.00 
   8.17-12.30 60 1.30 (0.89, 1.89) 68 1.25 (0.83, 1.87) 36 1.14 (0.70, 1.83) 98 1.12 (0.80, 1.57) 
   12.31-19.34 72 1.01 (0.71, 1.43) 63 1.11 (0.74, 1.68) 45 0.78 (0.50, 1.20) 84 1.09 (0.78, 1.54) 
   ≥19.35 63 0.94 (0.65, 1.37) 67 0.93 (0.61, 1.40) 55 0.93 (0.61, 1.40) 77 0.97 (0.68, 1.38) 
   P for trend
3
 
 
0.05 
 
0.35 
 
0.69 
 
0.71 
Isoflavones 
        
   0-0.31 65 1.00 59 1.00 48 1.00 89 1.00 
   0.32-0.46 56 1.00 (0.68, 1.47) 57 1.26 (0.84, 1.87) 60 1.03 (0.68, 1.58) 90 1.29 (0.92, 1.82) 
   0.47-0.62 73 0.70 (0.48, 1.03) 68 0.94 (0.62, 1.44) 42 1.14 (0.71, 1.81) 81 0.86 (0.60, 1.25) 
   ≥0.63 80 0.75 (0.49, 1.13) 64 1.01 (0.65, 1.57) 41 0.97 (0.60, 1.58) 78 0.92 (0.62, 1.37) 
   P for trend
3
 
 
0.65 
 
0.77 
 
0.60 
 
0.88 
Lignans 
        
   0-0.044 68 1.00 50 1.00 62 1.00 83 1.00 
   0.045-0.060 72 0.85 (0.60, 1.23) 55 1.45 (0.95, 2.22) 50 0.73 (0.47, 1.13) 85 1.22 (0.86, 1.73) 
   0.061-0.079 57 0.98 (0.67, 1.45) 66 1.05 (0.70, 1.59) 41 0.61 (0.39, 0.96) 99 1.08 (0.77, 1.51) 
   ≥0.080 77 0.78 (0.54, 1.14) 77 0.97 (0.65, 1.46) 38 0.58 (0.37, 0.92) 71 1.05 (0.72, 1.53) 
   P for trend
3
 
 
0.28 
 
0.43 
 
0.07 
 
0.55 
1
Adjusted for stage (localized, regional, distant, unknown), and dietary energy intake (kilocalories, continuous). 
2
Hazard ratio (95% confidence 
interval). 
3
P-value for trend for continuous variable. 
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Table 3.5. Distribution (N [%]) of Characteristics Among Control Participants and Esophageal 
and Gastric Cancer Patients by Tumor Type, U.S. Multi-Center Study: Connecticut, New Jersey, 
and Western Washington State, 1993-1995. 
 
 
Controls 
Esophageal 
Adenocarcinoma 
Gastric 
Cardia 
Adenocarcinoma 
Esophageal 
Squamous 
Cell Carcinoma 
Other Gastric 
Adenocarcinoma 
Characteristic N=662 N=274 N=248 N=191 N=341 
Age 
     
   <57 170 (25.7) 69 (25.2) 59 (23.8) 28 (14.7) 57 (16.7) 
   57-64 170 (25.7) 46 (16.8) 51 (20.6) 50 (26.2) 57 (16.7) 
   65-71 145 (21.9) 64 (23.4) 60 (24.2) 52 (27.2) 71 (20.8) 
   >71 177 (26.7) 95 (34.7) 78 (31.5) 61 (31.9) 156 (45.8) 
Sex 
     
   Male 528 (79.8) 228 (83.2) 210 (84.7) 151 (79.1) 237 (69.5) 
   Female 134 (20.2) 46 (16.8) 38 (15.3) 40 (20.9) 104 (30.5) 
Race 
     
   White 617 (93.2) 271 (98.9) 241 (97.2) 151 (79.1) 292 (85.6) 
   Other 45 (6.8) 3 (1.1) 7 (2.8) 40 (20.9) 49 (14.4) 
Education 
     
   <High School 120 (18.1) 62 (22.7) 51 (20.6) 74 (38.7) 107 (31.4) 
   High School 165 (24.9) 85 (31.1) 82 (33.2) 61 (31.9) 99 (29.0) 
   Some College 170 (25.7) 72 (26.4) 57 (23.1) 33 (17.3) 77 (22.6) 
   College or more 207 (31.3) 54 (19.8) 57 (23.1) 23 (12.0) 58 (17.0) 
   Missing 0 1 1 0 0 
Income level, US $ 
     
   <15,000 83 (12.5) 52 (19.0) 36 (14.5) 56 (29.3) 78 (22.9) 
   15,000-29,999 165 (24.9) 84 (30.7) 78 (31.5) 66 (34.6) 105 (30.8) 
   30,000-49,999 172 (26.0) 63 (23.0) 65 (26.2) 50 (26.2) 95 (27.9) 
   50,000-74,999 121 (18.3) 40 (14.6) 34 (13.7) 9 (4.7) 43 (12.6) 
   ≥75,000 121 (18.3) 35 (12.8) 35 (14.1) 10 (5.2) 20 (5.9) 
Cigarette Use 
     
   Ever 425 (64.2) 213 (77.7) 196 (79.0) 175 (91.6) 244 (71.8) 
   Never 237 (35.8) 61 (22.3) 52 (21.0) 16 (8.4) 96 (28.2) 
Geographic Center 
     
   Connecticut 193 (29.2) 74 (27.0) 77 (31.1) 75 (39.3) 108 (31.7) 
   New Jersey 322 (48.6) 134 (48.9) 110 (44.4) 84 (44.0) 164 (48.1) 
   Washington 147 (22.2) 66 (24.1) 61 (24.6) 32 (16.8) 69 (20.2) 
Tumor Stage 
 
    
   Localized 73 (26.6) 31 (12.5) 45 (23.6) 68 (20.1) 
   Regional 70 (25.6) 114 (46.0) 72 (37.7) 148 (43.8) 
   Distant 75 (27.4) 68 (27.4) 33 (17.3) 95 (28.1) 
   Unknown 56 (20.4) 35 (14.1) 41 (21.5) 27 (8.0) 
 
 
 
 
 
Table 3.6. Sensitivity Analysis of Mean Intakes (mg/day) of Anthocyanidins (Bananas Included versus Excluded), U.S. Multi-Center 
Study, Connecticut, New Jersey, and Western Washington State: 1993-1995. 
 
  
Controls 
(N=662) 
Esophageal Adenocarcinoma  
(N=274) 
Gastric Cardia Adenocarcinoma 
(N=248) 
  Mean 
Standard 
Deviation Range Mean 
Standard 
Deviation Range Mean 
Standard 
Deviation Range 
Anthocyanidins, Bananas Included  14.78 11.84 0-83.18 13.34 16.80 0.09-166.59 15.50 16.31 0.41-127.54 
Anthocyanidins, Bananas Excluded 12.76 11.54 0-82.85 11.73 16.60 0.09-166.07 13.65 15.81 0.41-127.54 
  
Esophageal Squamous Cell 
Carcinoma 
(N=191) 
Other Gastric Adenocarcinoma  
(N=341) 
  
Mean 
Standard 
Deviation Range Mean 
Standard 
Deviation Range 
Anthocyanidins, Bananas Included  13.51 14.88 0.12-97.54 13.32 9.78 0.42-67.98 
Anthocyanidins, Bananas Excluded 11.86 14.69 0.12-97.31 11.06 9.20 0.42-60.43 
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Table 3.7. Sensitivity Analysis of the Major Sources of Anthocyanidins (Bananas Included 
versus Excluded) Among a Population-based Sample of Control Participants Without 
Esophageal or Gastric Cancer With Information on Dietary Intake, U.S. Multi-Center Study: 
Connecticut, New Jersey, and Western Washington State, 1993-1995. 
 
Flavonoid/Phytoestrogen Class Main FFQ Line Item Sources (%) 
Anthocyanidins, Bananas Included Wine (29.1), banana (13.7), fruit juice  
   (10.6), other fruit (fruit cocktail,  
   grapes, pineapple, blueberries,  
   applesauce) (9.0), apples (7.5),  
   pies (6.0), bean soup (5.9) 
Anthocyanidins, Bananas Excluded Wine (33.7), fruit juice (12.3), other fruit  
   (fruit cocktail, grapes, pineapple,  
   blueberries, applesauce) (10.4), apples (8.7),  
   pies (7.0), bean soup (6.9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.8. Sensitivity Analysis of Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for the Association Between 
Anthocyanidin Intake (Bananas Included versus Excluded) and Esophageal and Gastric Cancer Incidence by Tumor Type, U.S. 
Multi-Center Study: Connecticut, New Jersey, and Western Washington State, 1993-1995. 
 
    
Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Other Gastric  
Adenocarcinoma 
Variable and  
intake (mg/day) 
Controls 
(N=660) 
Cases 
(N=274) OR (95% CI)
2
 
Cases 
(N=248) OR (95% CI)
2
 
Cases 
(N=191) OR (95% CI)
2
 
Cases 
(N=341) OR (95% CI)
2
 
Anthocyanidins,  
Bananas Included          
   0-7.21 166 98 1.00 67 1.00 67 1.00 92 1.00 
   7.22-11.53 165 69 0.65 (0.45, 0.96) 67 0.98 (0.65, 1.47) 51 0.68 (0.43, 1.06) 89 0.91 (0.63, 1.32) 
   11.54-18.47 165 59 0.54 (0.36, 0.81) 63 0.91 (0.60, 1.38) 37 0.44 (0.27, 0.72) 91 0.89 (0.61, 1.29) 
   ≥18.48 166 48 0.43 (0.29, 0.66) 51 0.71 (0.46, 1.10) 36 0.43 (0.26, 0.70) 69 0.70 (0.47, 1.03) 
   P for trend
3
 
  
0.06 
 
0.91 
 
0.11 
 
0.10 
Anthocyanidins,  
Bananas Excluded          
   0-5.53 165 100 1.00 57 1.00 71 1.00 95 1.00 
   5.54-9.57 166 64 0.59 (0.40, 0.87) 76 1.27 (0.84, 1.92) 50 0.68 (0.43, 1.06) 97 1.04 (0.72, 1.50) 
   9.58-15.92 165 60 0.56 (0.37, 0.83) 63 1.07 (0.70, 1.65) 36 0.40 (0.25, 0.66) 85 0.85 (0.58, 1.24) 
   ≥15.93 166 50 0.45 (0.30, 0.68) 52 0.84 (0.54, 1.31) 34 0.41 (0.25, 0.67) 64 0.68 (0.45, 1.01) 
   P for trend
3
   0.14  0.79  0.24  0.07 
1
Adjusted for age (continuous), sex, race (white, other), geographic center (Connecticut, New Jersey, Washington), cigarette smoking 
(ever/never), dietary energy intake (kilocalories, continuous). 
2
Odds ratio (95% confidence interval). 
3
P-value for trend for continuous variable. 
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Table 3.9. Sensitivity Analysis of Adjusted1 Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Anthocyanidin Intakes 
(Bananas Included versus Excluded) and Overall Mortality in Esophageal and Gastric Cancer Cases by Tumor Type, U.S. Multi-
Center Study: Connecticut, New Jersey, and Western Washington State, 1993-1995 through 2000. 
 
 
Esophageal  
Adenocarcinoma 
Gastric Cardia  
Adenocarcinoma 
Esophageal  
Squamous  
Cell Carcinoma 
Other Gastric  
Adenocarcinoma 
Variable and  
intake (mg/day) 
Cases 
(N=274) HR (95% CI)
2
 
Cases 
(N=248) HR (95% CI)
2
 
Cases 
(N=191) HR (95% CI)
2
 
Cases 
(N=338) HR (95% CI)
2
 
Anthocyanidins,  
Bananas Included 
           0-6.23 83 1.00 52 1.00 57 1.00 70 1.00 
   6.24-10.11 61 0.93 (0.65, 1.35) 64 0.76 (0.51, 1.12) 52 0.77 (0.50, 1.18) 86 1.27 (0.89, 1.82) 
   10.12-16.23 67 0.88 (0.62, 1.26) 66 0.80 (0.54, 1.18) 41 1.46 (0.94, 2.26) 89 1.22 (0.84, 1.76) 
   ≥16.24 63 0.87 (0.60, 1.26) 66 0.63 (0.42, 0.95) 41 1.01 (0.66, 1.56) 93 1.14 (0.80, 1.63) 
   P for trend
3
 
 
0.14 
 
0.25 
 
0.94 
 
0.55 
Anthocyanidins,  
Bananas Excluded         
   0-4.77 85 1.00 45 1.00 58 1.00 74 1.00 
   4.78-8.34 58 1.15 (0.79, 1.68) 74 0.84 (0.56, 1.25) 49 0.73 (0.48, 1.12) 82 1.06 (0.74, 1.51) 
   8.35-13.75 62 0.96 (0.67, 1.37) 62 0.68 (0.45, 1.04) 43 1.11 (0.72, 1.70) 97 1.09 (0.77, 1.54) 
   ≥13.76 69 0.83 (0.58, 1.19) 67 0.66 (0.43, 1.02) 41 0.87 (0.56, 1.36) 85 0.97 (0.67, 1.40) 
   P for trend
3
  0.12  0.26  0.66  0.35 
1
Adjusted for stage (localized, regional, distant, unknown), and dietary energy intake (kilocalories, continuous). 
2
Hazard ratio (95% confidence 
interval). 
3
P-value for trend for continuous variable. 
 
 
 
1
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CHAPTER 4: DIETARY FLAVONOID INTAKE AND BARRETT’S ESOPHAGUS IN WESTERN 
WASHINGTON STATE 
 
Introduction 
Over the last two decades, the incidence rate for esophageal adenocarcinoma has been among 
the most rapidly increasing of any cancer type in the United States (U.S.).1,2 Esophageal 
adenocarcinoma is thought to arise in Barrett’s esophagus, specialized intestinal metaplasia of 
the lower esophageal epithelium.3 Studying precursor lesions may provide insight into the 
etiology of cancer by elucidating risk factors that act early in disease initiation. Epidemiologic 
studies have shown that diets high in fruit and vegetable intake are inversely associated with 
risk of Barrett’s esophagus.4 Flavonoids, a group of bioactive polyphenolic compounds naturally 
occurring in fruits, vegetables, and beverages of plant origin, may partially account for the 
inverse dietary association of fruits and vegetables with Barrett’s esophagus.5  
Experimental studies support the hypothesis of an inverse association between flavonoid 
exposure and Barrett’s esophagus. For example, flavan-3-ol inhibited Barrett’s esophagus cell 
growth through down-regulation of cyclin D1 protein expression.6 Lignans are other polyphenolic 
compounds that have antioxidant properties, anti-inflammatory and pro-apoptosis effects, and 
promote cell cycle arrest.7 One epidemiologic investigation to date has examined the 
association between dietary flavonoid intake and risk of Barrett’s esophagus.8 This case-control 
study of 151 Barrett’s esophagus cases from the Veterans Affairs Medical Center in Houston, 
Texas, considered one class of flavonoids, isoflavones, and found an inverse association.8 
However, intake of isoflavone-containing foods in the U.S. is limited; whereas the other five 
flavonoid classes are found in foods more commonly consumed by Americans,9 yet their 
associations with Barrett’s esophagus have not been considered. 
168 
To determine whether intakes of total flavonoids or specific flavonoid classes are 
associated with risk of Barrett’s esophagus, we compared flavonoid intake between patients 
newly diagnosed with Barrett’s esophagus and general population controls who participated in a 
community-based case-control study.10  
 
Methods 
To conduct this ancillary study, we built upon data collected for the Study of Reflux Disease, a 
case-control investigation conducted in western Washington state.10,11 This study was approved 
by the Institutional Review Boards of the participating institutions.  
Study Population. Eligible case participants were men and women, aged 20-80 years 
without previously diagnosed Barrett’s esophagus who underwent upper endoscopy for 
gastroesophageal reflux disease (GERD) symptoms between 1997 and 2000 at community 
gastroenterology clinics.10,11 Consenting participants had four-quadrant biopsy specimens 
collected. Specimens were evaluated by one of three university-based pathologists, who were 
blinded to the endoscopy findings. Barrett’s esophagus was considered present if at least one 
biopsy specimen had specialized intestinal metaplasia (SIM). Case participants were classified 
into one, two, or three diagnostic categories indicating disease progression, based on the 
presence (and length) or absence of visible columnar epithelium [visible Barrett’s esophagus 
(VBE)] during endoscopy: 1) SIM (i.e., all cases), 2) SIM and VBE (VBE cases), and 3) SIM and 
VBE greater than two centimeters [long-segment Barrett’s esophagus (LSBE) cases].10 The first 
and most inclusive category (SIM cases) adheres to the concept of “ultra-short segment 
Barrett’s esophagus.”12 The latter two categories were selected because they are consistent 
with the American College of Gastroenterology definition of Barrett’s esophagus,13 enhancing 
the clinical relevance of our study results.  
 Community-based control participants were identified using a modified Waksberg 
random digit dialing technique,14 which identifies individuals living in the same geographic area 
169 
as case participants by utilizing the first five digits of each case’s residential telephone number 
as the sampling unit.15 Controls were individually matched to cases on age (±3 years) and sex.10  
 Study participants included 193 cases (92.8% of eligible) and 211 community controls 
(68.7% of eligible).10 Of those, 87.4% (170 cases, 183 controls) provided adequate dietary 
intake information (see Exposure Assessment below) and are the focus of the current report. 
Their demographic characteristics are shown in Table 4.5.  
Exposure Assessment. Information on potential risk factors, including demographic 
characteristics, tobacco and alcohol use, consumption of other beverages (e.g., coffee and tea), 
history of medical conditions, medication use, and occupational history, was obtained by a 45-
minute structured questionnaire administered face-to-face by trained interviewers. The time 
between endoscopy and interview for case participants was 1-2 months.10 Written informed 
consent was obtained from each participant prior to interview. 
 Dietary intake for the one year prior to interview was assessed by a validated self-
administered, 131-item food frequency questionnaire (FFQ).16 In total, 177 cases (91.7%) 
and 192 controls (91.0%) completed FFQs. Individuals with estimated total energy intake of 
<500 or >4,000 kilocalories/day for women or <800 or >5,000 kilocalories/day for men were 
excluded based on implausible energy intake (7 cases, 9 controls).11,17 With this exclusion, a 
total of 170 case and 183 control participants were available for the current study.  
 Assessment of Dietary Flavonoid Intake. Intakes of total flavonoids, six classes of 
flavonoids (anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols, and isoflavones), and 
lignans was estimated from 91 food and beverage FFQ items that contained measureable 
amounts of flavonoids.18-20 A study-specific flavonoid database was developed by linking the 
FFQ data with the 2011 U.S. Department of Agriculture (USDA) Database for the Flavonoid 
Content of Selected Foods18 and the 2008 USDA-Iowa State University Database on the 
Isoflavone Content of Selected Foods.19 To assess lignan content, specifically 
secoisolariciresinol and matairesinol, we supplemented the USDA databases with data from 
170 
foods consumed by a North American population.20  
Some FFQ items represented groups of foods or beverages. For flavonoid intake 
calculations, the individual foods and beverages represented in a single item were weighted, 
based on the relative frequency of consumption in the general American population.16 For 
example, the FFQ item of “apples and pears” was assigned a weight of 0.75 for “apples” and 
0.25 for “pears.” To calculate the flavonoid intake, the weight assigned to each food in the FFQ 
item was multiplied by the flavonoid content of that food, summed across all foods in the FFQ 
item, and then multiplied by the number of times consumed per day and by the serving size.9   
Statistical Analysis. Unconditional logistic regression was used to calculate odds ratios 
(ORs) and corresponding 95% confidence intervals (CIs) for the association between flavonoid 
intakes and risk of Barrett’s esophagus. Conditional logistic regression was also performed on 
matched pairs of cases and controls.21 Results were similar; therefore, only unconditional 
logistic regression results are reported. All analyses were conducted using SAS version 9.2 
(SAS Institute, Cary, NC). All p-values are two-sided. 
 Flavonoid intakes were categorized in quartiles, based on the distributions of intakes 
among the control participants.17 To examine linear trend, we also utilized restricted 
quadratic spline coding (Figure 4.1). Tests for linear trends were based on continuous 
flavonoid values in mg/day. 
 Effect measure modification by cigarette smoking (evaluated as continuous pack-
years and as dichotomous, ever/never) and body mass index (BMI, kg/m2) at interview 
(evaluated as continuous and as dichotomous, <25 or ≥25 kg/m2) was assessed using 
likelihood ratio tests to compare regression models with and without a multiplicative term;21 
there was no evidence of effect measure modification by either covariate (p≥0.05) on the 
association between total flavonoid intake and Barrett’s esophagus in any of the models.  
 Potential confounders included BMI (evaluated as continuous and as dichotomous, 
<25 or ≥25 kg/m2), race (white, other), income (<$45,000, ≥$45,000-74,999, ≥$75,000), 
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education (≤high school, technical school, ≥college), and cigarette smoking (ever/never). If 
variable elimination changed the log odds ratio by ≥10%, the variable was considered a 
confounder and included in the model;21 only BMI met this criterion.  Total energy intake was 
included for adjustment on an a priori basis.22 Thus, the final models included BMI 
(continuous), total energy intake (kilocalories, continuous), and the matching factors age 
(continuous) and sex. 
 To determine whether associations with flavonoids varied by diagnostic category, 
Barrett’s esophagus patients were categorized into progressively more exclusive groups by 
segment length12 and then each case subgroup was compared to all of the controls. To 
explore the threshold associations seen in restricted quadratic splines (Figure 4.1), we 
dichotomized exposures and compared the bottom quartile versus the upper three quartiles. 
 Sensitivity Analysis. The USDA Flavonoid Database assigns a value of 7.39 mg/100 
g of banana for anthocyanidins,18 which is controversial.23 We therefore conducted a 
sensitivity analysis excluding the anthocyanidin value for bananas, which did not 
substantially alter our results (Tables 4.6-4.9).  
 
Results 
As shown in Table 4.1 for this western Washington study population, control participants 
consumed similar amounts of total flavonoids (median=75.37 mg/day) as Barrett’s esophagus 
case participants (median=75.55 mg/day). However, control participants consumed a smaller 
dietary intake of flavan-3-ols (median=17.35 mg/day), which were the largest contributor to total 
flavonoid intake, than case participants (median=25.56 mg/day). 
Table 4.2 lists the major sources of flavonoids among the control participants. For total 
flavonoids, 47.2% of mean intake was from black tea (58.96 mg/day), 12.2% from 
orange/grapefruit juice (15.31 mg/day), and 6.8% from wine (8.48 mg/day). Black tea contains 
flavan-3-ols, flavonols, and lignans; orange/grapefruit juice contains flavanones, flavonols, 
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isoflavones, and lignans; and wine contains anthocyanidins, flavan-3-ols, flavanones, flavones, 
flavonols, and lignans.   
Barrett’s esophagus risk was modestly reduced in relation to intake of anthocyanidins 
(highest versus lowest quartile of intake, OR=0.59, 95% CI: 0.31-1.12), flavanones (OR=0.71, 
95% CI: 0.37-1.35), flavonols (OR=0.89, 95% CI: 0.47-1.69), isoflavones (OR=0.68, 95% CI: 
0.34-1.36), and lignans (OR=0.64, 95% CI: 0.32-1.26), but the confidence intervals were wide  
(Table 4.3). In contrast, there was little or no association between total flavonoids (OR=1.09, 
95% CI: 0.56-2.11) or flavan-3-ols (OR=0.88, 95% CI: 0.45-1.71) and risk of Barrett’s 
esophagus. A modest increased risk of Barrett’s esophagus was observed for flavones 
(OR=1.26, 95% CI: 0.63-2.52).  
As presented in Table 4.4, the strength of inverse associations between flavonoid intake 
and Barrett’s esophagus appeared to increase with increasing disease specificity. For example, 
comparing the upper three quartiles to the bottom one, the odds ratio for the association with 
anthocyanidin intake (for which wine, bananas and fruit juice were the major dietary sources) 
was reduced by 51% for SIM (OR=0.49, 95% CI: 0.30-0.80), by 44% for VBE (OR=0.56, 95% 
CI: 0.31-1.02), and by 56% for LSBE (OR=0.44, 95% CI: 0.21-0.92). The corresponding risk 
reductions were similarly pronounced for LSBE and flavanones (OR=0.49, 95% CI: 0.24-1.00) 
and flavonols (OR=0.53, 95% CI: 0.24-1.17). 
   
Discussion 
This is the first epidemiologic study, to our knowledge, to examine the association between total 
and all classes of flavonoid and lignan intakes and risk of Barrett’s esophagus. In our analysis, 
we found modest, imprecise decreases in the odds ratios with increasing intakes of 
anthocyanidins, flavanones, flavonols, isoflavones, and lignans when all Barrett’s esophagus 
stages were considered together. While we did not observe a significant trend, the inverse 
associations for anthocyanidins, flavanones, and flavonols were slightly more pronounced when 
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we considered segment length. For example, risk reductions ranged from 47 to 56% for LSBE in 
relation to these flavonoid classes. 
Our findings are consistent with the one previous epidemiologic study that found a 
decreased risk of Barrett’s esophagus associated with dietary isoflavone intake, the only 
flavonoid class considered in that investigation.8 Foods containing high levels of isoflavones are 
infrequently consumed in the U.S.,9 which is consistent with reports from our study population 
(Table 4.1).  In our study we observed a suggested risk reduction for Barrett’s esophagus in 
relation to anthocyanidin intake. Our findings are consistent with interim clinical trial results that 
found reduced markers of oxidative stress in Barrett’s esophagus patients consuming 
anthocyanidin-rich freeze-dried black raspberries.24   
Barrett’s esophagus is a potential precursor lesion of esophageal adenocarcinoma, thus 
risk factors for this lesion could be involved in tumor initiation or promotion, whereas factors 
associated with tumor invasion should be more closely involved in cancer progression.25 Our 
finding of a possible inverse association between anthocyanidin intake and Barrett’s esophagus 
is consistent with a previous study of esophageal adenocarcinoma conducted in the United 
States 26 that found a significant decrease in invasive cancer risk associated with increased 
anthocyanidin intake. These observations suggest that anthocyanidin may play a role in both 
initiation and progression of esophageal adenocarcinoma. 
 In our study reported here, we observed possible risk reductions for the associations 
between anthocyanidins, flavanones, and flavonols in relation to all diagnostic Barrett’s 
esophagus categories. Importantly, Barrett’s esophagus segment length is related to the risk of 
developing esophageal adenocarcinoma.27 However, our study population included a limited 
number of patients with VBE or LSBE. Because of data sparseness when we examined 
associations with the case participants categorized by segment length, we grouped flavonoid 
intake into two categories, rather than four.21 Categorization of flavonoid exposures into two 
categories for the segment length analysis was conducted after examining the spline analysis 
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by collapsing quartiles 2-4 versus quartile 1. Therefore, results from these subgroup analyses 
should be interpreted with caution.  
 Our findings do not support an inverse association between total flavonoid intake or 
flavan-3-ol intake and risk of Barrett’s esophagus. Additionally, a modest increased risk of 
Barrett’s esophagus was observed for flavones. These results are at odds with experimental 
studies that have shown flavan-3-ols and flavones to have important chemopreventive effects 
against Barrett’s esophagus.6,28 In an in vitro study, Polyphenon E, a flavan-3-ol derived from 
green tea, inhibited growth and down-regulated the expression of cyclin D1 protein, which was 
associated with G(1) cell cycle arrest, in Barrett’s esophagus cells.6 One animal study has 
shown that a synthetic flavone derived from Dysoxylum binectariferum, Flavopiridol, reduces 
Barrett’s esophagus development.28 However, it is important to note that these experimental 
studies administered pure flavonoids derived from plants – green tea and D. binectariferum; 
whereas, our study utilized dietary intake of flavonoids from various foods and beverages. We 
found that the main sources of flavan-3-ols and flavones in our study population were black tea 
and pizza, respectively. Thus, our observation of an increased risk of Barrett’s esophagus 
associated with flavone intake may be confounded by other dietary habits and lifestyle choices 
linked to high pizza intake.  
 A recent report, based on data from the same parent study as the present report, found 
an inverse association between fruit and vegetable intake and Barrett’s esophagus.11 
Flavonoids are concentrated in fruits and vegetables;29 therefore, flavonoid intake may be a 
marker for some other factor associated with a healthy diet and lifestyle, rather than act as a 
causative factor itself.11 The parent study assessed a number of relevant lifestyle factors, 
including cigarette smoking, alcohol intake, and BMI;10 however, in our ancillary study, BMI was 
the only covariate that influenced our results and was included in the final adjusted models.  
A potential source of error in estimating flavonoid content in food, especially in fruits and 
vegetables, is the variability of environmental conditions, horticultural practices, degree of 
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ripeness, plant variety, storage conditions, industrial processing, and cooking methods, all of 
which may vary regionally and over time.18,19,29 Organically and sustainably grown foods, 
compared to those produced by conventional methods, also have higher polyphenol 
concentrations.30 Additionally, the FFQ line item for wine did not distinguish between red and 
white wine, which have different concentrations of flavonoids. Thus, food items reportedly 
consumed by this study population may differ from the foods utilized to create the estimates 
included in the databases.18-20 To estimate the impact such influences, the USDA Food 
Composition and Nutrient Data Laboratories determined the flavonoid content for more than 60 
fruits, vegetables, and nuts by sampling foods from four U.S. regions during two seasons of the 
year. While flavonoid content variability was high within and between foods, the average 
flavonoid content was similar to values reported in the USDA databases.31  
Another potential source of error in estimating an association between flavonoid intake 
and risk of Barrett’s esophagus is the bioavailability of flavonoid compounds. Little is known 
about the absorption of flavonoids in the body, and metabolism of flavonoids varies by 
individual.32 Additionally, currently measured flavonoid biomarkers are of limited usefulness in 
epidemiologic studies because of the variation in absorption profiles, with maximum 
concentrations reached between 0.5-9 hours after dietary intake.32 Thus, these biomarkers may 
not be highly correlated with usual adult dietary intake, which is the target exposure for cancer 
etiology studies, including studies of precursor lesions. While variation in dietary flavonoid 
content and flavonoid bioavailability may be a study limitation, it is a common limitation for all 
studies that rely on nutritional databases to estimate dietary intakes.17   
Patients with GERD symptoms are recommended to omit foods that are chemically or 
mechanically irritating;33 therefore, Barrett’s esophagus patients may have already made 
changes to their usual diets by the time of FFQ administration. Foods that are irritating vary by 
individual,34 so we are unable to determine how such potential changes in diet could have 
affected our flavonoid intake estimates. While some flavonoid-containing foods may be 
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recommended for GERD patients to avoid (e.g., coffee, tea, alcohol, citrus, tomatoes, chocolate, 
peppers, and onions), one dietary study showed that intakes of fruits, vegetables, and alcohol 
did not differ by symptomatic GERD status.35 As all cases in this study had GERD, it is still 
possible that the association between BE and flavonoid intake is due to reverse causation.   
For a FFQ, assessing diet for the year prior to diagnosis is a standard time interval, as it 
does not require extensive recall.17 Responses are assumed to reflect usual adult diet. Whether 
the time period assessed accurately reflects intakes during the time relevant to Barrett’s 
esophagus development is unknown. However, because all existing studies conducted among 
Barrett’s esophagus patients have relied on a FFQ,11,36,37 a cohort study would be required, with 
employment of multiple alternative dietary assessment methods repeatedly over time, to 
overcome the limitations of existing studies. Such an alternative study design would be 
inefficient, because only 10-15% of symptomatic GERD patients develop BE in their lifetime.38   
Our study FFQ did not assess dietary supplement use. Clinical studies of flavonoid 
supplements began in the early 1990s,39 and a U.S. patent was granted for Ginkgo biloba 
extract, EGb 761, in 1995.40 While it is possible that some participants were taking flavonoid-
containing supplements, it is unlikely that use was widespread during this study time period.  
 The difference that we observed in mean intake of total flavonoids between case and 
control participants was minimal, roughly equivalent to half of a medium apple per week. 
However, absolute differences in dietary flavonoid intakes need to be interpreted with caution, 
as a FFQ was utilized to collect relative, not absolute, dietary information. While FFQs have 
acknowledged measurement errors, they are useful for ranking individuals’ dietary intake 
relative to one another, which was our primary objective.17  
 In summary, our finding of modest inverse associations between anthocyanidins, 
flavanones and flavonols in relation to Barrett’s esophagus suggests that dietary intake of these 
compounds may lower risk of this precursor lesion. In contrast, total dietary flavonoid intake 
does not appear to be associated with decreased risk of developing Barrett’s esophagus in our 
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study sample. This is the first epidemiologic study to determine the association between the six 
flavonoid classes, total flavonoids and lignans and Barrett’s esophagus; therefore, further 
research is needed before definite conclusions can be made about the role of dietary flavonoids 
and lignans in relation to Barrett’s esophagus risk.  
 
 
 
 
 
 
 
 
 
 
 
Table 4.1. Mean Intakes (mg/day) of Flavonoids and Lignans Among Cases and Controls With Information on Dietary Intake, Study 
of Reflux Disease, Western Washington State, 1997-2000. 
 
  
Controls 
(N=183)   
Cases  
(N=170) 
  Mean Standard Deviation Range   Mean Standard Deviation Range 
Total Flavonoids 125.03 123.10 5.83-819.34 
 
123.55 134.39 10.52-707.45 
   Anthocyanidins 13.84 10.67 0.29-55.42 
 
13.47 13.15 0.36-85.19 
   Flavan-3-ols 73.01 114.23 1.71-739.93 
 
78.06 125.34 1.85-659.00 
   Flavanones 21.97 26.08 0.01-143.37 
 
17.20 21.62 0.02-146.23 
   Flavones 2.19 1.56 0.19-11.69 
 
2.15 1.19 0.13-6.68 
   Flavonols 11.89 6.63 1.74-42.60 
 
11.47 6.87 2.04-39.00 
   Isoflavones 2.14 5.90 0.02-55.18 
 
1.20 2.55 0.04-19.95 
Lignans 0.056 0.029 0.011-0.160 
 
0.051 0.030 0.009-0.176 
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Table 4.2. Major Dietary Sources of Flavonoids and Lignans Among a Community-based Sample of Control Participants Without 
Barrett’s Esophagus, Study of Reflux Disease, Western Washington State, 1997-2000. 
 
Flavonoid/Phytoestrogen Class Representative Flavonoids Main FFQ1 Line Item Sources (%) 
Total Flavonoids 
 
Black tea (47.2),  orange/grapefruit juice 
(12.2),  
   wine (6.8), oranges/grapefruit (4.7),  
   apples/pears (3.5), bananas (3.0) 
   Anthocyanidins Cyanidin, Delphinidin, Malvidin, Pelargonidin,   
   Peonidin, Petunidin 
Wine (31.2), bananas (14.8), fruit juice (11.3),  
   fruit cocktail/applesauce (8.5),  
   strawberries/kiwi (8.0), apples/pears (7.6),  
   bean soups (5.5) 
   Flavan-3-ols (+)-Catechin, (+)-Catechin-3-gallate, (-)- 
   Epicatechin, (-)-Epicatechin-3-gallate,  
   (-)-Epigallocatechin, (-)-Epigallocatechin-3- 
   gallate, (+)-Gallocatechin, (+)-Gallocatechin- 
   3-gallate, Theaflavin, Theaflavin-3-gallate,  
   Theaflavin-3’-gallate, Theaflavin-3,3’- 
   digallate, Thearubigins 
Black tea (78.2), green tea (3.5), wine (3.3),  
   apples/pears (3.0), beer (2.7), bananas (2.3) 
   Flavanones Eriodictyol, Hesperetin, Naringenin Orange/grapefruit juice (68.6),  
   oranges/grapefruit (26.3), wine (2.8) 
   Flavones Apigenin, Luteolin Pizza (38.4), wine (12.4), vegetable soup (8.0),  
   cream soup (6.8), mixed salad (6.1) 
   Flavonols Isorhamnetin, Kaempferol, Myricetin, Quercetin Black tea (15.6), onions (11.0),  
   apples/pears (9.4), wine (7.2), mixed   
   salad (5.9), beer (5.7) 
   Isoflavones Daidzein, Genistein, Glycitein Tofu (76.5), coffee (5.9), chili with beans (5.7),  
   milk (5.2) 
Lignans Matairesinol, Secoisolariciresinol Coffee (31.0), wine (12.6), orange/grapefruit  
   juice (9.4), onions (3.8), peanuts (3.7), black  
   tea (3.5) 
1
FFQ: Food frequency questionnaire.  
 
 
1
7
9
 
180 
Table 4.3. Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for the Association 
Between Flavonoid and Lignan Intake and Barrett’s Esophagus, Study of Reflux Disease, 
Western Washington State, 1997-2000. 
 
Variable and  
intake (mg/day)   
Controls 
(N=183)   
Cases 
(N=170)   OR 
 
95% CI 
Total Flavonoids 
      
 
   0-42.38 
 
46 
 
44 
 
1.00  
   42.39-75.36 
 
46 
 
41 
 
1.10 0.59, 2.08 
   75.37-166.98 
 
45 
 
46 
 
1.37 0.73, 2.58 
   ≥166.99 
 
46 
 
39 
 
1.09 0.56, 2.11 
   P for trend
2
 
 
    
0.81  
Anthocyanidins 
 
     
 
   0-6.12 
 
46 
 
64 
 
1.00  
   6.13-9.82 
 
45 
 
24 
 
0.33 0.17, 0.63 
   9.83-18.26 
 
47 
 
46 
 
0.58 0.32, 1.06 
   ≥18.27 
 
45 
 
36 
 
0.59 0.31, 1.12 
   P for trend
2
 
 
    
0.91  
Flavan-3-ols 
 
     
 
   0-9.50 
 
45 
 
44 
 
1.00  
   9.51-17.35 
 
46 
 
22 
 
0.51 0.25, 1.03 
   17.36-107.34 
 
46 
 
70 
 
1.78 0.98, 3.23 
   ≥107.35 
 
46 
 
34 
 
0.88 0.45, 1.71 
   P for trend
2
 
 
    
0.54  
Flavanones 
 
     
 
   0-3.80 
 
45 
 
55 
 
1.00  
   3.81-12.90 
 
47 
 
41 
 
0.71 0.39, 1.32 
   12.91-29.64 
 
46 
 
41 
 
0.81 0.44, 1.48 
   ≥29.65 
 
45 
 
33 
 
0.71 0.37, 1.35 
   P for trend
2
 
 
    
0.27  
Flavones 
 
     
 
   0-1.15 
 
46 
 
37 
 
1.00  
   1.16-1.88 
 
46 
 
39 
 
1.10 0.57, 2.13 
   1.89-2.82 
 
45 
 
49 
 
1.46 0.75, 2.85 
   ≥2.83 
 
46 
 
45 
 
1.26 0.63, 2.52 
   P for trend
2
 
 
    
0.61  
Flavonols 
 
     
 
   0-6.99 
 
46 
 
52 
 
1.00  
   7.00-10.86 
 
46 
 
44 
 
0.83 0.45, 1.53 
   10.87-14.89 
 
46 
 
28 
 
0.60 0.31, 1.16 
   ≥14.90 
 
45 
 
46 
 
0.89 0.47, 1.69 
   P for trend
2
 
 
    
0.50  
Isoflavones 
 
     
 
   0-0.24 
 
46 
 
41 
 
1.00  
   0.25-0.52 
 
45 
 
56 
 
1.22 0.65, 2.29 
   0.53-1.16 
 
47 
 
39 
 
0.82 0.42, 1.60 
   ≥1.17 
 
45 
 
34 
 
0.68 0.34, 1.36 
   P for trend
2
 
 
    
0.09  
Lignans 
 
     
 
   0-0.033 
 
45 
 
53 
 
1.00  
   0.034-0.051 
 
46 
 
52 
 
0.91 0.50, 1.67 
   0.052-0.070 
 
46 
 
28 
 
0.46 0.22, 0.94 
   ≥0.071 
 
46 
 
37 
 
0.64 0.32, 1.26 
   P for trend
2
  
    
0.15  
1
Adjusted for age (continuous), sex, body mass index (continuous), and kilocalories (continuous). 
2
P-
value for trend for continuous variable. 
 
 
Table 4.4. Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for the Association Between Flavonoid and Lignan Intake 
and Barrett’s Esophagus Segment Length,2 Study of Reflux Disease, Western Washington State, 1997-2000. 
 
        Clinical SIM2 
 
Clinical VBE2 
 
Clinical LSBE2 
Variable and  
intake (mg/day)   
Controls 
(N=183)  
Cases 
(N=170) 
OR 95% CI 
P for  
trend3  
Cases 
(N=86) 
OR 95% CI 
P for  
trend3  
Cases 
(N=48) 
OR 95% CI 
P for  
trend3 
Total Flavonoids 
 
    
 
    
 
    
 
 
   0-42.38 
 
46 
 
44 1.00  
  
25 1.00  
  
16 1.00  
 
   ≥42.39 
 
137 
 
126 1.19 0.70, 2.01 0.81 
 
61 0.93 0.50, 1.73 0.97 
 
32 0.71 0.33, 1.52 0.70 
Anthocyanidins 
 
    
 
    
 
    
 
 
   0-6.12 
 
46 
 
64 1.00  
  
31 1.00  
  
20 1.00  
 
   ≥6.13 
 
137 
 
106 0.49 0.30, 0.80 0.91 
 
55 0.56 0.31, 1.02 0.45 
 
28 0.44 0.21, 0.92 0.67 
Flavan-3-ols 
 
    
 
    
 
    
 
 
   0-9.50 
 
45 
 
44 1.00  
  
20 1.00  
  
15 1.00  
 
   ≥9.51 
 
138 
 
126 1.06 0.63, 1.78 0.54 
 
66 1.21 0.63, 2.32 0.81 
 
33 0.75 0.35, 1.60 0.95 
Flavanones 
 
    
 
    
 
    
 
 
   0-3.80 
 
45 
 
55 1.00  
  
31 1.00  
  
20 1.00  
 
   ≥3.81 
 
138 
 
115 0.74 0.45, 1.22 0.27 
 
55 0.55 0.31, 0.99 0.38 
 
28 0.49 0.24, 1.00 0.12 
Flavones 
 
    
 
    
 
    
 
 
   0-1.15 
 
46 
 
37 1.00  
  
20 1.00  
  
10 1.00  
 
   ≥1.16 
 
137 
 
133 1.25 0.71, 2.20 0.61 
 
66 1.11 0.56, 2.19 0.42 
 
38 1.66 0.67, 4.15 0.96 
Flavonols 
 
    
 
    
 
    
 
 
   0-6.99 
 
46 
 
52 1.00  
  
29 1.00  
  
17 1.00  
 
   ≥7.00 
 
137 
 
118 0.77 0.46, 1.30 0.50 
 
57 0.59 0.31, 1.10 0.48 
 
31 0.53 0.24, 1.17 0.63 
Isoflavones 
 
    
 
    
 
    
 
 
   0-0.24 
 
46 
 
41 1.00  
  
20 1.00  
  
9 1.00  
 
   ≥0.25 
 
137 
 
129 0.92 0.53, 1.60 0.09 
 
66 0.82 0.41, 1.61 0.35 
 
39 0.98 0.40, 2.42 0.30 
Lignans 
 
    
 
    
 
    
 
 
   0-0.033 
 
45 
 
53 1.00  
  
24 1.00  
  
10 1.00  
 
   ≥0.034  138 
 
117 0.71 0.41, 1.21 0.15 
 
62 0.80 0.42, 1.54 0.13 
 
38 1.35 0.56, 3.26 0.52 
1
Adjusted for age (continuous), sex, body mass index (continuous), and kilocalories (continuous). 
2
Barrett’s esophagus segment length categories 
are progressively exclusive groups. SIM: Specialized intestinal metaplasia, VBE: visible Barrett’s esophagus, LSBE: long-segment Barrett’s 
esophagus. 
3
P-value for trend for continuous variable. 
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Table 4.5. Distribution (n [%]) of Characteristics Among Barrett’s Esophagus Cases and 
Controls with Information on Dietary Intake, Study of Reflux Disease, Western Washington 
State, 1997-2000. 
 
  Control participants Barrett’s Esophagus participants 
Characteristic N=183 N=170 
Age   
 
   20-39 25 (13.7) 22 (12.9) 
   40-49 46 (25.1) 42 (24.7) 
   50-59 55 (30.1) 53 (31.2) 
   60-80 57 (31.1) 53 (48.2) 
Sex   
 
   Male 113 (61.7) 100 (58.8) 
   Female 70 (38.3) 70 (41.2) 
Race   
 
   White 169 (92.9) 152 (91.6) 
   Other 13 (7.1) 14 (8.4) 
Education   
 
   ≤ High School 32 (17.5) 43 (25.3) 
   Technical School 6 (3.3) 9 (5.3) 
   College or more 145 (79.2) 118 (69.4) 
Income level, US $     
   <45,000 55 (31.4) 50 (32.5) 
   ≥45,000-74,999 51 (29.1) 49 (31.8) 
   ≥75,000 69 (39.4) 55 (35.7) 
Cigarette Use     
   Ever 89 (48.6) 109 (64.1) 
   Never 94 (51.4) 61 (35.9) 
Body Mass Index   
   <25 kg/m2 57 (31.1) 33 (19.4) 
   ≥25 kg/m2 126 (68.9) 137 (80.6) 
Segment Length1 
  
  
   SIM 170 (100.0) 
   VBE 86 (50.6) 
   LSBE 48 (28.2) 
1
Barrett’s esophagus segment length categories are progressively exclusive groups. SIM: Specialized 
intestinal metaplasia, VBE: visible Barrett’s esophagus, LSBE: long-segment Barrett’s esophagus. 
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Figure 4.1. Restricted Quadratic Spline Graph of the Adjusted1 Odds Ratios (represented by the 
solid line) and 95% Confidence Intervals (represented by the dotted lines) of the Association 
Between Anthocyanidin Intake and Barrett’s Esophagus, Study of Reflux Disease, Western 
Washington State, 1997-2000. 
 
 
1
Adjusted for age (continuous), sex, body mass index (continuous), and kilocalories (continuous). 
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Table 4.6. Sensitivity Analysis of Mean Intakes (mg/day) of Anthocyanidins (Bananas Included 
versus Excluded) Among Cases and Controls With Information on Dietary Intake, Study of 
Reflux Disease, Western Washington State, 1997-2000. 
 
  
Controls 
(N=183)   
Cases  
(N=170) 
  Mean 
Standard 
Deviation Range   Mean 
Standard 
Deviation Range 
Anthocyanidins,  
   Bananas  
   Included 
13.84 11.31 0.29-55.42 
 
13.47 14.21 0.36-85.19 
Anthocyanidins,  
   Bananas  
   Excluded 
11.80 10.67 0.18-52.97 
 
11.78 13.15 0.36-79.93 
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Table 4.7. Sensitivity Analysis of the Major Sources of Anthocyanidins (Bananas Included 
versus Excluded) Among a Community-based Sample of Control Participants Without Barrett’s 
Esophagus With Information on Dietary Intake, Study of Reflux Disease, Western Washington 
State, 1997-2000. 
 
Flavonoid/Phytoestrogen Class Main FFQ1 Line Item Sources (%) 
Anthocyanidins, Bananas Included Wine (31.2), bananas (14.8), fruit juice (11.3),  
   fruit cocktail/applesauce (8.5),  
   strawberries/kiwi (8.0), apples/pears (7.6),   
   bean soups (5.5) 
Anthocyanidins, Bananas Excluded Wine (36.6), fruit juice (13.3),  
   fruit cocktail/applesauce (10.0),  
   strawberries/kiwi (9.3), apples/pears (9.0),   
   bean soups (6.4) 
1
FFQ: Food frequency questionnaire.  
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Table 4.8. Sensitivity Analysis of Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals 
(CI) for the Association Between Anthocyanidin Intake (Bananas Included versus Excluded) and 
Barrett’s Esophagus, Study of Reflux Disease, Western Washington State, 1997-2000. 
 
Variable and  
intake (mg/day)   
Controls 
(N=183)   
Cases 
(N=170)   
OR 95% CI 
Anthocyanidins,  
   Bananas Included 
      
 
   0-6.12 
 
46 
 
64 
 
1.00  
   6.13-9.82 
 
45 
 
24 
 
0.33 0.17, 0.63 
   9.83-18.26 
 
47 
 
46 
 
0.58 0.32, 1.06 
   ≥18.27 
 
45 
 
36 
 
0.59 0.31, 1.12 
   P for trend2 
 
    
0.91  
Anthocyanidins,  
   Bananas Excluded 
 
      
   0-4.68  45  54  1.00  
   4.69-8.29  46  40  0.65 0.35, 1.19 
   8.30-15.26  47  42  0.62 0.33, 1.16 
   ≥15.27  45  34  0.64 0.33, 1.22 
   P for trend2      0.90  
1
Adjusted for age (continuous), sex, body mass index (continuous), and kilocalories (continuous). 
2
P-
value for trend for continuous variable. 
 
 Table 4.9. Sensitivity Analysis of Adjusted1 Odds Ratios (OR) and 95% Confidence Intervals (CI) for the Association Between 
Anthocyanidin Intake (Bananas Included versus Excluded) and Barrett’s Esophagus Segment Length,2 Study of Reflux Disease, 
Western Washington State, 1997-2000. 
 
        Clinical SIM2 
 
Clinical VBE2 
 
Clinical LSBE2 
Variable and  
intake (mg/day)   
Controls 
(N=183)  
Cases 
(N=170) 
OR 95% CI 
P for  
trend3  
Cases 
(N=86) 
OR 95% CI 
P for  
trend3  
Cases 
(N=48) 
OR 95% CI 
P for  
trend3 
Anthocyanidins,  
   Bananas Included 
 
    
 
    
 
    
 
 
   0-6.12 
 
46 
 
64 1.00  
  
31 1.00  
  
20 1.00  
 
   ≥6.13 
 
137 
 
106 0.49 0.30, 0.80 0.91 
 
55 0.56 0.31, 1.02 0.45 
 
28 0.44 0.21, 0.92 0.67 
Anthocyanidins,  
   Bananas Excluded  
                
   0-4.68  45  54 1.00    24 1.00    15 1.00   
   ≥4.69  138  116 0.64 0.39, 1.05 0.90  62 0.81 0.43, 1.52 0.33  33 0.69 0.32, 1.50 0.43 
1
Adjusted for age (continuous), sex, body mass index (continuous), and kilocalories (continuous). 
2
Barrett’s esophagus segment length categories 
are progressively exclusive groups. SIM: Specialized intestinal metaplasia, VBE: visible Barrett’s esophagus, LSBE: long-segment Barrett’s 
esophagus. 
3
P-value for trend for continuous variable. 
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CHAPTER 5: DISCUSSION 
 
 
The purpose of this dissertation was to examine the association between flavonoid intake and 
esophageal and gastric cancer along the cancer continuum (normal tissue  precancerous 
conditions  invasive cancer  mortality). Chapter 4 examines the association between 
flavonoids and the precancerous lesion, Barrett’s esophagus. Chapter 3 examines the 
association between flavonoids and invasive esophageal and gastric cancer incidence and 
survival. This novel approach of examining the precancerous lesion and invasive cancer aimed 
to identify key windows of susceptibility that could signify when along the cancer continuum a 
potential intervention strategy of flavonoid use could be implemented in an effort to reduce the 
significantly high disease burden associated with these cancers. 
 
Figure 5.1. Literature of Epidemiologic and Clinical Studies Supporting Examination of the 
Association Between Flavonoid Intake and the Esophageal and Gastric Cancer Continuum. 
Gastroesophageal 
Reflux Disease 
Barrett’s 
Esophagus (BE) 
Esophageal and 
Gastric Cardia 
Adenocarcinoma 
(EA/GCA) 
Death 
Fruits/Vegetables, reduced risk. 
Navarro Silvera et al., 2008;  
Gonzalez et al., 2006. 
 
Freeze-dried berries, reduced 
oxidative stress markers in BE.  
Kresty et al., 2006. 
 
Flavonoids, reduced risk. 
Bobe et al., 2009 (anthocyanidins); 
Lagiou et al., 2004 (flavanones); 
Ekstrom et al., 2011 (flavonols);  
Lin et al., 2012 (lignans, case-control). 
 
Flavonoids, no reduced risk. 
Vermeulen et al., 2013, Zamora-Ros et 
al., 2012  (all, EPIC), 
Lin et al., 2012 (lignans, cohort). 
Fruits/Vegetables, reduced risk. 
Thompson et al., 2009;  
Kubo et al., 2008;  
Anderson et al., 2007. 
 
Isoflavones, reduced risk. 
Jiao et al., 2013. 
Synthetic flavonoids,  
no reduced risk. 
Schwartz et al., 2001 (flavone). 
This study proposed to determine the effects of flavonoids at these points, where there 
is potential to intervene before progression into EA/GCA. 
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Summary of Results 
In this study, modest decreasing risks were found with increasing intakes of anthocyanidins, 
across all stages of the cancer continuum. Anthocyanidin intake was associated with a 
decreased risk of BE development (quartile 4 versus quartile 1, OR=0.59, 95% CI: 0.31-1.12). 
This association was also found across all categories of BE segment length (quartiles 2-4 
versus quartile 1, SIM OR=0.49, 95% CI: 0.30-0.80; VBE OR=0.56, 95% CI: 0.31-1.02; LSBE 
OR=0.44, 95% CI: 0.21-0.92). Reduced risk of invasive EA and GCA incidence was shown for 
increasing levels of anthocyanidin intake (quartile 4 versus quartile 1, EA OR=0.43, 95% CI: 
0.29-0.66; GCA OR=0.71, 95% CI: 0.46-1.10). Reduced risk of mortality among EA and GCA 
cases was also shown for higher levels of anthocyanidin intake (quartile 4 versus quartile 1, EA 
HR=0.87, 95% CI: 0.60-1.26; GCA HR=0.63, 95% CI: 0.42-0.95). Additionally, anthocyanidin 
intake was associated with decreased risk of ESCC and NCGA incidence (quartile 4 versus 
quartile 1, ESCC OR=0.43, 95% CI: 0.26-0.70; NCGA OR=0.70, 95% CI: 0.47-1.03).  
Further, flavanones, flavonols, isoflavones, and lignans were associated with a 
decreased risk of BE development. Flavanones were associated with a decreased risk of EA 
incidence; flavanones, flavones, isoflavones, and lignans were associated with a decreased risk 
of ESCC incidence; and lignans were associated with a decreased risk of NCGA incidence. 
Flavones, isoflavones, and lignans were associated with risk reduction in all-cause mortality for 
EA cases; flavan-3-ols were associated with a risk reduction in all-cause mortality for GCA 
cases; lignans were associated with risk reduction in all-cause mortality for ESCC cases; and 
flavanones were associated with risk reduction in all-cause mortality for NCGA cases.  
 
Study Strengths 
Cancer Continuum. Esophageal adenocarcinoma (EA) and gastric cardia adenocarcinoma 
(GCA) have been among most rapidly increasing cancer types in the U.S. and other Western 
countries.1,2 EA/GCA appears to develop through a sequence of pathologic events.3 Chronic or 
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severe gastroesophageal reflux disease (GERD) can cause ulceration of the normal esophageal 
squamous mucosa followed, in some people, by the development of Barrett’s esophagus (BE).4  
BE is the only known potential precursor of EA/GCA.5 This dissertation examined the 
association between flavonoid intake and esophageal and gastric cancer along the BE-
adenocarcinoma cancer continuum (normal tissue  gastroesophageal reflux disease  
Barrett’s esophagus  invasive esophageal/gastric cardia adenocarcinoma  mortality). This 
approach is novel because it allows examination of the precancerous lesion and invasive 
cancer, which allows identification of key windows of susceptibility that could signify when along 
the cancer continuum a potential intervention strategy of flavonoid use could be implemented. 
This also lends plausibility to studying a particular class of flavonoids further as a potential 
chemopreventive agent if it is observed that it affects all stages of carcinogenesis, as was the 
case with anthocyanidins. Our findings, if confirmed, suggest that adequate dietary 
anthocyanidin intake may lower risk of these cancers and could potentially be used to reduce 
the significantly high disease burden associated with these tumors. However, this does not 
preclude flavonoid classes that do not affect all stages of carcinogenesis as potential risk 
reduction strategies, as other classes could differentially affect the cancer stages of initiation, 
promotion, and progression.6 For example, flavanones reduced the risk of Barrett’s esophagus 
development and esophageal adenocarcinoma incidence but had no association with mortality 
among esophageal adenocarcinoma cases.  
Experimental Studies. Most experimental studies support the hypothesis of an inverse 
association between flavonoids and BE and esophageal and gastric cancer. For example, 
flavan-3-ol inhibited growth through down-regulation of cyclin D1 protein expression in BE cells,7 
and anthocyanidin-containing freeze-dried berries inhibited the formation of esophageal tumors 
in rats caused by N-nitrosomethylbenzylamine (NMBA), which has long been long been used to 
model ESCC in rats.8,9 
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Geographic Variation. This study is significant because EA/GCA have rapidly increasing 
incidence rates in the U.S. and other Western countries,1,2 but incidence rates in Asian countries 
remain comparatively low.10 The rates of EA/GCA vary 50- to 60-fold between high and low 
incidence countries.10 These geographic differences in incidence do not appear to be only due 
to genetic variation between racial/ethnic groups, as incidence rates of EA/GCA in Asian 
migrants to the U.S. tend to approach those of European-American incidence rates within a few 
generations.11-13  
The geographic variation in incidence rates of EA/GCA and results of migrant studies 
have led to the hypothesis that the variability is in part due to differences in dietary composition, 
including energy intake and micronutrient intake.1,14 This study was inspired by geographic 
differences in the incidence of these tumors. As Asian countries have lower incidence rates of 
EA/GCA and consume more flavonoid-rich foods than Western countries,15,16 it is possible that 
flavonoids or a specific flavonoid class may decrease BE and EA/GCA risk. We considered all 
classes of flavonoids (anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols, 
isoflavones), as many of these flavonoid classes occur more frequently in foods consumed by 
Western populations (e.g., tomatoes, green peppers, berries, and citrus fruits).17 
Flavonoid and Lignan Database. The most recent U.S. Department of Agriculture 
(USDA) databases were utilized to create the exposure assessment: 2011 USDA Database for 
the Flavonoid Content of Selected Foods18 and the 2008 USDA-Iowa State University Database 
on the Isoflavone Content of Selected Foods.19 Additionally, these were supplemented with 
lignan content (i.e., secoisolariciresinol and matairesinol) from a North American population.20 
Fred Hutchison Cancer Research Center FFQs are generally processed by the University of 
Minnesota Nutrition Data System for Research (NDSR), which was not linked with the most 
current USDA databases at time of exposure creation, thus necessitating the creation of study-
specific flavonoid composition databases from other sources. 
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Study Design and Sample Size. BE and esophageal and gastric cancer are rare 
diseases; therefore, a case-control study is the most efficient study design. Although a cohort 
study could overcome the limitation of recall bias, this study design is inefficient. The current 
study is a practical and cost-efficient use of resources because dietary data was previously 
collected using a valid, reliable FFQ from the Fred Hutchison Cancer Research Center.21,22 This 
allowed estimation and ranking of dietary intake of flavonoids. Additionally, the BE and EGA 
study data collection and management have been performed in similar ways, as Dr. Thomas 
Vaughan was a principal investigator in both studies.  
  Our study benefited from a larger population than similar studies published previously. 
The EGA study is a population-based study of 274 EA, 248 GCA, 191 ESCC, and 341 NCGA 
cases and 662 frequency-matched controls with plausible dietary intake information. The 
number of EA cases is larger than in the Black-White Study, a previous study that had 
examined flavonoids and EA incidence, which had 161 cases.23 The community-based BE study 
also has a larger sample size (n=170 BE cases with plausible dietary intake) than the previous 
study to examine isoflavones, which had 151 BE cases.24 Additionally, the population-based 
design of the EGA study allows for generalizability of the results to a broader population than in 
previous studies. 
 
Study Limitations 
Exposure Misclassification: Dietary Recall. FFQs were assessed for the year prior to interview 
(BE cases) or 3-5 years prior to diagnosis (esophageal and gastric cancer cases).  
Responses were assumed to reflect usual adult diet, but whether the time period assessed 
accurately reflects intakes during the time relevant to BE or esophageal/gastric cancer 
development is unknown. However, because all existing studies conducted among BE25-27 and 
esophageal/gastric cancer patients25,28-36 have relied on FFQs, one would need to conduct a 
new cohort study and employ multiple alternative dietary assessment methods over time to 
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overcome this issue of nondifferential misclassification. Such an alternative study design would 
be inefficient, because only 10-15% of symptomatic GERD patients develop BE in their 
lifetime37 and the lifetime risk of esophageal or gastric cancer is less than one percent.38 
 There is also potential for differential exposure misclassification in the EGA study, as 
many of the case participants were experiencing symptomatic GERD (e.g., 55% of EA cases 
versus 29% of controls). Thus, a larger proportion of case participants were experiencing 
symptomatic reflux and considering dietary choices that could impact GERD symptoms more 
carefully. Therefore, it is possible that a greater number of case participants recalled their 
dietary intake more accurately than the control participants. This type of recall bias would 
increase the likelihood of detecting spurious results. 
Lack of Certain Flavonoid-rich Foods and Supplements in FFQ. The FFQs did not 
assess certain foods that contain high-levels of flavonoids. In the BE and EGA FFQ, 
raspberries, which contain high levels of anthocyanidins,18 were not included. Additionally, the 
EGA FFQ did not ask about tofu intake, which is a primary source of isoflavones.19 Thus, the 
results could be more pronounced (i.e., if cases consumed higher quantities of raspberries or 
tofu) or attenuated (i.e., if controls consumed higher quantities of raspberries or tofu) with the 
assessment of these additional dietary sources of flavonoids.  
The study FFQs did not assess dietary supplement use. Clinical studies of flavonoid 
supplements began in the early 1990s,39,40 and a U.S. patent was granted for Ginkgo biloba 
extract, EGb 761, in 1995.34 While it is possible that some study participants were taking 
flavonoid-containing supplements, it is unlikely that use was widespread during the time period 
the parent studies were recruiting participants (EGA 1993-1995 and BE 1997-2000). 
Bioavailabilty of Flavonoids. A potential source of error in estimating the amount of 
flavonoid intake necessary to reduce the risk of BE or esophageal/gastric cancer is the 
bioavailability of flavonoid compounds. However, little is known about the absorption of 
flavonoids in the body, and metabolism of flavonoids varies by individual.41 Additionally, the use 
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of current flavonoid biomarkers is of limited usefulness in epidemiologic studies, because of the 
variation in absorption profiles, with maximum concentrations reached between 0.5-9 hours 
after dietary intake.42 Thus, these biomarkers may not be highly correlated with usual adult diet, 
which is the target exposure for cancer studies, including precursor lesions. While the variation 
in dietary flavonoid content and flavonoid bioavailability may be a study limitation, this is a 
limitation for all studies that rely on nutritional databases to estimate dietary intake.43   
Flavonoid Classification. In this study, flavonoids were categorized by classes 
(anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols, and isoflavones) and also 
combined into total flavonoids. However, this may mask effects of individual flavonoids. For 
instance, the flavonoid class anthocyanidins is composed of six individual flavonoids: cyanidin, 
delphinidin, malvidin, pelargonidin, peonidin, and petunidin. Thus, by combining all of these 
individual flavonoids into the category of anthocyanidins, there is potential that risk reductions 
are being diluted if the association between exposure and outcome is strong for one flavonoid in 
the class but not others.   
Healthy Lifestyle. Recent reports from the parent studies found modest inverse 
associations between fruit and vegetable intake and BE27 and both histologic types of 
esophageal cancer.30 Flavonoids are concentrated in fruits and vegetables;44 therefore, it is 
possible that flavonoid intake is a marker for a healthy diet and lifestyle, rather than a causative 
agent.27 Lifestyle factors, including cigarette smoking, alcohol intake, and BMI, were assessed 
in the parent studies.45 BMI was the only covariate that influenced the BE results, and cigarette 
smoking was the only covariate that influenced the esophageal/gastric cancer results. These 
were adjusted for in the final models.  
Error Estimating Flavonoid Content. A potential source of error in estimating flavonoid 
content in food, especially fruits and vegetables, may be associated with the variability of 
environmental conditions, horticultural practices, degree of ripeness, plant variety, storage 
conditions, industrial processing, and cooking methods, which may vary regionally and over 
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time.17-19,41,46-51 Organically and sustainably grown foods, compared to those produced by 
conventional methods, also have higher polyphenol concentrations.51,52 To estimate the impact 
of these potential influences, the USDA Food Composition and Nutrient Data Laboratories 
determined the flavonoid content for over 60 fruits, vegetables, and nuts by sampling foods from 
four U.S. regions at two times of the year. While flavonoid content variability was high within and 
between foods, the average flavonoid content was similar to values reported by the USDA.53 
Additionally, the FFQ line item for wine did not discern between red and white wine, which have 
different concentrations of flavonoids. Thus, the food sources consumed by this study 
population may be different than the foods utilized to create the databases estimates.18-20 
Sample Size Limitations. While this study has a larger sample size than previous studies 
to examine the association between BE25-27 and esophageal/gastric cardia adenocarcinoma,25,28-
36 the sample size is still small to examine stratifications of the data – specifically segment 
length for BE and cyclin D1 status, p53 status, and stage for esophageal and gastric cancer.    
Multiple Comparisons. The issues of multiple comparisons needs to be considered when 
discussing the results of this dissertation, as there were 72 comparisons just within the main 
analyses. Examination of the exposures of total flavonoids, six classes of flavonoids, and 
lignans and the outcomes of BE development, EA/GCA/ESCC/NCGA incidence, and survival 
among EA/GCA/ESCC/NCGA cases was conducted. Additionally, outcomes were stratified by 
BE tumor segment length, esophageal/gastric cancer stage, and cyclin D1/p53 status. Thus, 
there is a high likelihood of some statistically significant results arising due to chance, due to the 
number of comparisons examined. While this is a highly debated topic in epidemiology, it is 
generally accepted that adjusting for multiple comparisons undeservedly reduces power. 
Therefore, associations should be evaluated individually based on biologic plausibility and 
consistency with published results.54-56  
In this dissertation, more credence was given to results that were consistent across the 
continuum of cancer development (i.e., anthocyanidins). While it is possible that classes of 
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flavonoids affect the stages of cancer development differentially, the consistency of risk 
reduction across the cancer development continuum for anthocyanidins was striking.   
Generalizability and Selection Bias. While the population-based and community-based 
designs of the EGA and BE studies increase the generalizability of the results, generalizability is 
limited due to potential selection bias. The majority of participants were Caucasian males with 
low socioeconomic status, and a large proportion of esophageal and gastric cancer participants’ 
report was based on proxy response. However, the overwhelming majority of individuals that 
develop esophageal and gastric cancer are white males.57-63 Thus, the results are still largely 
generalizable to those at highest risk of developing these deadly cancers.  
 
Future Direction 
Disentangling Effects of Antioxidants. Flavonoids may be associated with risk reduction of BE or 
esophageal/gastric cancer due to chemopreventive properties, as demonstrated in experimental 
studies, such as  regulation of cell cycle, proliferation, and apoptosis.7-9 However, these 
chemopreventive properties are common to many other constituents of fruits and vegetables, 
including fiber, vitamins, minerals, and other phytochemicals.64 Vitamin C, vitamin E, fiber, and 
beta-carotene are also inversely associated with BE and esophageal/gastric cancer in 
population studies.65 However, considering these other nutrients as covariates for the 
association between flavonoids and risk of BE or esophageal/gastric cancer is problematic, due 
to the inherently high collinearity between flavonoids and other chemopreventive agents in fruits 
and vegetables. Thus, more sophisticated statistical techniques, which can be utilized in future 
analyses, will be required to disentangle the effects of flavonoids from other antioxidants or to 
examine if the combination of antioxidants, including flavonoids and lignans, in dietary intake of 
fruits and vegetables is affecting the development of BE or esophageal/gastric cancer incidence 
and survival.66   
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Utilizing Flavonoid Gram Weights. In this analysis, flavonoid gram weights were utilized 
to create the exposure variables. The alternative is to utilize the molecular weight of flavonoids. 
That is, it might not be the grams of flavonoids that are important for risk reduction of 
esophageal/gastric cancers but the number of molecules of flavonoids consumed. As some 
flavonoids in the USDA database are presented as glycones (i.e., containing a sugar molecule) 
and some are presented as aglycones (i.e., not containing a sugar molecule), the issue of 
determining molecular weights for flavonoids is further complicated.18 However, this is an issue 
that should be dealt with in future research, as there is a wide range of molecular weights in the 
flavonoids contributing to certain classes, particularly flavan-3-ols.67  
Possible Future Research Designs. In an ideal study to examine the association 
between flavonoid intake and the EGA cancer continuum, a cohort study would be undertaken 
whereby individuals were followed for outcomes along the continuum of GERD  BE  
EA/GCA  death, and flavonoid intake was assessed utilizing multiple techniques, including 
biomarkers, 24-hour recall and FFQs, administered repeatedly over time. However, a study of 
this nature would be extraordinarily inefficient because only 10-15% of symptomatic GERD 
patients develop BE in their lifetime37 and the lifetime risk of esophageal or gastric cancer is less 
than one percent.38 Thus this “ideal” cohort study would demand extensive effort from each 
participant annually (because of the need for repeated multiple measures per year over 20+ 
years of time), which could result in high participant drop-out – affecting internal validity of the 
study – and still yield only a small number of outcomes.  
An alternative study design to consider is a new case-control study whereby BE cases 
and population-based controls are enrolled. Similarly to the parent BE study examined here, BE 
cases would be enrolled from individuals experiencing symptomatic GERD. Participants would 
be asked to provide 24-hour dietary recalls, urine collections, and a FFQ for each of the four 
seasons. Additionally, all participants would be asked to complete a FFQ for the time prior to 
symptomatic GERD. As flavonoids are concentrated in fruits and vegetables, which can have 
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seasonal availability, this study would be able to examine changing intakes of flavonoids by 
season. This proposed study would also allow a retrospective assessment of flavonoid intake 
for the time prior to symptomatic GERD. However, this recalled dietary intake could still be 
influenced by current dietary intake. In the proposed study, though, there would be multiple 24-
hour dietary recalls, urine collections, and FFQs. Thus, the correlation between these measures 
can be examined, and if an individual repeatedly under- or over-reports dietary intake, the FFQ 
that assessed dietary intake prior to symptomatic GERD could be corrected for this 
misreporting. One could consider also including a GERD control group, however, over-matching 
of cases and controls (both of whom would have GERD) could result in detecting no differences, 
when in fact there should be. 
Prior to implementing this “ideal” case-control study, a pilot study would need to be 
undertaken to determine feasibility. First, determination of whether first morning urine or 24-hour 
urine collection is needed to adequately capture flavonoid variability. Second, determination of 
participant compliance for collecting and returning urinary specimen(s) and competing the 24-
hour recalls and FFQs is needed. Finally, determination of the associations between urinary 
biomarkers of flavonoid intake and self-reported intakes from 24-hour recalls and FFQs is 
needed to assess necessary exposure assessments to include in the “ideal” case-control study.  
Due to the highly lethal nature of EA/GCA, a similar study utilizing 24-hour dietary recalls 
and urinary biomarkers would be challenging. A case-control study could be undertaken utilizing 
only one time point (i.e., 24-hour recall, urinary collection, and FFQ at interview) with the 
knowledge that study participants would primarily be individuals with less progressed cancers. 
In the parent EGA study, rapid case ascertainment was utilized, but 29.6% of EA/GCA cases 
required a proxy interview. 
In summary, the “ideal” cohort approach with multiple, repeated measures over time 
would be costly, and likely to induce low retention rates with low outcome numbers, which would 
yield results that were unstable and not very informative. In contrast, the “ideal” case-control 
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approach would be challenging to interpret because of the potential impact of GERD influencing 
dietary recall, and it would apply to only those individuals with less aggressive disease. Given 
the multiple challenges associated with identifying an ideal study approach with which to 
address the proposed research questions, the study design used here, although less than ideal, 
was very cost-efficient. 
 
Public Health Implications 
Esophageal and gastric cancer have very poor survival prognoses (normally less than a year),68 
and the only known potential precursor of esophageal and gastric cardia adenocarcinoma is 
Barrett’s esophagus.5 These findings, if confirmed, suggest that adequate dietary anthocyanidin 
intake may lower risk of these cancers. This would allow some esophageal and gastric cancer 
to be prevented before individuals develop these deadly cancers or offer support for use of 
flavonoids as novel chemotherapy drugs. 
 
Figure 5.2. Study Results for Dietary Flavonoid Intake (quartile 4 versus 1) and Risk of The 
Esophageal and Gastric Cancer Continuum.  
 
Gastroesophageal 
Reflux Disease 
Barrett’s 
Esophagus (BE) 
Esophageal and 
Gastric Cardia 
Adenocarcinoma 
(EA/GCA) 
Death 
Esophageal Adenocarcinoma 
↓ 8%  Total Flavonoids 
↓ 57%  Anthocyanidins 
↑ 2%  Flavan-3-ols 
↓ 44%  Flavanones 
↓ 16%  Flavones 
↓ 20%  Flavonols 
↑ 65%  Isoflavones 
↓ 25%  Lignans  
 
Gastric Cardia Adenocarcinoma 
↑ 32%  Total Flavonoids 
↓ 29%  Anthocyanidins 
↑ 17%  Flavan-3-ols 
↑ 23%  Flavanones 
↑ 9%  Flavones 
↑ 42%  Flavonols 
↑ 56%  Isoflavones 
↑ 1%  Lignans  
 
↑ 9%  Total Flavonoids 
↓ 41%  Anthocyanidins 
↓ 12%  Flavan-3-ols 
↓ 29%  Flavanones 
↑ 26%  Flavones 
↓ 11%  Flavonols 
↓ 32%  Isoflavones 
↓ 36%  Lignans  
Esophageal Adenocarcinoma 
↓ 2%  Total Flavonoids 
↓ 13%  Anthocyanidins 
↓ 7%  Flavan-3-ols 
↑ 15%  Flavanones 
↓ 17%  Flavones 
↓ 6%  Flavonols 
↓ 25%  Isoflavones 
↓ 22%  Lignans  
 
Gastric Cardia Adenocarcinoma 
↓ 12%  Total Flavonoids 
↓ 37%  Anthocyanidins 
↓ 29%  Flavan-3-ols 
↓ 10%  Flavanones 
↓ 14%  Flavones 
↓ 7%  Flavonols 
↑ 1%  Isoflavones 
↓ 3%  Lignans  
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Conclusion 
This study of the esophageal and gastric cardia adenocarcinoma cancer continuum indicates 
that dietary intake of certain classes of flavonoids, particularly anthocyanidins, may reduce the 
risk of Barrett’s esophagus and esophageal/gastric cancer. Future studies should examine 
individual flavonoids, disentangle effects of antioxidants, and utilize molecular weights for 
flavonoids. If it is confirmed in future epidemiologic studies that certain classes of flavonoids 
reduce the risk of esophageal/gastric cancer, clinical trials utilizing these flavonoid classes as 
chemopreventive therapies should be undertaken.  
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